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Mapping the Genomic Context of Mutagenesis
Harald Sager Vöhringer
The accumulation of genomic mutations leads to the formation of cancer. For this reason, many
efforts have been undertaken to characterise mutational processes in terms of their genomic imprints.
A particularly successful approach is matrix-based mutational signature analysis, which identifies
prototypical mutation patterns by applying non-negative matrix factorisation to catalogues of single
nucleotide variants and other mutation types. However, mutagenesis is a multifaceted event that is
affected by the genomic organisation of DNA and cellular processes such as transcription, replication,
and DNA repair processes. Moreover, since many mutational processes also generate characteristic
multi nucleotide variants, insertion and deletions, and structural variants, it appears valuable to jointly
deconvolve broader mutational catalogues to better understand the complex nature of mutagenesis.
In this thesis, I present TensorSignatures, an algorithm to learn mutational signatures jointly
across different variant categories as well as their genomic localisation and properties. The analysis
of 2,778 primary and 3,824 metastatic cancer genomes of the PCAWG consortium and the HMF
cohort shows that practically all signatures operate dynamically in response to various genomic
and epigenomic states. The analysis pins differential spectra of UV mutagenesis found in active
and inactive chromatin to global genome nucleotide excision repair. TensorSignatures accurately
characterises transcription-associated mutagenesis, which is detected in 7 different cancer types.
The algorithm also extracts distinct signatures of replication- and double strand break repair-driven
mutagenesis by APOBEC3A and 3B with differential numbers and length of mutation clusters. As a
fourth example, TensorSignatures reproduces a signature of somatic hypermutation generating highly
clustered variants around the transcription start sites of active genes in lymphoid leukaemia, distinct
from a more general and less clustered signature of Pol⌘-driven translesion synthesis found in a broad
range of cancer types. Finally, I demonstrate TensorSignatures’ utility by applying it to multiple
datasets in various collaboration projects.
Taken together, TensorSignatures adds great detail and refines mutational signature analysis
by jointly learning mutation patterns and their genomic determinants. This sheds light on the
manifold influences that underlie mutagenesis and helps to pinpoint mutagenic influences which
cannot easily be distinguished based on the mutation spectra alone. As mutational signature analysis
is an essential element of the cancer genome analysis toolkit, TensorSignatures may help make the
growing catalogues of mutational signatures more insightful by highlighting mutagenic mechanisms,
or hypotheses thereof, to be investigated in greater depth.

PETE: The Visilia Oaks and our 240-pound catcher, Jeremy Brown, who, as you know,
is scared to run to second base. This was in a game six week ago. This guy’s
gonna’ start with a fastball. Jeremy’s gonna take him to deep center. Here’s
what’s interesting, because Jeremy’s gonna do what he never does. He’s gonna
go for it. He’s gonna round first and he’s gonna go for it. Okay? This is all of
Jeremy’s nightmares coming to life.
BILLY: Aw, they’re laughing at him.
PETE: And Jeremy’s about to find out why. . . Jeremy’s about to realise that the ball
went 60 feet over the fence. He hit a home run and didn’t even realise it.
BILLY: How can you not be romantic about baseball ?
PETE: It’s a metaphor.
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Chapter 1
Introduction
Cancer is the second leading cause of death globally, responsible for approximately 9.7 mil-
lion deaths in 20181. While we nowadays take the molecular foundations of carcinogenesis
for granted, it took almost 200 years to arrive at these insights, and began with biological
concepts established by the nineteenth-century giants Mendel and Darwin, who outlined the
foundation for genetics and evolution.
Gregor Mendel established the basic rules of genetics by tracking the breeding of pea
plants in 1860. He found out that genetic information can be understood as a collection
information packets, in today’s language genes, that define distinct physical traits in an
organism. Since genetic information is passed in its entirety from parent to offspring,
many organisms store their genetic information in twofold redundancy, allowing them to
preserve the genetic information from both parents. Different versions of a gene are called
alleles. For example, if an organism carries two identical versions of a gene, it is said to be
homozygous, while an individual with two distinct copies is heterozygous with respect to the
gene (Weinberg, 2013).
In the early twentieth century, it seemed that genetic variability must have been established
at the evolutionary beginnings of a species, but this view was challenged when researchers
found out that genetic information is corruptible. Mutations can change the information
content of a gene, thus interchanging one allele into another, or creating completely novel
gene versions. In some sense, mutations provide species the means to tinker with their
genomes, giving organisms the opportunity to continually improve their phenotype, i.e. the
composite of observable characteristics of an organism, due to new versions of genes. This
results in a diversification of alleles over the evolutionary history of a species, such that older
species harbour more distinct alleles in comparison to more recent ones (Weinberg, 2013).
1According to the World Health Organisation (2018).
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However, not all mutations turn out to be advantageous, in fact, most of them have
adverse effects, some mutations may be even deleterious. Charles Darwin recognised the
interplay between evolutionary forces driving the formation of mutations and environmental
constraints: Nature naturally select alleles conferring favourable phenotypes, while alleles
with unfavourable effects are continually discarded (Weinberg, 2013). This insight has
profound consequences to conceptualise cancer, because tumours take advantage of mutations
to ensure their persistence, thereby exploiting evolutionary mechanisms against their host
organisms.
Watson and Crick inaugurate the biological revolution of the twentieth century
Although the concepts of Mendel and Darwin are probably the most pervasive in biology,
it took almost 100 years to resolve the structure of the molecule that embodies the genetic
constitution of a cell. The time had come in 1953, when Watson and Crick announced the
discovery of the deoxyribonucleic acid (DNA) double helix, and humbly2 acknowledged
that “It has not escaped our notice that the specific pairing we have postulated immediately
suggests a possible copying mechanism for the genetic material.” (Watson and Crick, 1953),
thereby providing the molecular and mechanistic bases that explain evolution, enable modern
genetics, and would launch the biological revolution of the twentieth century.
Initially, a large proportion of DNA had no known biological function, and was therefore
termed as “junk DNA” (Gregory, 2011). In fact, only 1.5 % of a mammalian genome is dedi-
cated to encode protein sequences, and another 2 % is important to regulate gene expression
and other functions (Lander, 2011; Weinberg, 2013). Consequently, since mutations affect
random locations in the genome, most genomic alterations have no or very little effect on
the cellular or organismic phenotype. For this reason, mutations in non-encoding genomic
regions are said to be silent or neutral, because from an evolutionary point of view, they
confer neither advantages nor disadvantages. The lack of phenotypical implications made
it impossible for early geneticists to detect neutral mutations, and it only became feasible
after the first DNA sequencing techniques were invented. These revealed that each human
genome carries its own unique collection of genomically silent mutations, often comprising
millions of so-called genetic polymorphisms (Lander, 2011).
While the configuration of genetic polymorphisms is transmitted from parent to offspring,
it is important to distinguish them from germline or somatic mutations. Germline mutations
affect every cell of the offspring by striking the genome of a sperm or egg, or their precursor
2It should be mentioned that Watson and Crick made use of Rosalind Franklin’s crystallographic evidence,
which was shown to them without her consent by her colleague Maurice Wilkins, to confirm their guess about
the double helical DNA structure.
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stem cells within the gonads, respectively. On the other hand, somatic mutations arise
everywhere else except from the germline, and only affect particular cells. Some somatic
mutations may drive cancer formation, as they change the properties of the affected cell
and all of its descendants (clones) within a tissue (Weinberg, 2013). Such mutations affect
genomic regions that encode genes with oncogenic or tumor suppressive potential. Over time,
the descendants of this clone will acquire further mutations, eventually equipping some of
the daughter cells with additional invasive properties, allowing them to turn into to malignant
tumours.
In particular, the cells involved in tumour formation develop the following properties: (1)
cell growth and division in absence of proper signals, (2) continuous growth and division
even in presence of contrary signals, (3) avoidance of apoptosis, (4) limitless number of
cell divisions, (5) promotion of blood vessel construction, and (6) invasion of tissue and
formation of metastases (Hanahan and Weinberg, 2000, 2011). To acquire these capabilities,
normal cells undergo a multistage transformation in which a pre-cancerous lesion progresses
to a malignant tumour. This process results from an interaction between an individual’s
genetic predisposition and various environmental factors, which induce genomic alterations
that change the normal cellular program.
The origins of cancer
While the principles established by Mendel and Darwin are essential to conceptualise the
disease, they tell us little about how mutations actually emerge and how cellular factors
influence mutagenesis. The first evidence indicating that mutations are not purely spontaneous
and random was given by the fact that the incidence of many cancers vary by country.
Although heredity or environment could account for this variation, epidemiological studies
found lifestyle factors to be the main determinants of the country-by-country variation in
cancer incidence. This idea was supported by laboratory research that narrowed down
chemical and physical agents such as tobacco, coal dust and X-rays as potent carcinogens.
In addition, viruses were found to cause leukemias in chickens, raising the possibility that
cancer is an infectious disease (Weinberg, 2013). However, in 1975 Ames provided strong
experimental support for the hypothesis that carcinogenic substances induce cancer by
mutating genes, indicating that a large fraction of cancers may be attributed to the exposure
to a wide range of substances (Ames et al., 1975). Over time, researchers characterised
the impact of different mutagens on DNA, which revealed that many carcinogens introduce
specific mutations.
With the advent of next-generation sequencing techniques, it became feasible to detect
the entirety of somatic mutations within cancer genomes, including both driver and neutral
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mutations. While the analysis of driver mutations leads to the identification of genes with
oncogenic or tumor suppressive potential, it is less obvious what value is gained by analysing
neutral mutations that lack phenotypic consequences. However, although neutral mutations
do not promote tumour progression, they still resemble a genomic imprint of carcinogenic
exposure due to an endogenous or exogenous mutagenic source, thereby conveying great
information about the etiologic (causative) mechanisms of cancer development (Helleday
et al., 2014).
While the analysis of sequenced cancer genomes largely confirmed that cancer types
such as melanomas or lung cancers exhibit predominantly mutations that one would expect
considering the mutagens they have been exposed to, it surprisingly also revealed that muta-
genesis does not occur uniformly on the genome, indicating that the genomic organisation
and biological processes involving DNA affect mutagenesis (Schuster-Böckler and Lehner,
2012). At the same time, the first attempts to systematically characterise the mutational
patterns of cancers were made by applying mathematical approaches to mutation count
data (Alexandrov et al., 2013a). Over time, these efforts provided more than 50 different
single base substitution (SBS) patterns, so-called mutational signatures, indicative for a range
of endogenous mutational processes, as well as genetically acquired hypermutation and
exogenous mutagen exposures (Alexandrov et al., 2018).
This overview of carcinogenesis illustrates the complexity of the topic and shall prepare
the reader for the intricacy that has yet to be explored when mutagenesis is studied on a whole
genome level. So far, a number of studies have analysed cancer genomes to extract mutational
processes using computational pattern recognition algorithms such as non-negative matrix
factorisation (NMF) over catalogues of single nucleotide variants (SNVs) and other mutation
types. However, these mutational signatures characterise mutational processes only in terms
of their mutational imprint but fail to take into account the complexity of the genome, or
reflect the multitude of different mutation types caused by a single process. The goal of
this research was to address these shortcomings by developing a novel method capable of
incorporating genomic determinants such as the local genome structure, or fundamental DNA
involving processes including transcription and replication. To motivate this, I will start by
reviewing the fundamental properties of DNA and its nuclear organisation (Sec. 1.1), as
well as transcription and replication (Sec. 1.2). In Sec. 1.3, I will provide an overview of
endogenous and exogenous mutational processes, and discuss in Sec. 1.4 the mechanisms
cells have evolved to repair them. Sec. 1.5 discusses mutagenesis in the context of the
genome, and Sec. 1.6 introduces the computational method NMF, which is at the heart of
mutational signature analysis, and summarises the insights that have been drawn from this
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methodology. Finally, in the last section of this chapter (Sec. 1.7), I will briefly layout the
structure of this thesis.
1.1 Eukaryotic DNA structure and organisation
The fact that DNA plays a central role in various important cellular processes and consists of
structurally and functionally distinct compartments introduces complexity to mutagenesis
and DNA repair. To appreciate this, I will review in this section the basic (Sec. 1.1.1) and
higher order structure (Sec. 1.1.2) of the molecule.
1.1.1 Nucleotides are the building blocks of the DNA double helix
Nucleotides make up the basic building blocks of DNA and are crucial to mediate the
structure and functionality of the molecule. They comprise three components: a five carbon
sugar (desoxyribose), a phosphate group, and one of four possible nitrogenous bases: the
purines adenine (A) and guanine (G), and the pyrimidines cytosine (C) and thymine (T). The
sugar component misses a hydroxyl group at its 2’-carbon, which is normally present in
ribose, attaches to the base component via an N-glycosidic bond at its 1’ carbon, and forms a
covalent bond with a phosphate group to connect to neighbouring nucleotides via its 3’ or
5’ carbon (Fig. 1.1a, Alberts et al. (2007)). A single DNA strand is formed by connecting
a sequence of nucleotides. Here, the carbon numbering is key to describing the intrinsic
directionality of the polymer which is in standard orientation 5’ to 3’ (Fig. 1.1b).
Structural properties of the DNA double helix enable protein interactions
Two DNA strands, when aligned in opposite directionality, may interact through non-covalent
hydrogen bonds between their bases. Hydrogen bonding contributes to the specificity of base
pairing, because T preferentially pairs with A, and C preferentially pairs with G through
two and three hydrogen bonds, respectively (Fig. 1.1b). The geometries of the A:T or T:A
and G:C or C:G base pairs are the same, allowing for symmetry and base stacking, and
enabling two complementary strands to intertwine, thereby forming the characteristic double
helix. The helical structure of double-stranded DNA (dsDNA) features structural properties
important for DNA interactions with proteins. Particularly, it constitutes a major groove
which allows proteins with fitting domains to bind while distinguishing between A:T and
T:A base pairs and between G:C and C:G base pairs, thus enabling sequence specific protein



































Fig. 1.1 DNA structure and organisation. a. Nucleotides comprise three distinct structural
components: a ribose, a base and a phosphate group. b. Two antiparallel DNA strand align
to each other by forming hydrogen bonds (dashed lines) between complementary nucleotides.
c. The DNA double helix features DNA-protein interaction by exposing a major and a minor
groove. d. A nucleosome is composed of a H3/H4 tetramer and two H2A/H2B dimers. e.
Nucleosomal DNA binding is facilitated by minor-groove interactions between the histone
protein complex and DNA. f. H1 linker histones enable further compaction and promote
higher order DNA structure (not shown).
proteins to only differentiate between A:T/T:A and G:C/C:G base pairs (Fig. 1.1c, Alberts
et al. (2007)).
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1.1.2 Nucleosomes establish several layers of DNA compaction
The total length of the human genome corresponds to a 3⇥109 long sequence of base pairs.
This corresponds to a 2 m long unrolled string of DNA, whereas an average human nucleus
has a diameter of only 10 µm, suggesting that cells must have evolved efficient ways to
compress the linear molecule.
Histone proteins form the core of nucleosomes
The first stage of compaction is achieved by wrapping 147 bp DNA 1.7⇥ around disk-shaped
octameric histone protein complexes (each DNA-protein complex contains two copies of
H2A, H2B, H3 and H4, Fig. 1.1d, Luger et al. (1997)). Histone proteins are highly conserved
across eukaryotes, positively charged due to a high of amount basic amino acids such as
arginine and lysine, and exhibit unstructured N-terminal tails that stick out of the DNA-
protein complex to enable regulation. The combination of histone proteins and associated
DNA is termed a nucleosome and represents the most basic structural unit of DNA packaging
(Alberts et al., 2007).
Histone proteins bind the phosphate back-bone and the minor groove of DNA. Although
these interactions are largely non-sequence-specific, there are certain sequence compositions
that facilitate DNA-histone interactions by inducing favourable configurations of the molecule
(Segal et al., 2006). Particularly well-suited sequences are alternating GC and AT-rich minor
groove sequences (Fig. 1.1e), because GC-rich minor grooves bend DNA towards the major
groove, and thus away from the histone, while AT-rich minor grooves bend the molecule
towards the minor groove and the nucleosome (Kaplan et al., 2009; Segal et al., 2006). In
this way, a single histone octamer forms approximately 40 hydrogen bonds with DNA.
Linker histone achieve further compaction and promote higher order nucleosomal or-
ganisation
Although nucleosomal DNA packaging compacts DNA by roughly ⇠5.5-fold, further com-
pression is required to fit the genome into the nucleus, which is achieved by assembling H1
linker histones to the DNA-protein complexes. In contrast to other histone proteins, H1 does
not locate to the nucleosomal core, but rather sits on top of the structure by binding to the nu-
cleosome bound DNA midpoint (dyad), thereby compacting the molecule up to 40-fold (Fig.
1.1f, Ramakrishnan et al. (1993)). Linker histone binding also keeps in place the wrapped
DNA, facilitating the formation of higher-order structures involving many nucleosomes into
solenoid or zig-zag 30 nm fibres (Robinson et al., 2006; Schalch et al., 2005). It is believed
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that 30 nm fibres loop around a proteinaceous structure called nuclear matrix to form whole
chromosomes (Alberts et al., 2007).
1.2 Genome regulation and activity
DNA condensation is crucial to store DNA compactly, but also makes large parts of the
genome inaccessible to DNA-binding proteins, which represses many obligatory cellular
processes such as transcription or replication. For this reason, cells control structural and
functional properties of DNA by epigenetic modifications, which do not alter the sequence
information, but rather the state of DNA associated proteins or nucleotides to dynamically
modulate the accessibility of specific genomic regions.
1.2.1 Epigenetic regulation of DNA accessibility
The most basic level of DNA regulation is mediated by the way DNA is wrapped around the
histone core. DNA accessibility is highest at the DNA entry points to the nucleosome, and
declines gradually towards the dyad. To understand this, consider that DNA segments located
at nucleosomal entry points are much less tightly bound, enabling the DNA to temporarily
dissociate from the protein complex and expose their sequence to DNA-binding proteins.
In contrast, DNA proximal to the dyad is surrounded by tightly bound DNA on both sides,
making the latter event less likely to occur (Klemm et al., 2019; Li et al., 2005).
Histone remodelling complexes modulate DNA accesibility by sliding DNA around nu-
cleosomes and exchanging histone subunits
One important class of proteins dedicated to alter the accessibility of DNA are nucleosome
remodelling complexes, which utilise adenosine triphosphate (ATP) to slide DNA around the
disk-shaped protein complex, or catalyse the removal or the exchange of histone subunits,
often with non-standard histone isoforms that mark functionally distinct genomic regions
(Saha et al., 2006). For example, histone variant CENP-A is found at centromers and may
interact with microtubules during anaphase of mitosis (Chueh et al., 2005), H3.3 marks sites
of transcription (Chen et al., 2013), H2A.X indicates double strand breaks in DNA (Ayoub
et al., 2008), and H2A.Z appears to locate at boundary regions to nucleosome free regions
(Hatch and Bonner, 1990).





































Fig. 1.2 Epigenetic modulation of DNA accessibility. a. Acetylation of positively charged
amino acids in N-terminal histone tails reduces the nucleosomal affinity for bound DNA. b.
An example of epigenetic regulation of DNA accessibility via postranslational modification
of histone tails (see text).
Postranslational modification of histone tails modulate DNA access by structural per-
tubations and secondary effector proteins
Another form of epigenetic modulation is mediated by histone tails, which are unstructured
and positively charged, extend outside of the nucleosome, and are thus accessible to enzymes
that add or remove diverse molecules ranging from small acetyl groups to larger proteins
such as ubiquitin. The two most important histone modifications are acetylations and deacety-
lations of lysins by histone acetyltransferases (HATs) and histone deacetylases (HDAcs),
and methylations and demethylations of lysins or arginines by histone methyltransferases
(HMTs) and histone demethylases (HDMes) (Lee and Workman, 2007; Milazzo et al., 2020).
It is thought that histone acetylation makes DNA more accessible by neutralising the
(positive) amino group of lysins, thus reducing the affinity of histone N-terminal ends for the
negatively charged DNA (Fig. 1.2a). Acetylation also interferes with 30 nm fibre formation,
because the establishment of this higher order structure partly depends on interactions
mediated by positively charged histone tails and adjacent nucleosomes (Eberharter and
Becker, 2002). While acetylations induce direct structural perturbations, other histone
modifications like methylations, but also acetylations, mediate their effects via effector
proteins equipped with domains that recognise certain histone modifications. Examples
for such domains are bromodomains which recognise acetylated nucleosomes, or TUDOR
(Huang et al., 2006; Lee et al., 2008), PHD finger (Iwase et al., 2007), and chromodomains
that direct effector proteins to methylated histone tails (Min et al., 2003).
The association of flexible histone extensions to effector proteins with histone modifica-
tion recognising domains allow the propagation of histone states, enabling cells to quickly
alter functional and structural properties of specific genomic segments (Fig. 1.2b). For
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instance, a HDAc with a bromodomain may promote genome silencing in active genomic
regions. The bromodomain enables the enzyme to target acetylated histone tails, which are
mainly found in transcribed genomic regions. Once bound to such a nucleosome, the HDAcs
may deacetylate the N-terminal tails of the bound and adjacent nucleosomes to promote
chromatin condensation (Fig. 1.2b).
Histone codes mark functionally distinct genomic regions
The discovery of histone tail modifications led to the proposition of the histone code hy-
pothesis, stating that specific posttranslational modifications serve to recruit distinct proteins
with matching recognition domains, which then alter the chromatin structure to promote
certain downstream events (Jenuwein, 2001; Strahl and Allis, 2000). Today, this theory
is considered certain, particularly the methylation of H3K4 and H3K36 correlates with
transcriptional activation, while demethylation of the former silences genomic regions, tran-
scriptional repression is associated with H3K9 and H3K27 methylation (Hublitz et al., 2009),
and trimethylation of H3K9 indicates constitutive heterochromatin (Hyun et al., 2017).
Cytosine methylations regulate the transcription rate of genes and affect local chro-
matin structure via methyl-CpG-binding domain proteins
Cytosine methylation at CpG sites alter the accessibility to regulatory proteins, thus influenc-
ing the transcription rate of genes. Interestingly, this may either result in the activation or
repression of genes depending on the location of the methylation within the gene. Methylated
cytosines at gene regulatory regions may also remodel the local chromatin structure by
recruiting methyl-CpG-binding domain (MBD) proteins, which interact with nucleosome
remodelling complexes and HDAcs, leading to gene silencing (Bhattacharya et al., 1999).
1.2.2 Mechanics of transcription
Transcription is the process by which the information in DNA is copied into a new molecule
of ribonucleic acid (RNA). While there are three different RNA polymerases in eukaryotes
to generate various RNA products, I will focus in this section on RNA polymerase II
(RNA Pol II). This polymerase exclusively transcribes messenger RNA (mRNA), which is
subsequently translated into proteins. In eukaryotes, transcription is naturally repressed due
to the nucleosomal organisation of DNA, making transcriptional activation the dominant
mode of regulation.
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Proximal and distal DNA regulatory elements control transcription
Transcriptionally active regions constitute a promoter, i.e. a site that directs RNA Pol II to
bind a gene. The core promoter is a ⇠60 bp long sequence encompassing a transcription start
site (TSS), and up to four general transcription factor (TF) binding sites such as the TATA
box, indicative for how efficiently RNA Pol II is recruited (Alberts et al., 2007). The proximal
promotor subsumes the core promotor plus regulatory elements 200-400 bp upstream of it.
The size of a full promotor ranges from 400 to 10 kbp, contains the proximal promotor and
long range promotors, including enhancers or insulators (Fig. 1.3a).
Enhancers may be located upstream, downstream, or within transcribed regions (generally
in introns). While some details of enhancer actions are still elusive, it is established that
enhancer RNA (eRNA) is required for looping, which brings enhancer and proximal promoter
elements together (Kim et al., 2010; Wang et al., 2011a). Enhancer recruit many of the same
factors as the promoter (e.g. nucleosome remodelling complexes) and provide in this way
activation reinforcement. In contrast, insulators establish chromatin boundaries by blocking
the action of enhancers through competing looping mechanisms, or by forming chromatin
boundaries by stopping the propagation of active histone states (Gaszner and Felsenfeld,
2006; West et al., 2002).
Transcription comprises three distinct stages: initiation, elongation and termination
Transcription initiation starts with the assembly of the pre-initiation complex constituting
several (general) TFs, which bind to recognition sites such as the TATA-box, and RNA
Pol II at the proximal promotor (Fig. 1.3b). Subsequently, TFIIH promotes DNA opening
by translocating DNA towards the TSS, and initiates promotor escape by phosphorylating
serine-5 of RNA Pol II C-terminal domain (CTD) (Goodrich and Tjian, 1994), which is the
unstructured “tail” of the enzyme, consisting of 52 heptapeptide repeats (Hsin and Manley,
2012). This starts transcription by freeing RNA Pol II from the Mediator (Fig. 1.3b), a large
multi protein complex that is thought to bind unphosphorylated CTD to elaborate RNA Pol
II’s surface area, enabling the transcription machinery to interact with a larger number of
TFs, which often locate to distal enhancer elements. Serine-5 phosphorylation also recruits
capping enzymes targeting the 5’ end of nascent mRNA (Spangler et al., 2001). The 5’
cap protects mRNA from exonucleases and helps the translation machinery to recognise
transcripts (Fig. 1.3b, Alberts et al. (2007)).
Many promoters feature a promoter proximal pausing event mediated by negative elon-
gation factor (NELF) and DRB sensitive factor (DSIF) which arrest RNA Pol II shortly








































Fig. 1.3 Eukaryotic transcription. a. Structure and components of an eukaryotic promotor.
b. The three phases of transcription constitute initiation, elongation and termination (see
main text for details). c. DNA organisation at a transcribed loci.
elongation factor (P-TEFb) initiates processive transcription by phosphorylating NELF and
DSIF, causing the former to leave the transcription machinery. During transcription elonga-
tion, P-TEFb also phosphorylates serine-2 of RNA Pol II CTD (Fig. 1.3b), which recruits
RNA splicing enzymes and the 3’ processing machinery necessary to add the Poly A tail to
emerging mRNA transcripts. At the same time, the amount of serine-5 CTD phosphorylation
decreases, causing mRNA 5’ end modifying enzymes to leave the CTD (Narita et al., 2003).
Transcription termination does not rely on RNA Pol II, but is initiated by the polyA-
signal of the mRNA transcript, which is usually located shortly after the stop codon. This
recognition sequence is detected and bound by the 3’ processing machinery located at the
RNA Pol II CTD, which cleaves the nascent mRNA and adds an untemplated poly-A tail
to the transcript, thus protecting the newly generated mRNA molecule from 3’ degradation
(Guhaniyogi and Brewer, 2001). At this stage, RNA Pol II continues to elongate the cleaved
RNA molecule, which is due the lack of a 5’ cap prone to degradation by exonucleases. This
enzyme ”chews off” the RNA from the active site of RNA Pol II, resulting in reannealing of
the coding and template strand DNA (Fig. 1.3b), thus removing the substrate for RNA Pol II,
which is unable to bind DNA again without the help of general TFs (Kim et al., 2004).
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The chromatin structure of actively transcribed genomic regions
There are strong links between transcription regulation and the epigenetic configuration of
transcribed loci: Promoter and TSS are usually nucleosome free, enabling TFs and RNA
Pol II to bind and initiate transcription, while regions upstream of promotors are acetylated,
characteristic of accessible chromatin. However, a somewhat surprising observation is that
coding regions, downstream from gene promotors, are usually in deacytelated form, raising
the question how RNA Pol II transcribes through poorly accessible chromatin (Fig. 1.3c,
Owen-Hughes and Gkikopoulos (2012); van Steensel and Furlong (2019)).
As it turns out, phosphorylated RNA Pol II CTD itself regulates transcribed loci by
recruiting HMT SET2, which methylates H3K26. This recruits HDAcs to remove acetyl
groups from histone tails, resulting in tightly organised chromatin (Venkatesh and Workman,
2013). To nevertheless transcribe through the condensed chromatin, the transcription machin-
ery makes use of the facilitates chromatin transcription complex (FACT), which removes
a H2A/H2B dimer from a nucleosome, leaving behind a histone hexamer (hexasome) that
is easier to transcribe through. FACT in conjunction with transcription elongation factor
SPT6 restore the nucleosomal structure by subsequently reconstituting removed histone parts
(Venkatesh and Workman, 2013).
1.2.3 DNA replication
Cells employ DNA replication in mitosis or meiosis to produce two identical replicas of the
DNA molecule.
DNA synthesis at a replication fork requires three different polymerases
The replication fork is a structure that forms within dsDNA during DNA replication. Here,
the antiparallel strands are split into single-stranded DNA (ssDNA), ready to be processed by
DNA polymerases. In fact, eukaryotic replication involves three different DNA polymerases.
DNA polymerase " (Pol ") and DNA polymerase   (Pol  ) copy leading and lagging strand,
respectively (Alberts et al., 2007). While the leading strand DNA polymerase always copies
DNA in the same direction as the movement of the replication fork, lagging strand DNA
synthesis occurs in the opposite direction, making it necessary for Pol   to replicate to a
stopping point, and then start again at a position closer to the replication fork. In contrast,
DNA polymerase ↵ (Primase) synthesises 6-8 bp RNA primers at replication forks to provide
primer:template junctions (PTJs) which serve as substrates for replicative polymerases (Frick
and Richardson, 2001).
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Temporal properties of the DNA synthesis reaction and the structure of DNA poly-
merases ensure high-fidelity DNA synthesis
DNA synthesis requires a PTJ, i.e. a primer with a free 3’OH annealed to a longer stretch of
template ssDNA, and all four types of deoxyribonucleotide triphosphates (dNTPs). DNA
polymerases recognise PTJs as substrates and extend the primer 3’OH by adding dNTPs
matching the template sequence. It is important to realise that DNA polymerases cannot
distinguish a correct from an incorrect dNTP by interacting with the incoming dNTP alone.
When a matching base enters the active site, it base pairs the template nucleotide, which
positions the ↵-phosphate group of the incoming dNTP close to the primer 3’ OH, facilitating
quick catalysis (Alberts et al., 2007). However, in the absence of a correct base pair, the
↵-phosphate of the incoming dNTP is not in close proximity to the primer 3’ OH, resulting
in much slower catalysis and enabling the incorrect dNTP to fall out of the active site again
(Alberts et al., 2007).
While temporal regulation plays an important role in accurately distinguishing between
similar dNTPs, structural features of DNA polymerases enforce additional spatial constraints
to ensure high fidelity DNA synthesis. To understand this, recall that replicative DNA
polymerases have the shape of a hand (Doublié and Zahn, 2014), with the palm binding
the PTJ through interactions with the phosphate backbone, and non-sequence, but Watson-
Crick specific minor groove interactions, enabling the enzyme to detect whether the newly
synthesised dsDNA displays the hydrogen donor/acceptor pattern of matching base pairs.
In contrast, the finger domains of DNA polymerases properly orient participating reactants,
particularly important is the so called O-helix, which clamps the incoming residue so that
water cannot enter the active site, and only the nucleophilic attack of the primer 3’-OH can
occur (Hübscher et al., 2002; Johnson, 1993; Joyce and Steitz, 1994).
The exonuclease domain of replicative DNA polymerases increase fidelity of DNA syn-
thesis
Temporal properties of the chemical reaction and structural features of DNA polymerases
enable cells to replicate DNA with error rates of 1 mistake per 105 bp synthesised, an
unacceptably high rate considering that the human genome has the size of 3⇥109 bp3. The
mistakes escaping these precautionary measures are mostly transitions (A>G or C>G), and
due to the chemistry of nucleotides, which may spontaneously switch from keto to enol
form (tautomery), albeit these transitions are rare and last only very brief periods of time
(Wang et al., 2011b). To understand this, consider that a guanine in its common keto state
3This corresponds to 3,000 errors per round of replication (Kunkel, 2009)!
1.2 Genome regulation and activity 15
pairs with cytosine, but rather interacts with thymidine in its enol form due to an altered
pattern of exposed hydrogen acceptors/donors. In this way, temporarily present enols in
the template DNA may cause the incorporation of wrong dNTPs. However, as soon as an
enol switches back to its energetically more favourable keto form, the wrongly incorporated
base destabilises the PTJ enough to create a small region of ssDNA at the 3’ end, for which
the DNA polymerase proofreading exonuclease domain has a 10-fold higher affinity in
comparison to the DNA polymerase active site. The proofreading exonuclease domain will
remove a few nucleotides before the PTJ, allowing to restore the dsDNA and enabling DNA
polymerase to proceed with DNA synthesis (Swan et al., 2009). Overall, the presence of the
3’ to 5’ exonuclease domain increases the accuracy of replicative polymerases by a 100-fold
so that one round replication would leave an imprint of 30 mutations, which is still to high,
but is addressed by additional DNA repair mechanism discussed in later sections (Kunkel,
2009).
Other enzymes at the replication fork involve helicases, replication protein A, and
topoisomerases
Although DNA polymerases perform most of the work during DNA replication, cells also
rely on various other enzymes to ensure flawless proceeding of the DNA copying process.
For example, one problem eukaryotic cells face is the burden of copying vast amounts of
DNA due to their large genome size, making processive (fast) DNA replication indispensable.
To accomplish this, cells employ replicative helicases, which are hexameric ring-shaped
molecules that unwind DNA at the replication fork under the consumption of ATP. The
molecular structure of DNA helicase suggests that the enzyme encircles the leading strand in
eukaryotes (Enemark and Joshua-Tor, 2006), and promotes movement of the replication fork
by a “paddling” mechanism that pulls the bound ssDNA through the enzyme’s central hole,
thereby displacing both DNA strands and enabling up to 6⇥ faster replication (Ha, 2007).
Pol   synthesis of the lagging strand is discontinuous, and occurs in the opposite direction
to replication fork progression, causing the latter strand to remain for a longer period in
fragile ssDNA configuration (Alberts et al., 2007). To stabilise the DNA during this critical
period, and to prevent premature reannealing of both DNA strands, cells employ replication
protein A (RPA), which readily binds ssDNA, but not dsDNA, in a non sequence specific
manner. Notably, RPA binding is cooperative, meaning that if one binds it is easier for a
second to bind as well, and it does not prohibit DNA polymerases to replicate over its bound
DNA (Bae et al., 2001).
Apart from RPA, additional enzymes are required to finalise the synthesis of the lagging
strand. To remove the RNA primer at the beginning of each Okazaki fragment, FEN1 de-
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grades most of the primer except the last rNMP, for which an additional 5’ to 3’ exonuclease
is recruited (Cerritelli and Crouch, 2009). The resulting gap is then filled by a DNA poly-
merase, and a specialised DNA ligase which links the newly generated DNA to following the
Okazaki fragment (Alberts et al., 2007).
Unwinding the double helix during DNA replication results in positive supercoiling,
which refers to the overwound DNA that has yet to be processed by the replication machinery.
This could lead to a stalling replication fork, because a surplus of DNA twists increases the
strain energy stored in the molecule, making it more difficult for DNA helicase to proceed
with unwinding the DNA. To overcome this issue, cells employ type I DNA topoisomerases4,
which cut a single strand of dsDNA and relax supercoils by pulling the other strand through
the incision such that the molecule unwinds (Champoux, 2001; Wang, 2002).
Random redistribution of parental DNA histone proteins to both daughter DNA en-
sures proper propagation of epigenetic states
Although replication is primarily associated with the duplication of DNA, it is also the
time when the chromosome structure of the genome is established and associated proteins
are copied. Importantly, the chromatin structure ahead of the replication fork needs to be
disassembled as the replication machinery moves along the genome, as well as put back
together in the right configuration on both daughter DNA molecules. Nucleosome assembly
typically proceeds with the following steps: first, H2A:H2B and H3:H4 dimer assemble,
followed by H3:H4 tetramer formation. Histone chaperones escort H3:H4 tetramers to
DNA, where the protein complex binds DNA by wrapping the molecule around it such that
the dyad and both ends of DNA (the entry and exit point) are bound to the tetramer. Two
H2A:H2B dimers subsequently join the 2 ⇥ H3:H4 DNA complex, thereby completing the
histone octamer (Dennehey and Tyler, 2014). As the replication fork passes, nucleosomes
of the parental DNA are disassembled, and the pool of freed H3:H4 tetramers are randomly
distributed to both daughter DNA molecules, enabling to rebuild nucleosomes from this point.
Although the newly generated DNA also comprises some completely new nucleosomes,
marks present on redistributed histones suffice to reconstitute the original epigenetic state,
due to histone modifying enzymes capable of propagating the signals present on parental
histones (Sec. 1.2.1) (Ransom et al., 2010; Serra-Cardona and Zhang, 2018).
4There are also type II topoisomerases, but these are less relevant for DNA replication.
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Replication starts at different times at various loci of the genome
The discussion of DNA replication so far naively suggests to initiate a replication fork at the
beginning of a chromosome, and to replicate its DNA until DNA polymerase reaches to its
end. This is however not the case, as eukaryotic DNA replication starts at multiple sites of
the genome, termed origin of replication (ORI), where DNA is initially unwound and DNA
synthesis is started. This brings the advantage of parallelism, which enables cells to replicate
the genome much faster.
The human genome contains approximately 30,000 ORI, initiating at characteristic times,
with some firing early and others rather late in S-phase. Although there is little known about
the mechanisms orchestrating the temporal pattern or its significance, it is thought that the
timing pattern of ORI initiation may help to ensure that replication finishes even in presence
of DNA damage. Replication forks may stall upon encountering DNA alterations. When
DNA damage(s) block the progression of two convergent replication forks stemming from
two early-firing origins, then a late-firing origin from the unreplicated region in between may
be activated to close the gap between stalled adjacent forks (Yekezare et al., 2013).
1.3 DNA damage
The information encoded in the DNA sequence of each organism ensures its survival and
must therefore be passed on correctly to the next generation. However, not only the mere
fact that the DNA molecule has to survive within a physiological environment, but also the
exposure to exogenous factors may harm the molecule in various ways. In this section, I will
outline in what ways endogenous (Sec. 1.3.1) and exogenous (Sec. 1.3.2) sources may harm
genetic information.
1.3.1 Endogeneous sources of DNA damage
Endogenous DNA damage arises mainly due to hydrolytic and oxidative reactions of nucle-
obases with water and reactive oxygen substances (ROS), which are both naturally present
within cells.
Spontaneous and enzymatic hydrolytic deamination of cytosines
Although DNA is a chemically stable molecule, the presence of water in cells causes constant
hydrolysis of nucleobases. For example, hydrolytic deamination of cytosines causes the
formation of uracil (U), which basepairs with A rather than G (Fig: 1.4a). If an U:A mismatch
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remains unrepaired before replication, it may manifest as a C:G to T:A transition. In vivo rates
are difficult to estimate, because Cs in ssDNA deaminate with much higher rates compared
to Cs in dsDNA, albeit it is thought to occur about 100-500 times per human cell per day
(Frederico et al., 1990; Lindahl and Nyberg, 1974; Shen et al., 1994). The significance of this
mutagenic process is highlighted by greatly increased C>T mutation frequencies in uracil-
DNA glycosylase deficient cells (Sec. 1.4.2), which lack the ability to remove the altered
base (Duncan and Weiss, 1982). In addition to spontaneous hydrolysis of cytosines, cells
enzymatically induce the deamination of Cs in regular cellular processes such as somatic
hypermutation (SHM) during antibody development due to activation-induced cytidine
deaminase (AID) activity, and to mediate host defence against retroviruses by members of
the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) enzyme
family.
Hydrolytic deamination of 5-methyl cytosines escape the base excision repair pathway
More problematic are hydrolytic reactions at 5-methylcytosines (5-meCs), which often occur
in CpG-islands of eukaryotic genomes. Deamination of 5-meC transforms the base to a T
rather than an U (Fig. 1.4b), thus precluding it from detection by uracil-DNA glycosylase
(Sec. 1.4.2). If the mismatch repair (MMR) pathway (Sec. 1.4.3) fails to repair the resulting
T:G mismatch prior to replication, such a site may manifest as T:A transition. Moreover,
deamination rates of 5-meCs have been found to be threefold higher than that of unmethylated
C, making the former especially vulnerable to this mutagenic process (Lindahl and Nyberg,
1974).
Hydrolytic cleavage of the N-glycosidic bond between the sugar and base components
of a nucleotide produce abasic sites
Spontaneous hydrolysis often targets the base-sugar N-glycosidic bond leaving behind what
is called an apyrimidinic or apurinic site (AP-site) (Lindahl et al. (1993), Fig. 1.4c). The
total number of AP-sites generated in a single cell is estimated to be larger than 10,000 per
day, and mostly due to depurinations which are 20⇥ more rapidly released in comparison
to pyrimidines. Unrepaired AP-sites may cause replication stalling with subsequent error
prone translesion synthesis in which a low accuracy DNA polymerase inserts a random base
opposite to an AP-site (Sec. 1.4.4).
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Fig. 1.4 Endogenous and exogenous DNA lesions. a. Hydrolytic deamination of cytosine
turns the base into uracil which base pairs with adenine rather than guanine. b. The
additional methyl group present in 5-methyl-cytosine turns the nucleobase into a thymine
after deamination. c. Hydrolytic deamination may also occur at the N-glycosidic bond
connecting the base to its ribose molecule, leaving behind an abasic-site. d. The oxidation
of guanines may lead to the formation of 8-oxo-dG which base pairs with adenine rather
than cytosine. e. Methylation of guanine produces O6-methylguanine, which may interact
with thymine instead of cytosine. f. 5-bromouracil stabilises its enol enabling the base to
predominantly base pair guanines. g. Intercalating agents may cause deletions. h. UV
radiation introduces pyrimidine dimers by covalently linking two adjacent bases. i. X-rays
may introduce double strand breaks.
Cellular byproducts engage in oxidatitve reactions with DNA
Another source of endogenous DNA damage stems from reactive oxygen substances (ROS),
which may be produced as a byproduct of metabolic reactions. ROS like superoxide (O 2 ),
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hydrogen peroxide (H2O2), hydroxyl radicals (OH ), and singlet oxygen (1O2) oxidise
bases and may sometimes even cause single or double-strand breaks if cellular antioxidant
defence mechanisms fail to neutralise these compounds (De Bont and Van Larebeke, 2004;
Devasagayam et al., 2004).
It was estimated that 7,8-dihydro-8-oxoguanine (8-oxo-dG) is the most common modified
base in human genomes, with steady state levels ranging from 0.07 to 145.25 adducts per
Mbp (Higuchi and Linn, 1995; Spencer et al., 1996). The altered structure of 8-oxo-dG
allows the compound to preferentially base pair with A rather then C (Fig. 1.4d), inducing
C:G to T:A transversions when cells fall short to repair the alteration before the next round
of replication.
1.3.2 Exogenous sources of DNA damage
Exogenous DNA damage occurs when chemical agents and environmental factors interact
with DNA. Examples of chemical substances with genotoxic properties include polycyclic
aromatic hydrocarbons (PAHs), alkylating agents, base analogs, and intercalators, whereas
environmental factors comprise ionising radiation such as UV-light and X-rays. In contrast
to endogenous DNA damage, which is usually confined to hydrolytic deamination and
oxidation reactions, exogenous agents interact in various ways with DNA, and may introduce
more severe types of DNA lesions such as double strand breaks (DSBs). Interestingly, the
genotoxic effect of these substances often make these chemical agents useful in anti-cancer
treatment. Here, I will briefly present the most common sources of exogenous damage,
mention the utility of certain substances in context of cancer therapy, and point out the DNA
repair mechanisms which help to restore induced DNA lesions.
Polycyclic aromatic hydrocarbons present in tobacco smoke turn into potent carcino-
gens after passing the liver
PAHs are widely distributed carcinogens found in tobacco smoke, car exhaust fumes, or
charred food. Their structure usually contains two or more aromatic rings and are known
to be generally inert (Baird et al., 2005; Boffetta et al., 1997; Boström et al., 2002; Kew,
2013). However, as soon as PAHs reach the liver, the P-450 system converts these molecules
to reactive intermediates, capable of binding to DNA to create bulky adducts, which interfere
with transcription or replication (Xue and Warshawsky, 2005). Prominent examples of
PAHs include benzo(a)-pyrene, present in tobacco smoke, and aflatoxins which is a food
contaminant (Boström et al., 2002).
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Alkylating agents cause base modifications or DNA crosslinks
Another class of chemical species that may cause DNA damage are alkylating agents,
which may origin from physiological processes such as DNA methylation (De Bont and
Van Larebeke, 2004), but also happen to be anticancer treatment. In context of DNA damage,
alkylating agents may be subdivided into mono and bifunctional agents, depending on
the number of bonds they can form to nucleobases. Monofunctional methylating agents
predominantly target nitrogen atoms (80 %), and only sometimes the oxygen atom of
nucleobases. Cells repair adducts formed at N-atomes with the help of base-excision repair
(BER) (Sec. 1.4.2), nucleotide-excision repair (NER) (Sec. 1.4.2) and alpha-ketoglutarate-
dependent dioxygenase (AlkB) homologues. In contrast, bifunctional alkylating agents
induce more complex and potentially deleterious inter-strand cross-links which require NER
to be resolved.
For example, the highly mutagenic O6-methylguanine (O6-meG) mispairs T instead of a
C, which may lead to G to A transitions (Fig. 1.4e). For this reason, cells have dedicated a
single protein O6-methylguanine-DNA methyltransferase (MGMT) (Sec. 1.4.1), whose sole
purpose is to detect and remove O6-meG from the genome (Kondo et al., 2010).
Base analogs mimic the structure of nucleotides allowing them to be incorporated into
DNA by DNA polymerases or to interfere with nucleotide metabolism
Base analogs are derivatives of nucleobases with high structural similarity. This makes them
useful in cancer therapy, as tumour cells have elevated rates of nucleotide turnover due to
their propensity to divide faster in comparison to normal cells. This may lead, for example,
to an intolerable accumulation of base analog-induced mutations in DNA, or to the inhibition
of enzymes involved in the biogenesis of nucleotides (Tsesmetzis et al., 2018).
Prominent examples for base analogs include 5-bromouracil, which stabilises its enol
rather than its keto form, enabling the uracil derivative to basepair with G instead of an A (Fig.
1.4f, Kaufman (1984)). 6-mercaptotpurine inhibits purine nucleotide synthesis and is used to
fight acute leukemia (Karran and Attard, 2008). Finally, 5-fluorouracil is a thymine analogue
which inhibits the biosynthesis of T, which is especially deleterious for fast dividing cells as
the lack of dNTPs brings replication to a standstill (Miura et al., 2010).
Intercalating agents cause the formation of deletions or insertions
Intercalators are typically large and planar ring-shaped molecules, which do not damage
DNA by breaking bonds or modifying bases, but harm the double helix by fitting in between
adjacent base pairs. To incorporate intercalating agents, DNA must be partially unwounded to
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open space between its bases. These conditions are met during replication where intercalators
may cause deletions or insertions dependent on whether they sneak into the nascent or
template strand DNA, respectively (Fig. 1.4g, Ferguson and Denny (2007); Wakelin (1986)).
Moreover, intercalating agents may induce rearrangement events by interfering with the
action of topoisomerases trying to unwind supercoiled DNA (Nitiss, 2009).
Intercalating agents such as etidium bromide, acridine orange or proflavin are used as
nucleic acids stains, because their aromatic rings make them good chromophores. Some
intercalators are used in chemotherapeutic treatment to slow down DNA replication in cancers
such as Hodgkins’ lymphoma (Mišković et al., 2013).
Ionising radiation causes double strand breaks and bulky DNA adducts
Ionising radiation is emission in form of traveling particles (neutrons, ↵ or  -particles), or
electromagnetic waves (higher ultraviolet (UV) spectrum,   or X-rays) with sufficient energy
to detach electrons from atoms or molecules (Borrego-Soto et al., 2015). In this way, ionising
radiation may destabilise DNA directly by altering or breaking the structure of the double
helix, or indirectly by turning inert molecules to reactive species such as ROS (Sec. 1.3.1)
(Lomax et al., 2013).
Exposure to sunlight causes the formation of so-called UV-products at genomic sites
where two pyrimidines are adjacent to each other. Mechanistically, UV-light triggers a
”ring-opening” event allowing the double-bonds present in neighbouring pyrimidines to
form covalent bonds with the residue right next to it (Fig. 1.4h). It is estimated that up
to 50-100 mutagenic reactions per second occur in a single skin cell during UV exposure.
Two common UV-light induced lesions are cyclobutan pyrimidine dimers (CPDs), mostly
involving two thymidines, and 6-4 photoproducts (6-4PPs) which arise at sites where Cs
and Ts are next to each other (Ikehata and Ono, 2011). Since both lesion types may cause
replicative polymerases to stall and induce error-prone translesion synthesis, cells employ
NER (Sec. 1.4.2) to fix such lesions before the next round of replication.
X- and  -rays introduce DSB by directly breaking bonds in the DNA sugar-phosphate
backbone (Fig. 1.4i), or indirectly by facilitating the formation of reactive oxygen species.
Both X and  -rays are used in low dosages for medical imaging purposes and in cancer
radiotherapy (Little, 1993; Lomax et al., 2013).
1.4 DNA repair mechanisms
Cells evolved mechanisms capable of monitoring DNA, recognising damage and inducing
an appropriate repair response to protect themselves against DNA damages. In this section,
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I will outline the most important DNA damage repair pathways, including direct reversal
DNA repair (Sec. 1.4.1), excision repair (Sec. 1.4.2), mismatch repair (MMR, Sec. 1.4.3),
translesion synthesis (Sec. 1.4.4) and repair mechanisms to handle DSBs (Sec. 1.4.5).
1.4.1 Direct reversal DNA repair
Perhaps the simplest, but also the most specific form of DNA repair is direct reversal DNA
repair. These repair mechanisms rely on a single enzyme, detecting and directly repairing
specific types of lesions.
The most prominent example for this type of DNA repair is MGMT, which removes
inappropriately placed methyl groups from the oxygen at the sixth position of guanine (O6-
meG, see also Sec. 1.3.2 and Fig. 1.4e). MGMT does not act as a true enzyme, because the
protein can only complete the process once, which highlights the importance of clearing this
lesion from the genome (Yarosh, 1985). Another example is photolyase, which completes
direct reversal repair of UV-induced thymine dimers (Sec. 1.3.2, Fig. 1.4h). Note that human
cells, as opposed to bacteria, fungi and some animals, do not express photolyase, but rather
rely on NER (Sec. 1.4.2) to fix UV induced alterations (Li et al., 1993).
1.4.2 Excision repair
In contrast to direct reversal DNA repair, excision repair mechanisms are more versatile
regarding the types of DNA lesion they recognise and repair. This makes them mechanistically
more complicated, although the two main types of excision repair, BER and NER, can be
conceptualised into three main phases: recognition, excision and repair. BER tends to
repair endogenous DNA damages resulting from sources such as reactive oxygen species
or depurination events. These alterations have in common that they do not cause large
distortions to the DNA double helix. In contrast, NER focuses on helix distorting DNA
modifications which are often due to exogenous genotoxins. Examples for such alterations
are UV-induced pyrimidine dimers and bulky base adducts created by mutagens like aflatoxin
B1 or polycyclic hydrocarbons.
Base excision repair
BER is initiated by DNA glycosylases, which recognise and remove a range of base mod-
ifications by cleaving off the glycosidic bond connecting the aberrant base to the DNA
backbone. For example, DNA uracil glycosylase recognises Us that are usually not present
in DNA, but may arise due to spontaneous deamination of cytosines (Sec. 1.3.1, Fig. 1.4a).
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AP (apurinic/apyrimidinic) endonucleases subsequently cut the phosphodiester bond 5’ to
AP-sites that were left behind by DNA glycosylases. This nick serves as the substrate for
weakly processive 5’ to 3’ exonucleases, which remove the AP phosphodiester backbone
and roughly up to 3 bases. DNA polymerase   (Pol  ) fills the single stranded gap in the
DNA with complementary nucleotides, and DNA ligase restores the molecule by forming
a phosphodiester bond between adjacent nucleotides (Braithwaite et al., 2005; Weinberg,
2006).
Nucleotide excision repair
There are two activation pathways which trigger DNA damage repair by NER in a genome
location dependent manner. While global genome NER (GG-NER) surveils the entire genome
including coding and non-coding regions, a second mechanism termed transcription coupled
NER (TC-NER) provides additional protection for transcribed regions and is triggered by
stalling of RNA Pol II (Schärer, 2013).
A multitude of different proteins including XPC+DDBI/XPE are involved in initiating
GG-NER in eukaryotes. This protein complex binds to the strand opposite of the lesion,
mediates DNA opening by recruiting TFIIH (Lee et al., 2014), and attracts various other
factors such as RPA or XPA. Eukaryotes employ two distinct endonucleases to excise a 24-32
bp long stretch of ssDNA including the lesion. XPA recruits ERCC1-XPF to make the first
incision on the 5’ side of the bubble, while XPG mediates the second cut on the respective
3’ side (Fagbemi et al., 2011). The excised oligonucleotide is subsequently removed by
DNA helicase activity of TFIIH. In the final step of NER, replicative Pol " or Pol   fill the
excised gap (Lehmann, 2011; Ogi et al., 2010), and DNA ligases seal the nick between newly
synthesised and adjacent nucleotides (Petruseva et al., 2014).
TC-NER couples NER to transcriptional activity (Sec. 1.2.2). In TC-NER, stalling of
RNA Pol II triggers recognition of a DNA lesion, and recruits transcription coupled repair
factor (TCRF), which uses ATP hydrolysis to displace RNA Pol II and subsequently recruits
NER proteins (Schärer, 2013).
1.4.3 Mismatch repair
Like excision repair mechanisms, MMR follows the theme of orchestrating different proteins
to conduct a three step process involving recognition of DNA damage, excision and subse-
quent repair. However, one challenge MMR has to overcome is to choose the parental strand
before excising the mis-incorporated base. This is difficult, because in contrast to other DNA
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assaults which come along with structural distortions, mismatch errors fail to display any
obvious lesion marks (Heller and Marians, 2006; Pluciennik et al., 2010).
Mismatch recognition by MutS In eukaryotes, DNA damage recognition is mediated by
Mutator S protein (MutS), which is a heterodimer composed of the subunits MutS homolog
2 (Msh2) and MutS homolog 6 (Msh6). MutS:ADP surveils the entire genome by scanning
roughly 700 base pairs in a non-directional and energy independent manner. In ADP bound
form, MutS temporarily binds to DNA with a half-life ⇠1 s after which it will fall off. To
detect mismatches and smaller indels, MutS encircles double stranded DNA while slightly
bending the molecule. It is thought that mismatches and smaller indels allow the double helix
to be bend more easily in comparison to intact DNA that tries to stay planar. Upon damage
recognition, MutS:ADP exchanges ADP for ATP, which results in a conformational change
allowing the protein to form a more stable complex with the selected DNA, thus marking a
mismatch site (Fishel and Lee, 2016; Hsieh and Yamane, 2008).
Nick-directed nascent strand detection The next step of MMR deals with excising the
wrongly inserted base in the newly synthesised DNA strand. A small number of bacterial
species, including E. coli recognise nascent DNA by the temporal lack of DNA methylation.
However, in most bacterial and eukaryotic cells, the newly synthesised DNA is identified by
the presence of nicks (e.g. at Okazaki fragments) which facilitate sliding clamp loading. The
orientation of proliferating cell nuclear antigen (PCNA) guides MMR endonucleases to cut
the newly synthesised strand (Flores-Rozas et al., 2000; Iyer et al., 2008; Pluciennik et al.,
2010).
Mismatch bound MutS:ATP recruits and activates Mutator L protein (MutL) by trigger-
ing its ATPase domain that hydrolyses bound ATP to ADP. Unlike the ATP-bound form,
MutL:ADP exhibits an unspecific endonuclease activity. MutL and MutS then bind to PCNA
which instructs MutL to cut newly synthesised DNA randomly close to the lesion. Quickly
after MutL placed the cut, its bound ADP is exchanged with ATP thereby inactivating the
enzyme (Kadyrov et al., 2006).
Nick-directed strand repair To remove the DNA containing the misincorporated base,
the 5’ to 3’ exonuclease ExoI removes all DNA between the closest nick and the cut site of
MutL. It is not very well understood how ExoI is recruited to these sites since the closest nick
might often be not proximal to the mismatch site. However, as soon the strand is removed, it
can readily be resynthesised by Pol   and PCNA (Iyer et al., 2006).
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1.4.4 Translesion synthesis
Replicative DNA polymerases easily stall at sites where they encounter corrupted bases in
the template (Sec. 1.2.3). At this point, it is too late to excise the DNA damage, because this
would lead to a break in the unwound DNA, and eventually cause a replication fork collapse
with deleterious consequences. To ensure survival, cells employ translesion polymerases,
which replicate through the damage by “guessing” what base to insert opposite to an aberrant
base, thus having error rates up to 1 mis-incorporated base per 100 bases replicated (Knobel
and Marti, 2011; McCulloch and Kunkel, 2008).
A commonality amongst translesion polymerases is the lack of a 3’ to 5’ exonuclease
activity and a less restrictive active site capable of accommodating damaged DNA, e.g. due
to the lack of an O-helix (Sec. 1.2.3, Knobel and Marti (2011)). Although many translesion
polymerases are interchangeable, they replicate over different types of lesions with different
efficiencies, and hence there are at least nine distinct translesion polymerases in mammalian
cells (Knobel and Marti, 2011). Some polymerases are specialised to fill bases opposite to
AP-sites, while others extend nascent DNA opposite to bulky DNA adducts. For example,
pyrimidine dimers are preferably recognised by DNA polymerase ⌘ (Pol ⌘), which by default
places two As opposite to such lesions (Hendel et al., 2008; McCulloch et al., 2004; Takata
et al., 2006). DNA polymerase  (Pol ) synthesises past 8-oxo-dG and tends to incorporate
As more often than Cs (Irimia et al., 2009; Weinberg, 2006).
Polymerase switching
Stalled replication forks initiate translesion synthesis by switching PCNA bound Pol " or Pol
  with a translesion polymerase. In comparison to replicative DNA polymerases, error-prone
polymerases are less processive, causing them to fall off the sliding clamp shortly after
synthesising across the lesion (Lovett, 2007).
1.4.5 Double strand break repair
Double strand break repair (DSBR) is essential, as DSBs are the most toxic form of DNA
damage. The two major pathways for DSBR are non-homologous end joining (NHEJ) and
recombinational repair (RR). Under normal circumstances, cells deal with most of the double
strand breaks by employing the classical NHEJ pathway or RR. The choice between NHEJ
and recombinational repair depends on the cell cycle phase of the cell. While NHEJ usually
repairs most of the DSBs at any point in the cell cycle phase, RR takes over during S-phase,
when the homologous DNA of the newly replicated chromosome is available (Scully et al.,
2019).
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Non-homologous end joining
Conceptually, the easiest way to fix a DSB is to directly concatenate both broken ends
back together. To accomplish this, eukaryotic cells have two NHEJ pathways with different
degrees of fidelity at their disposal.
Classical NHEJ Classical NHEJ is initiated by the heterodimeric surveillance protein Ku
70-90, which monitors DNA for DSBs and binds to double stranded ends (Britton et al.,
2013). From there it recruits DNA protein kinases helping to keep both DSB ends together
(Gottlieb and Jackson, 1993). DNA protein kinases also recruit and activate Artemis, a
nuclease that processes the DNA ends. In the final step of classical NHEJ, DNA ligases seal
the DNA (Ahnesorg et al., 2006; Nick McElhinny et al., 2000). Artemis activity in classical
NHEJ may leave small scars on the sequence by adding or removing a few nucleotides (Xie
et al., 2009). Although this may be harmful in protein coding parts of the genome, it has
little impact in non-coding regions. For this reason, the classical pathway is considered to be
high-fidelity (Fig. 1.5a, Scully et al. (2019)).
Alternative/Error prone NHEJ In contrast, alternative NHEJ is a low fidelity DNA repair
mechanism which is often associated with chromosome translocation or loss. Cells employ
this pathway in a final attempt to fix DSBs, for example when components of the classical
pathway are missing or their recruitment is delayed (Scully et al., 2019).
PARP1 initiates alternative NHEJ by binding to the broken DNA ends and recruiting
several repair proteins to polish bound DSB ends. However, rather than simply stitching the
broken DNA ends back together, alternative NHEJ relies on microhomolgy, i.e. that the ends
of concatenated DNA strings embed sequences that base pair to each other. This may pull
together DNA ends from different chromosomal locations, which often breaks the integrity
of large genomic segments (Fig. 1.5b, Lieber (2008)).
Recombinational repair
In comparison to NHEJ, RR is a complex process to resolve DSBs which subsumes multiple
subpathways, each with specific enzymatic requirements. However, RR can be subdivided
into three steps: presynapsis including DSB formation and DNA strand resection, synapsis
encompassing strand invasion, and postsynapsis which can be further split into three differ-
ent modes of homologous recombination (HR): break induced annealing (BIR), synthesis-
dependent strand annealing (SDSA), and HR resolution via double Holliday junction (dHJ).

























Fig. 1.5 DNA double strand repair via NHEJ and recombinational repair. a. Classical
NHEJ recognises DSBs with Ku70-80 proteins, fixes broken ends with DNA protein kinases
and Artemis and ligates broken ends with DNA ligases. b. Alternative NHEJ uses PARP1
and a few repair and trimming proteins to prepare DNA ends, potentially from different
chromosomes, and joins them subsequently by forming a region of microhomology. c.
Recombinational repair involves three major steps: presynapsis, synapsis and postsynapsis.
chromosome from either paternal or maternal origin, thus contributing possibly different
alleles to the genomic region to be repaired (Heyer et al., 2010).
Presynapsis The first step in presynapsis is to resect the DNA at both sides of a DSB with a
5’ to 3’ exonuclease (MRN complex in humans), which results in long and single stranded 3’
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overhangs. RPA’s high affinity for ssDNA quickly attracts the protein to resected overhangs,
eliminating secondary structures in ssDNA, and enabling RAD51 filament formation, which
catalyses homology search and DNA strand invasion (Mimitou and Symington, 2009).
However, RPA binding to ssDNA also displays a kinetic barrier, thus making so-called
mediator proteins mandatory to ensure RAD51 assembly, amongst them BRCA2, the human
breast and ovarian tumor suppressor protein (Fig. 1.5c, Heyer et al. (2010); Yang et al.
(2005)).
Synapsis During synapsis, the RAD51 coated single stranded 3’ overhang aligns to the
homologous DNA of its sister chromatid, where the intermediate invades its complementary
DNA to form Watson-Crick base pairs, thus displacing the originally aligned DNA strand to
form a so-called D-loop (Fig. 1.5c, Heyer et al. (2010)).
Postsynapsis In postsynapsis, HR can progress in three different ways. In BIR the D-loop
may be converted to a fully working replication fork if the other end of the DSB is missing.
Although this pathway recovers the lost chromosome completely, BIR results in loss-of-
heterozygosity since all alleles distal to the DSB are lost (Heyer et al., 2010). In SDSA
the extended D-loop re-anneals to the other resected end of its original chromosome, thus
avoiding crossovers and genomic rearrangements (Heyer et al., 2010; Pâques and Haber,
1999). Finally, via dHJ formation, which is rather rarely used in RR of somatic cells and
was originally discovered in meiotic recombination. Here, directly after D-loop formation,
the displaced DNA strand from the intact chromatid instead basepairs with the 3’ overhang
from the other side of the DSB. In this configuration, the 3’ overhangs are elongated by DNA
polymerases which use the DNA strands of the intact chromosome as a template to refill
the depleted DNA. In the next stage, the branches migrate, thereby giving rise to the dHJ
structure. Finally, the double Holliday junction is resolved by cleaving the DNA, which
yields different recombinant products (patched or crossover) dependent on how the DNA
was cut (Fig. 1.5c, Bzymek et al. (2010)).
1.5 Mutagenesis
The previous sections set the framework for the upcoming discussion on mutagenesis in
genomic context. Mutagenesis results from a combination of DNA damage and failed or
error prone attempts of DNA repair, and results in lasting mutations which may be detected
in sequencing experiments as SNVs, multi-nucleotide variants (MNVs), indels or structural
variants (SVs). Importantly, sequencing studies revealed that mutation rates vary across
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the human genome. In fact, mutagenesis is affected by various factors ranging from DNA
organisation to epigenetics, and fundamental cellular processes such as transcription and
replication.
1.5.1 DNA organisation affects mutagenesis
The nucleosomal organisation of DNA protects the molecule against spontaneous mutations,
helps to regulate oncogenic genomic regions, and affects intra nucleosomal mutation rates.
Nucleosomal packaging surpresses spontaneous hydrolytic deamination of cytosines
Nucleosomal-bound DNA undergoes fewer C>T mutations, because of suppressed hydrolytic
deamination of cytosines (Sec. 1.3.1), and exhibits lowered rates of G>T and A>T mutations
relative to nucleosome-depleted DNA (Chen et al., 2012). These effects are reflected by
fewer SNVs at highly positioned nucleosomes (Schuster-Böckler and Lehner, 2012).
Aberrant expression of H1 linker histones leads to the expression of transcriptional
programs that favour cencer cell renewal
Linker histone induced higher order DNA structures protect the integrity of the genome, as it
has been shown that aberrant expression of H1 has links to cancer. Particularly, absence of
the H1 histone leads to decreased nucleosomal DNA interactions in AT-rich genomic regions,
which is coupled to the derepression of close genes, resulting in expression of transcriptional
programs that support cancer cell renewal (Torres et al., 2016).
The mode of nucleosomal DNA-binding affects mutagenesis
Pich et al. (2018) found that tumours like oesophageal adenocarcinomas, gastric cancers
and malignant lymphomas show a relative increase of mutation rates peaked at minor
grooves facing towards histones (AT-rich), while cancers like skin melanoma and lung
adenocarcinoma show the opposite pattern, with maxima of mutation rates in the minor
groove facing away from the nucleosome (GC-rich, Fig. 1.1). The analysis of mutation
types found at nucleosome-bound minor grooves revealed that mutation enrichment in
aforementioned cancers could be linked to mutation types that are characteristic for the
respective tumour. For example, oesophageal cancers exhibit elevated rates of T>C mutations
in minor grooves facing towards nucleosomes, while C>A and C>T base substitutions,
characteristic for lung cancers and skin melanomas, tend to occur with an unexpected high
rate at minor grooves facing away from the histone octamer.
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1.5.2 Epigenetic modulation affects mutagenesis
Epigenetic states enable cells to modulate genomic activity flexibly, and are yet persistent
through multiple cell divisions. For this reason, epigenetic states have a great influence on
mutagenesis, for example, by providing cancers the means to modify cellular properties by
gaining epigenetic control of the genome to express oncogenic traits.
Histone marks correlate with mutation rates
Schuster-Böckler and Lehner (2012) showed that histone marks and other genomic features
are highly correlated with local SNV densities. Marks associated with active chromatin, par-
ticularly H3K4me3 and H3K9ac, anti-correlate with mutation rate densities, while repressive
chromatin due to H3K9me3, H3K9me2 and H4K20me3 correlate positively with base substi-
tution rates. They also revealed that a combination of genomic features may even explain
up to 60 % of the variance in cancer mutation rates, indicating interdependencies among
different chromosome features (Schuster-Böckler and Lehner, 2012). Additionally, Polak
et al. (2015) showed that chromatin states accounting for the cell type of the corresponding
cancer, as well as replication timing, explain even up to 86 % of the variance in mutation
rates across human genomes.
Mutagenesis and DNA methylation
DNA methylation may influence mutagenesis in cancer genomes in various ways. On the
one hand, 5-meC undergoes spontaneous deamination at higher rates than its unmethylated
counterpart, which inevitably leads to C>T substitutions if MMR fails to repair the resulting
mismatch (Sec. 1.3.1). On the other hand, aberrant DNA methylation may influence
mutagenesis indirectly by silencing tumour suppressive genes such as the MLH1 gene
involved in MMR, thus increasing mutation rates by several orders of magnitude in MMR-
deficient cells5. Moreover, severe hypomethylation seems to be associated with genomic
instability, as DNA methyltransferase deficiency in mouse models display higher frequencies
of structural mutability (De and Michor, 2011; Li et al., 2012), and germline mutations in the
DNA methyltransferase DNM3B gene cause the ICF syndrome, characterised by centromeric
instability (Okano et al., 1999).
5Epigenetic silencing of DNA repair is not limited to MLH1, but has also been reported for several other
genes including MGMT, BRCA1, WRN, FANCF and CHFR (Toyota and Suzuki, 2010).
32 Introduction
1.5.3 Mutagenesis in context of transcription
Actively transcribed genes and associated regulatory regions are especially important to cells
as disruptive mutations in coding regions may have deleterious consequences. For this reason,
transcription encourages the activity of DNA repair mechanisms such NER and MMR.
DNase I hypersensitivity assays reveal hypo-mutated promotor regions
Open chromatin regulatory regions, including promotors, enhancers and insulators, have
been extensively mapped in diverse organisms using DNase I hypersensitivity seq assays
(Thurman et al., 2012), and been associated with reduced local densities of somatic mutations
in a range of cancer genomes. The reduction of SNV frequencies in DNase I hypersensitive
sites (DHSs) compared to the genome average could not be attributed to confounding factors
such as differences between intergenic regions and genes, the distance to TSS, replication
timing, GC content or distances to telomeres or centromers, which suggested excision repair
mechanisms as the most likely explanation for the local mutation rate reduction (Polak et al.,
2014). Moreover, the accessibility of DHSs encourages the activity of DNA repair pathways
such as NER or BER, as both mechanisms have been reported to prefer free DNA over
nucleosomal bound DNA (Amouroux et al., 2010; Bell et al., 2011). The analysis of four
NER deficient melanoma samples revealed increased mutation rates at DHSs, thus supporting
the theory that GG-NER is responsible for the hypomutation phenomenon at gene regulatory
regions (Polak et al., 2014).
RNA Pol II and transcription factor binding increases local mutation rates within pro-
motors
Interestingly, binding of TF to transcription factor binding sites (TFBSs) leads to 5⇥ larger
mutation rates at TFBS in comparison to neighbouring flanking DNA in skin melanoma,
thereby refining the hypomutation phenomenon observed in DNAase hypersensitive genomic
regions. Local elevation in mutation rates do not affect inactive TFBS, is present at distal
TFBS (enhancers), and was also detected in a normal skin sample, indicating that mutagenesis
due to protein occupancy is a normal process, and not necessarily bound to the deregulated
environment of a cancer cell. Further investigations in UV-irradiated cell lines subjected to
XR-seq, which captures NER excised DNA fragments, revealed that elevated mutation rates
observed at active TFBS are caused by a decrease of local NER activity (Sabarinathan et al.,
2016).
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Transcription-coupled nucleotide excision repair induces asymmetric mutagenesis
Imbalances in the distribution of mutations on template and coding strand DNA are mostly
caused by TC-NER (Sec. 1.4.2), which repairs DNA damages at sites where RNA Pol
II stalls (Donahue et al., 1994; Hanawalt and Spivak, 2008). Also, transcription levels
anti correlate with mutation rates on template strand DNA, consistent with the notion that
increased rounds of transcription provide more opportunity to clear lesions (Chapman et al.,
2011; Lawrence et al., 2013; Pleasance et al., 2010a). Conversely, coding strand DNA may
be more susceptible to mutations as it remains single-stranded during transcription, and
lacks the surveillance of TC-NER (Jinks-Robertson and Bhagwat, 2014). Transcriptional
asymmetries are particularly noticeable in tumours with high exposure to exogenous agents
such as UV-radiation or smoking, but are also evident in liver cancers (Haradhvala et al.,
2016).
DNA mismatch repair decreases mutation rates in exons
Frigola et al. (2017) found fewer mutations in exonic genomic regions in seven tumour
types, and especially in genomes with mutations in the POLE gene. They also observed
the colocalisation of the histone modification H3K36me3 in exonic regions, which has been
implicated in the recruitment of MutS of the MMR pathway. For this reason, the authors
speculated that MMR is responsible for lowered mutation rates in exons, and verified this
hypothesis by assessing exonic mutation rates in microsatellite instability (MSI) tumours
lacking MMR, which indeed showed elevated SNV frequencies in exons.
1.5.4 Mutagenesis and DNA replication
Replicative DNA polymerases in conjunction with MMR suppress error rates to 1 mistake
per 1010 replicated base pairs (Kunkel and Bebenek, 2000). However, there are multiple
factors ranging from local nucleotide composition to defective DNA polymerases that may
cause substantial variation in mutation rates due to replication.
Repetitive DNA sequences are prone to replication errors
Eukaryotic genomes harbour a great abundance of repetitive DNA elements, termed mi-
crosatellite sequences, which tend to favour mispairing during replication. This results
in higher mutation rates at microsatellites in comparison to genomic regions with a more
complex sequence composition (Jeffreys et al., 1988).
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Mutations in the exonuclease domain of DNA polymerase epsilon increase mutation
rates significantly
Mutations in the POLEexo domain may have dramatic effects on genomes and cause a
so-called hypermutator phenotype. The most frequent mutations are P286R (P=proline,
R=arginine), possibly leading to polymerase hyperactivity and increased tolerance to mis-
matches due to a decreased affinity of the exonuclease domain to ssDNA, and V411L
(V=valine, L=lysine) which functional implications are spurious, as this residue lies far away
from the active site and does not directly interact with DNA (Parkash et al., 2019; Xing et al.,
2019).
Some mutational processes introduce mutations with replicational asymmetries
Imbalances in the distribution of mutations on leading and lagging strand DNA may result
from differential processing of both parental strands by distinct enzymes, or due to the
extended time frame lagging strand DNA has to endure in vulnerable ssDNA form. Harad-
hvala et al. (2016) found replicational asymmetries in tumours with POLE mutations, MSI
and APOBEC associated tumours. Replicational asymmetries in these tumours were most
pronounced in early-replicating regions, and strand-specific mutation rates flipped sign at
replication timing minima (i.e. ORIs).
Replication timing affects mutagenesis
Studies investigating the association of replication timing with the evolutionary divergence
and SNP densities in human populations found that late replicating regions accumulated
more substitutions over the course of evolution (Chen et al., 2010; Stamatoyannopoulos
et al., 2009; Wolfe et al., 1989). The analysis of high-resolution maps of human replication
timing programs underpinned these findings by revealing strong correlations between base
substitution rates and replication timing, and additionally found that structural variation tends
to accumulate in early replicating regions (Koren et al., 2012). Supek and Lehner (2015)
identified variable MMR as the basis for the changes of base substitution rates in early and
late replicating regions by analysing mutation rates at megabase scale. This analysis revealed
that mutation rates are largely stable across cancer types and replication timing states, but
start to deviate in samples with inactivated MMR, in which late replicating regions are no
longer enriched in mutations.
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Inclusion of ribonucleotides during DNA replication
Ribonucleotides exhibit high structural similarity to dNTPs, as they only differ by a single
hydroxyl group on the 2’ carbon of their sugar component. Failure of DNA polymerases
to accurately discriminate between both compounds often leads to the mis-incorporation
of ribonucleotide triphosphates (rNTPs), which is not limited to, but most often due to
much greater nuclear levels of rNTPs relative to dNTPs (500-3000 µM vs. 12-30 µM).
While occasionally embedded ribonucleotide monophosphates (rNMPs) do not introduce
severe DNA distortions, their presence may impede progression of the replication machinery,
interfere with nucleosome assembly, or alter protein binding to DNA. For this reason, cells
remove incorrectly incorporated rNMPs via the proofreading function of DNA polymerases
and BER (Cerritelli and Crouch, 2016).
1.6 Mutational signature analysis
Although only a small number of mutations confer a selective advantage, i.e. represent
mutations that promote oncogenesis, the totality of mutations is characteristic for the sum of
the mutational processes that were acting in the cancerous cell. The recent advancement in
next-generation sequencing gives access to this information and hence there is a growing
interest to utilise this data to better understand the nature and genomic impact of various
mutational processes.
1.6.1 Mutational Signature Analysis
A particularly successful method pioneered by Alexandrov et al. (2013a) is mutational
signature analysis, which extracts common characteristic base substitution patterns from a set
of cancer genomes. Several basic types of base changes (C>A, C>G, C>T, T>A, T>C, and
T>G6) were long known to be characteristic for certain tumour types. For example, UV-light
induced pyrimidine dimers often manifest as C:G to T:A (C>T) mutations in skin melanoma,
whereas lung cancers suffer from high loads of G:C to T:A (C>A) substitutions due to the
carcinogens present in tobacco smoke. Since the formation of base substitutions is strongly
affected by the immediate sequence context, it is sensible to incorporate the flanking 5’ and
3’ base to the classification, which gives rise to a 96 trinucleotide classification (4⇥ 6 ⇥ 4).
In mutational signature analysis, the count of each trinucleotide mutation type and sample
is expressed in form of a matrix and then subjected to NMF, a mathematical procedure
6To avoid ambiguity due to the symmetry of nucleobases, mutations are always specified with respect to the
involved pyrimidine.
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which extracts a set of prototypical mutation patterns that are common to a large fraction of
cancer genomes, and their respective mutation loads in each of the samples. Mathematically,
this corresponds to a matrix factorisation, in which a catalogue of cancer genomes C is
decomposed into a set of mutational signatures S and their constituent activities or exposures
E
E [C] = S⇥E where C 2 Np⇥n0 ,S 2 R
p⇥s
+ ,and E 2 Rs⇥n+ (1.1)
where p is the number of mutation types (usually p = 96), n the number of cancer
genomes and s the number of mutational signatures.
1.6.2 Characterised mutational signatures
One reason for the great success of mutational signature analysis is the high interpretability
of identified signatures. The following section reviews the most important SBS signatures of
the Catalogue of Somatic Mutations in Cancer (COSMIC) catalogue.
SBS1 reflects a deamination signature with clock-like properties
One of the most pervasive phenomena in eukaryotic genomes, the deamination of 5-meC (see
Sec. 1.3.1), is captured by COSMIC SBS signature 1, which depicts a highly characteristic
N[C>T]G pattern indicative for C:G to T:A transitions at NpCpG (Alexandrov et al., 2013b).
SBS1 has been reported in at least 25 different cancer types and has clock-like properties,
i.e. the mutation load due to SBS1 is proportional to the age of the patient, indicating that
deamination of 5-meC is independent from cancer driving oncogenic alterations or certain
exogenous mutagenic sources, but rather adds constantly a certain number of mutations
per year (Alexandrov et al., 2015). Interestingly, SBS1 mutation rates differ in cancers, as
epithelial tissues with high turnover exhibit largest rates, making SBS1 mutations indicative
for a “molecular clock” that registers the number of mitoses cells experienced, as replication
with failure of MMR is required to manifest the mutational pattern (Alexandrov et al., 2015).
APOBEC mutagenesis (SBS2 and SBS13)
Another mutational process related to the deamination of cytosines is enzymatically catalysed
by members of the APOBEC enzyme family, whose physiological responsibilities include
the restriction of retroviridae and mobile retroelements. APOBEC enzymes recognise ssDNA
and mutate cytosines in TpC sequence context, with strong preference for A or T 3’ flanking
bases, leading to the characteristic T[C>K]W (W=A/T, and K=G/T) pattern of SBS2/13
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(Taylor et al., 2013). This mutational process was first characterised in breast cancers (Nik-
Zainal et al., 2012), but was also found in 16 other cancer types (Alexandrov et al., 2013a). It
was shown that T[C>K]W mutations exhibit a high degree of strand coordination, indicative
for APOBEC mutagenesis on lagging strand DNA during replication. Another property of
APOBEC mutagenesis is the tendency to generate highly clustered mutations, a phenomenon
termed kataegis7, which often colocalises with rearrangement breakpoints, suggesting that
the enzyme readily processes ssDNA at the sites of DSB.
The analysis of the higher order nucleotide context of APOBEC characteristic base substi-
tutions revealed a prevalent YT[C>K]A motif, indicative for the APOBEC3A isoform8 (Chan
et al., 2015). Consistent with APOBEC3A as the main contributor to mutagenesis, it was
found that individuals carrying at least one copy of an APOBEC3B deletion polymorphism
have a 2.37-fold increased relative risk for cancers with large contributions of SBS2/13
(Nik-Zainal et al., 2014). Finally, although SBS2 and SBS13 are most likely due to DNA
damage by APOBEC, the representation in two signatures with predominant contribution of
C>T and C>G mutations respectively, may be caused by differences in the involvement of
DNA repair mechanisms and translesion polymerases.
SBS3 is associated with homologous recombination deficiency
SBS3 exhibits an almost equal representation of all 96 mutation types, and is strongly
associated with BRCA1 and BRCA2 mutations, which play important roles in the mediation
of HR (Sec. 1.4.5). However, SBS3 may also contribute substantial amounts of mutations in
samples which do not exhibit any deficiencies in the aforementioned genes, indicating that
other mechanisms independent from BRCA1/2 may generate it (Alexandrov et al., 2013b).
Particularly, germline nonsense and frameshift mutations in PALB2, which binds and localises
BRCA2 to the nucleus, and silencing of RAD51C and BRCA1 via promotor methylation
were shown to induce SBS3 mutations as well (Polak et al., 2017).
Tobacco smoking manifests as genomic C>A mutations (SBS4)
SBS4 is characterised by C>A mutations and is most likely due to tobacco smoking. This
signature was initially discovered in lung adeno, squamous and small carcinomas, head and
neck, and liver cancers. The signature exhibits a transcriptional strand bias, indicating higher
mutation probabilities for C>A mutations on transcribed DNA, which is consistent with the
propensity of many tobacco carcinogens to form adducts with guanine (Alexandrov et al.,
7Kataegis is the greek word for thunderstorm (Nik-Zainal et al., 2012).
8As opposed to the APOBEC3B specific motif RT[C>K]A.
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2013b). Moreover, SBS4 shows strong similarities to the mutational spectrum observed in
cells exposed to polycyclic aromatic hydrocarbons (Alexandrov et al., 2016).
Deficiencies in the NER pathway may induce a flat mutational spectrum (SBS5)
SBS5 displays a relatively flat spectrum with a slight predominance of C>T and T>C
mutations. The signature has been proposed to be associated with tobacco carcinogens, but
was also found in cancers with no relation to tobacco consumption, thus making the concrete
aetiology of the signature unclear (Alexandrov et al., 2013b). SBS5 exhibits clock-like
properties in some cancers, thus contributing a constant rate of mutations, which range from
31.8 mutations/GB/year in papillary cell kidney caner to 2.8 in acute myeloid leukemias
(Alexandrov et al., 2015). Kim et al. (2016) proposed an association of SBS5 to NER (Sec.
1.4.2), because a signature enrichment analysis revealed an association to the ERCC2 gene,
which encodes a helicase that is needed to unwind DNA adjacent to a bulky DNA lesion.
Various mutational signatures indicate mismatch repair deficiency (SBS6/14/15/16/20/21/26/44)
A selection of mutational signatures are associated with the co-occurrence of small deletions
at nucleotide repeats. This phenomenon is known as microsatellite instability and is character-
istic for tumours with mismatch repair deficiency (MMRD) (Sec. 1.4.3). SBS6, for example,
is characterised by predominantly C>T at NpCpG, and its presence in colorectal cancers is
strongly associated with the inactivation of MMR genes. A very similar signature, SBS15,
with a greater prominence of C>T at GpCpN sites is found in lung and stomach cancers
(Alexandrov et al., 2013b). Moreover, Haradhvala et al. (2018) suggested the concurrent loss
of DNA polymerase proofreading proficiency and MMR as aetiology of SBS14 and SBS20.
UV-light induced mutational signatures (SBS7a/b/c/d)
SBS7 reflects mutagenesis due to UV-light, and was first described in malignant melanoma
with a strong transcriptional strand bias, consistent with the notion that UV-light induces
bulky adducts which are repaired with TC-NER (Alexandrov et al., 2013b). Hayward et al.
(2017) identified two signatures with high similarity to SBS7, thus suggesting a strong
link to UV-light exposure, possibly representing different photoproducts: SBS7a consists
predominantly of C>T at TCN, while SBS7b has larger contributions of C>T mutations
in CCN context. The latest update of the COSMIC catalogue of mutational signatures
introduced two novel UV-light signatures termed SBS7c and SBS7d. These signatures are
characterised by T>A at NTT and T>C at NTT mutations, respectively (Alexandrov et al.,
2020).
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Mutations in the exonuclease domain of the leading strand polymerase trigger SBS10
SBS10 produces large numbers of base substitutions in colorectal and uterine cancers, and
has been associated with mutations in the exonuclease domain of Pol " (Alexandrov et al.,
2013b). The latest instalment of the COSMIC catalogue splits this signature into two spectra
SBS10a and SBS10b, which resemble the spectral C>A and C>T parts of SBS10, respectively
(Alexandrov et al., 2020).
Mutational signatures associated with cancer treatments (SBS11 and SBS17a/b)
Temozolomide is an alkylating agent that is used to treat melanoma and tumours of the
central nervous system. The drug is quickly absorbed and converted to an active compound
that forms several DNA adducts, which are usually detected and cleared by BER or MGMT
(Poon et al., 2014). SBS11 displays a characteristic N[C>T]C pattern which is likely to
represent the effects of temozolomide treatment, as the signature was discovered in pretreated
malignant melanoma and glioblastoma multiforme (Alexandrov et al., 2013b).
Fluoropyrimidines are one of the most commonly used anticancer treatments of solid
cancers, which inhibit the growth of tumours by interfering with their nucleotide metabolism.
Christensen et al. (2019) identified fluorouracil (5-FU) treatment as the most likely cause for
the mutational pattern of SBS17, which is characterised by a striking peak of T>G mutations
in a CTT trinucleotide context. The latest version of the COSMIC catalogue tears apart the
T>C and T>G part of SBS17 into two signatures SBS17a and SBS17b (Alexandrov et al.,
2020).
Alcohol consumption may introduce characteristic T>C mutations at ApT dinucleotides
in liver cancers (SBS16)
SBS16 depicts a very characteristic T>C spectrum at ApT dinucleotides, was first discovered
in liver cancers, and exhibits a strong transcriptional strand bias indicative for all damage
occurring on adenines (Alexandrov et al., 2013b). Moreover, SBS16 is associated with
alcohol and tobacco consumption, and appears in liver cancers predominantly in highly
expressed genes, including CTNNB1 (Letouzé et al., 2017).
Mutational signatures due to chemical compounds (SBS22/24)
SBS22 is dominated by T>A mutations and is most likely due to the exposure to aristocholic
acid (Alexandrov et al., 2020), which is often the ingredient of traditional herbal remedies
for various health problems ranging from arthritis to menstrual symptoms. Like many other
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exogenous agents, the compound first needs to be metabolised, but can then form covalent
adducts with adenosines (Poon et al., 2014).
Aflatoxins are byproducts of mould growing on food, which are metabolised to epoxide
compounds that covalently bind to guanines, leading to G>T mutations (Poon et al., 2014). It
is thought that the C>A rich spectrum of SBS24 represents exposure to aflatoxins (Alexandrov
et al., 2020).
Defects in the base excision repair pathway introduce distinct C>T and C>A patterns
(SBS30 and SBS36)
SBS30 is dominated by C>T mutations and was first characterised in a single sample of
a breast cancer cohort (Nik-Zainal et al., 2016). Drost et al. (2017) were able to recover
SBS30 in CRISPR-Cas9 knocked out NHTL1 organoids, which are deficient in BER, as
the NTHL1 gene encodes a glycosylase (Sec. 1.4.2). Importantly, the authors were able to
verify a germline nonsense mutation in the NTHL1 gene in the sample where SBS30 was
first discovered.
SBS36 represents another mutational signature that is linked to BER deficiency. However,
SBS36 exhibits a spectrum dominated by C>A mutations and is linked to the inactivation of
the MUTYH gene. The MUTYH protein plays an important role in the removal of 8-oxo-dG,
as it scans newly synthesised DNA after replication and excises falsely incorporated adenines
at A:8-oxo-dG mispairs (Viel et al., 2017).
Signatures of somatic hypermutation (SBS9, 84, 85)
Several signatures have been reported to be associated with the activity of AID, which is
involved in the development of germinal B-cells. The enzyme deaminates cytosine to uracil
during somatic hypermutation such that dependent on the chosen DNA repair pathway,
different mutational patterns arise. Activation of the MMR pathway with recruitment of
Pol ⌘ gives rise to the non-canonical AID pattern characterised by A>C or A>G mutations
at WA motifs, and is represented by SBS9 (Alexandrov et al., 2013b). However, direct
replication over an U:G lesion, or removal of U via the BER pathway followed by replication,
induce the canonical AID signature characterised by a C>T or C>G mutations at WRCY
motifs. A signature matching this nucleotide motif was found by Kasar et al. (2015), who
extracted mutational signatures from clustered (and unclustered) single base substitutions.
The canonical AID signature is represented by SBS84 and SBS85 in the COSMIC catalogue
(Alexandrov et al., 2020).
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1.7 Aims of this thesis
The discussion of mutagenesis in context of epigenetic regulation and fundamental cellular
processes such as transcription and replication revealed a strong interplay between each of
the individual subprocesses. In fact, none of them occur in isolation, and to make things
even more complicated, they are often coupled to specific DNA repair mechanisms, such
as transcription to NER, and replication to MMR. Additionally, there exist a multitude of
different endogenous and exogenous mutagenic sources, each producing distinct mutational
patterns in different cell or tissue types, thus introducing another layer of complexity.
In this thesis, I provide solutions to outstanding tasks in the field of mutational signature
analysis. In particular, I aim to provide a novel framework to extract mutational signatures
that
1. takes into account genomic heterogeneity due to cellular processes such as transcription
and replication as well as the epigenome,
2. factors in the complete spectrum mutation types including MNV, indels, and structural
variants,
3. and introduces methodological improvements by performing the inference with a
robust noise model.
Chapter 2 shifts the focus to methodical aspects of mutational signature analysis. First, I
will introduce the reader to non-negative matrix factorisation, the method that is at the heart
of mutational signature analysis, and point out statistical considerations arising when NMF
is applied to mutation count data. Sec. 2.2 introduces the methodology - TensorSignatures - I
developed in the course of my PhD, assesses its properties, and compares the performance
of the algorithm to previous approaches. The last section of this chapter explores novel
approaches to deploy computationally intensive algorithms like TensorSignatures to cloud
computing platforms, thus making the usage of scientific research pipelines more efficient
and available to a broader community of users.
Chapter 3 showcases applications of TensorSignatures. In Sec. 3.1, I applied TensorSig-
natures to the PCAWG dataset which revealed the spectra and genomic properties of 20
tensor signatures. This analysis revealed two distinct mutational signatures of UV exposure
found in active and quiescent chromatin, and revealed transcription-associated mutagenesis
manifesting as A[T>C] mutations in a range of cancer types. TensorSignatures capability
to incorporate other mutation types enable the algorithm to distinguish two APOBEC sig-
natures reflecting highly clustered, double strand break repair initiated, and lowly clustered
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replication-driven mutagenesis. Lastly, I demonstrate two signatures indicative for somatic
hypermutation, producing a strongly clustered, TSS-associated signature in lymphoid cancers,
which is distinct from a weakly clustered TLS signature found in multiple tumour types. Sec.
3.2 verifies these finding in a completely independently sequenced cohort of the Hartwig
Medical Foundation (HMF), and Sec. 3.3 illustrates applications of TensorSignatures in a
variety of datasets.
Chapter 4 concludes my thesis with a summary of findings, and a review of potential
limitations of my research. Moreover, I will outline future perspectives and directions of
mutational signature analysis that could further expand the understanding of the interplay
between mutational processes and genomic features.
Chapter 2
Methods
The first chapter of this thesis introduced the genomic organisation of DNA, fundamental
biological processes such as replication and transcription, and how these factors influence
mutagenesis, as well as the great value of matrix-based mutational signature analysis as a
tool to characterise mutational patterns in cancer genomes. However, there are limitations
to this method, for example, it fails to account for the aforementioned genomic influences,
does not support the concomitant inclusion of mutation types other than single nucleotide
variants, and may be overly sensitive to statistical outliers. In this work, I addressed the
shortcomings of current mutational signature analysis approaches by developing a novel
non-negative tensor factorisation approach termed TensorSignatures. The key innovation
of this method lies in extending the definition of a matrix (a two-dimensional array) to a
tensor (a multi-dimensional array), which allows to categorise single nucleotide variants with
respect to a multitude of different genomic annotations. Moreover, the method supports the
incorporation of other mutation types, and employs a robust probabilistic model based on the
negative binomial distribution.
These features enable TensorSignatures to characterise mutational processes in greater
depth, for example, the method does not only yield signature spectra and corresponding
exposures, but also quantifies the degree of strand bias with regard to transcription or
replication, assesses the activity of signatures across distinct epigenetic regions, and reveals
a signature’s propensity to generate clustered mutations. Moreover, native inclusion of other
mutation types provides a more thorough understanding by revealing the full mutational
imprint of a mutational process, and imposing an appropriate statistical model enables
to select the appropriate number of signatures through validated estimators rather than
contentious heuristics. Finally, I implemented TensorSignatures using the modern machine
learning library TensorFlow, which enables GPU-accelerated inference of large amounts
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of data, thereby ensuring that the method is well-prepared for future applications when the
number of available cancer genomes markedly exceeds the ten thousands mark.
This chapter will be divided into four main themes. First, I will discuss some conceptual
limitations of non-negative matrix factorisation (NMF), the method underlying mutational
signature analysis, and point out the challenges of modelling count data. Also, I will show
how NMF models with general loss functions may be fitted using automatic differentiation
and gradient descent algorithms on machine learning platforms such as Tensorflow and
Pytorch (Sec. 2.1). Second, I will introduce in Sec. 2.2 the structure of the mutation count
tensor, and dive deep into the parametrisation of the TensorSignature model. Third, I will
assess the performance of the algorithm in simulation studies, and compare the inference to
other approaches that have been utilised previously (Sec. 2.3). The last section 2.4 of this
chapter explores possibilities to deploy research pipelines like TensorSignatures to cloud
computing platforms, and illustrates this by introducing the TensorSignaturesOnline web
application.
Contributions
This chapter is partly based on the bioarxiv manuscript “Learning Mutational Signatures and
their Genomic Properties with TensorSignatures” by Harald Vöhringer, Arne van Hoeck,
Edwin Cuppen and Moritz Gerstung. H.V. conducted all bioinformatic analyses and produced
the figures. A.v.H. and E.C. curated HMF data and provided computing resources for HMF
data analysis by H.V.. M.G. conceived and supervised the analysis and developed code for
categorising mutations. H.V. and M.G. wrote the manuscript with input from A.v.H. and E.C.
2.1 Properties and limitations of non-negative matrix fac-
torisation
Consider the NMF model (Eq. 1.1) used to decompose a catalogue of cancer genomes C into
a set of mutational signatures S and their constituent activities or exposures E, resulting in a
natural and interpretable part-based representation of the data. While NMF refers to a general
technique, most implementations minimise one of the following two objective functions over
S and E:




(Ci j  (SE)i j)2 (2.1)
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Fig. 2.1 Illustration of NMF solutions extracted from a simulated dataset generated
with 2-dimensional basis vectors. Left panel: Illustration of the data plane including
simulated data points, as well as the true and inferred basis vectors. Right panel: Addition
of a single outlier introduces significant bias to extracted NMF solutions (here we used the
standard sum of squared errors objective to compute depicted basis vectors).




(Ci j log(SE)i j  (SE)i j). (2.2)
To minimise these functions over S and E, NMF deploys “multiplicative update rules”
(Eq. 2.3), whose convergence may be proved using auxiliary functions (Lee and Seung,
2000).







Particularly, the algorithm initialises S and E with random non-negative values, and
minimises the objective function iteratively, by optimising the values of the first matrix E,
and using these updated values to calculate the next set of values in the second matrix S. This
process continues until the algorithm reaches a local minimum of the objective function.
2.1.1 The geometry of NMF solutions
NMF extracts a set of non-negative basis vectors forming a simplical cone, whose linear
combinations span the cloud of data points of the input matrix. To illustrate this, I simu-
lated 1,000 data points (green dots in Fig. 2.1) by computing random non-negative linear
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. Next, I applied NMF with different initial values to generate 50 solutions of
rank two (green rays in Fig. 2.1). Note how these rays surround the cloud of data points
implying that NMF solutions are based upon the set of points which make up the border of
the data cloud. It is important to keep that in mind when applying the algorithm, because it
indicates that outliers, i.e. data points deviating substantially from the data cloud, may affect
NMF solutions considerably. To illustrate this, I used the same simulated data set, but added
such an outlier (red point in Fig. 2.1). Applying NMF to this data yielded a substantially
different set of basis vectors (red rays in Fig. 2.1). This shows that the presence of just one
unusual data point may affect the solutions provided by NMF. For this reason, it seems to be
mandatory to use appropriate noise models for different types of input data.
2.1.2 The probabilistic interpretation of NMF
From a probabilistic point of view, minimising the sum of squared errors objective implies to
impose a Gaussian distribution to the count data in C
Ci j ⇠N ((SE)i j,s2). (2.4)
However, base substitution counts are clearly non-continuous and always   0. Applying
NMF to count data as outlined in Eq. 2.3, may yield improbable solutions since it applies
incorrect model assumptions. In context of count data, the divergence objective is more
appropriate, since the maximum likelihood interpretation of D(C||SE) implies
Ci j ⇠ Pois((SE)i j), where Pois(x|l ) =
l x
x!
e l , x 2 {0,1,2, . . .}. (2.5)
Although the Poisson distribution represents a reasonable choice for modelling single
base substitution counts, it implies certain limitations. Most importantly, the Poisson model
assumes equidispersion, i.e. the variance to mean ratio equals one:
if X ⇠ Pois(l ), then E[X ] = l ,and V[X ] = l . (2.6)
Therefore, when counts are larger on average, they also tend to be more variable. Close
inspection of the Poisson density reveals that as the mean l increases, the skew decreases
and the distribution becomes more bell-shaped. Note that this is crucially different to the
Normal model where the variance s2 is assumed to be constant (Eq. 2.4).
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2.1.3 Modelling overdispersion
Count data often varies more than we would expect if the generative process was truly Poisson.
If variances are larger than corresponding means, count data is classified as overdispersed. A
common cause for overdispersion is heterogeneity among subjects, which is very likely to
be observed in SNV count data, because cancer patients may be exposed to a multitude of
different exogenous and endogenous mutagenic factors. For example, cancers with mutations
in the exonuclease domain of Pol " often exhibit a hypermutator phenotype, characterised by
exceedingly large numbers of mutations in comparison to other cancers.
There are probabilistic models that can account for overdispersion, one of them is the so
called negative binomial (NB) distribution. A useful way to think about this distribution is
that it represents a generalisation of the Poisson distribution where the mean parameter l
(see Eq. 2.5) is itself a Gamma distributed random variable









Equation 2.7 tells us that the NB distribution has an additional non-negative dispersion
parameter t , which controls the variance of the distribution. Also, observe that
if X ⇠ NB, then E[X ] = µ, and V[X ] = µ + 1
t
µ2, (2.8)
implying that the NB distribution converges to a Poisson model as t ! •, while small
values of t enable to scale the degree of overdispersion relative to the Poisson.
Signs for overdispersion in SNV count data
In an attempt to estimate the heterogeneity of single base substitution counts, we separated
the SNV spectrum of skin melanoma samples by chromosome to obtain internal replicates.
We denote the count for single base substitution type i on chromosome j of sample k as Ci jk.
Under the simplifying assumption that mutational processes do not have preferences among
chromosomes, we would expect that the mean single base substitution count i in sample k,





Ci jk⇥Fi j (2.9)
where Fi j is the frequency of trinucleotide i on chromosome j. To estimate the degree of
dispersion, we used the estimator Ĉik to fit Ci jk with a generalised linear model using negative






















Fig. 2.2 Evidence for overdispersion in base substitution count data. The left panel
shows how expected base substitution counts correlate with observations (blue points),
and simulated observations drawn from a Poisson distribution (red points). The right plot
illustrates how the standard deviation relates to the mean (CV = sx̄ ) where blue points show
actual data, and red points simulated data sampled from a Poisson distribution. To estimate
the degree of overdispersion, we fitted a generalised linear model using NB regression (blue
line) and Poisson regression (red line). In this example, we used skin melanoma samples from
the PCAWG dataset, and used single base substitution counts from diploid chromosomes.
data from skin melanoma samples are highly overdispersed (Fig. 2.2). This situation makes
it difficult for NMF to extract representative signatures, because the method naturally selects
"corner points" of the data to define the basis of its low rank representation (Sec. 2.1.1).
There is a danger to find mutational signatures based on particular samples, rather than
spectra that are truly representative for a mutagenic biological process.
Examples from the literature indicating overfitting of mutational signatures
We found examples in the literature that are symptomatic for this issue. For example, Hayward
et al. (2017) report the identification three novel UV signatures. Although the authors justify
the existence of these signatures by proposing reasonable underlying mutational processes, it
remains to be proved whether these spectra are truly due to differential types of UV damage
(in this case cyclobutane pyrimidine dimers and indirect DNA damage after ultraviolet
radiation). Also, we found that there is at least one sample in their dataset in which the
contribution of these UV-signatures is almost at 100 %, which indicates that these samples
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may represent signature-defining outliers, fooling the algorithm to fit distinct signatures for
particular samples, rather than to identify truly prototypical mutational patterns.
2.1.4 Fitting NMF models with automatic differentation and gradient
descent
The simple formulation of the sum of squared errors and the divergence objective in NMF
enable the definition of simple iterative update rules based on coordinate descent (e.g. Eq.
2.3). However, the probabilistic implications of these functions render such NMF models to
be inappropriate for certain types of data. To nevertheless perform NMF with more realistic
error models, modern machine learning libraries such as Tensorflow provide a suitable
framework for easy implementation and execution.
TensorFlow: A library for defining computational graphs
Tensorflow is a versatile open-source end-to-end platform with the goal to facilitate the
creation and deployment of machine learning models. Internally it is a symbolic math library
that defines dataflows and uses differential programming, i.e. Tensorflow allows to define a
series of differentiable operations in specific order on data, making the framework particularly
suitable for applications such as neural networks. The library was initially developed by
GoogleBrain for internal Google use, but released to the public in 2015 under the Apache
License 2.0 (Abadi et al., 2016).
Tensorflow can be considered as a framework for defining computational graphs that
describe certain computations. A graph is a data structure consisting of nodes and edges,
which in Tensorflow describe local units of computation, and input and outputs, respectively.
In other words, in a Tensorflow computation graph, nodes represent operations, and the
values flowing along edges are tensors. An operation takes tensors as input and produces
tensors as output, and may represent common mathematical operation such as addition or
matrix multiplication, but also more complicated transformations such as convolutions. On
the other hand, tensors naturally represent the inputs or outputs of operations, for example, a
matrix multiplication takes two 2D tensors as input, and outputs another 2D tensor (Abadi
et al., 2016).
Two other important concepts in Tensorflow are variables and automatic differentiation.
A TensorFlow variable is a special type of operation that contains an internal state, i.e. a
tensor, whose value(s) can be changed by running operations on it. Specific operations allow
to read and modify the values of a variable, making them suitable to store model parameters





Fig. 2.3 A computational graph to compute a non-negative matrix factorisation in Ten-
sorFlow. A computational graph contains nodes and edges. In TensorFlow, these correspond
to operations and tensors, respectively.
evaluate the derivative of a function, which enables each node in a Tensorflow graph, to
compute its derivative with respect to its successor node (Abadi et al., 2016).
Training machine learning models in TensorFlow
To create a machine learning model in TensorFlow, users define a directed acyclic compu-
tational graph of model parameters and layers that terminate with a loss function. A layer
maybe considered as a composite of mathematical operations acting on the variables of the
model, while a loss function is a scalar function, quantifying the difference between the
predicted value of the model and the ground truth. To train a learning model, Tensorflow
will update the model parameters iteratively by computing forward and backward passes.
The forward pass subsumes all steps required to compute the prediction as defined in the
computational graph, and terminates with the layer that computes the objective function. In
contrast, the backward pass updates model parameters outgoing from the layer computing
the loss, by moving them in the direction that maximally decreases the output of the objective
function. To achieve this, Tensorflow uses backpropagation, an algorithm which makes use
of automatic differentiation to compute the gradient of the loss with respect to each parameter
using the chain rule, i.e. it computes the gradient one layer at a time by iterating from the
last layer to the first. To update the parameters, Tensorflow makes use of gradient descent,
which simply subtracts a scaled1 version of this gradient from the current parameter value
(Abadi et al., 2016).
1Scaling gradients is important to avoid numerical problems due to overflowing gradients, and determines
how fast the model learns. This is usually controlled via a hyperparameter termed “learning rate”.
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A computational graph to compute a NMF using the Tensorflow framework
Given the propensity of NMF to be highly affected by outliers (Sec. 2.1.1), and the likeliness
to find overdispersion in SNV count data (Sec. 2.1.3), I propose to compute the NMF based
on the NB distribution. If we assume that a single base substitution count Ci j is a NB
distributed random variable generated by a fixed number of mutational signatures S and their
corresponding exposures E, we may formulate the matrix decomposition as
Ci j ⇠ NB((SE)i j,t) where C 2 Np⇥n0 ,S 2 R
p⇥s
+ ,and E 2 Rs⇥n+ . (2.10)
To implement a NMF using a computational graph, one may consider to apply non-
linear functions such as the softmax and exponential function to the signature and exposure
matrix S and E, thus ensuring they remain positive and satisfy constraints for mathematical
identifiability. After matrix multiplying S and E to obtain a prediction for the true C, one





Ci j log(SE)i j  (t +Ci j) log(t +(SE)i j). (2.11)
by iteratively computing forward and backward passes until the weights of S and E reach
a local minimum. To illustrate how simple it is to achieve this using Tensorflow, I attached
the code that implements the graph from Fig. 2.3.
import tensorflow as tf
p, s, n = 96, 10, 100
C = tf.constant(counts)
E0 = tf.Variable( tf.random.normal(p, s) )
S0 = tf.Variable( tf.random.normal(s, n) )
E = tf.exp(E0)
S = tf.softmax(S0, dim=0)
Chat = tf.matmul(S, E)
loss = log_likelihood(C, Chat)
Together with the benefit of having native GPU support, which enables a massive speed




I developed TensorSignatures with the goal of creating a software to
1. characterise mutational processes with respect to various genomic properties at the
stage of signature definition,
2. define mutational processes in terms of their complete mutational imprint, and
3. introduce algorithmic improvements making the software less prone to fit spurious
mutational signatures.
In this section, I will explore the organisation of TensorSignatures’ input data (Sec. 2.2.1),
and explain the parameterisation of the model, allowing it to learn a mutational signature’s
properties and other mutation types (Sec. 2.2.2-2.2.6).
2.2.1 Multi-dimensional input data
The prime objective of TensorSignatures suggests to partition mutation counts with respect
to different genomic features. Such data may be represented in form of a multidimensional
tensor, or alternatively, as a flattened matrix. While the former implies to perform a tensor
factorisation, for which currently no out-of-the-box solution exists, the latter hardly scales
with increasing numbers of genomic states. Consider two genomic dimensions, for example,
transcription and replication, each with three states, i.e. coding, template and unknown
transcription strand, and leading, lagging and unknown replication strand. Representing such
data in a flattened array would require a (3 ·3 ·96)⇥n matrix, thus requiring to fit 864 (!)
parameters per signature (Eq. 1.1). In contrast, a tensor representation allows to parametrise
the model such that the number of required parameters per signatures scale additively with
the number of genomic states, thus making a characterisation of mutational signatures with
respect to multiple genomic states possible.
TensorSignatures receives two inputs: CSNV and Cother
To enable the genomic characterisation and the concurrent discovery of mutational signatures
with respect to their full mutational imprint, TensorSignatures receives two data inputs: a
mutation count tensor CSNV, whose multidimensional structure enables to annotate SNVs
with various genomic features, including




• and clustering state,
and a mutation matrix containing the counts of all other mutation types Cother.
The SNV mutation count tensor
Similar to conventional signature analysis (Alexandrov et al., 2013b), we classify SNVs with
respect to their trinucleotide context, but count pyrimidine ([C/T>·]) and purine ([A/G>·])
mutations separately, resulting in twice the number of features (192 rather than 96)2. However,
rather than appending purine mutation types to the SNV count matrix (i.e CSNV 2 N192⇥n0
where n denotes the number of samples), we include these additional features by introducing a
new dimension to the array CSNV 2N2⇥p⇥n0 , where p= 96. This structure may be understood
as two stacked matrices CSNVpyr 2 N
p⇥n
0 and CSNVpur 2 N
p⇥n
0 as shown in Eq. 2.12. Note the
organisation of the tensor, which matches the indices of pyrimidine mutation types to their
respective purine reverse complements.
C211 C212 . . . C21n
C221 C222 . . . C22n
C231 C232 . . . C23n
...
... . . .
...









C111 C112 . . . C11n
C121 C122 . . . C12n
C131 C132 . . . C13n
...
... . . .
...










Transcription directionality To assign single base substitutions to template and coding
strand, we partitioned the genome by transcription directionality (trx(+)/trx(-)) using GEN-
CODE v19 definitions. The transcription machinery synthesises RNA always in 5’ to 3’
direction, implying that template and coding strand of trx(-) genes are 5’ to 3’ and 3’ to 5’
2Classifying pyrimidine and purine base substitution types is at this stage pure convenience, as it allows to
assign transcription and replication directionality directly to each mutation. The redundancy in the representation
of mutation types is later resolved by adding purine mutation types to their pyrimidine equivalents from coding
and template strands, and leading and lagging strands.
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Fig. 2.4 Annotating SNVs with transcription directionality. To annotate SNVs with
template and coding strand annotation, we partitioned the genome into non-overlapping
trx(+) and trx(-) regions, which indicate transcription from the non-reference or reference
strand, respectively. If a genomic region did not contain a gene, or if genes are present on
both reference and non-reference strand, we assigned a * (star) to this region (removing
bidirectionally transcribed genomic regions reduces the percentage of the transcribed genome
from 53 % to 47 %).
oriented, and vice versa for trx(+) genes (Fig. 2.4). Since SNVs are called on the 5’ to 3’
strand of the DNA (i.e. + strand of the reference genome), we can unambiguously determine
whether the pyrimidine of the mutated Watson-Crick base pair was on the coding or template
strand. For example, a G>A substitution in a trx(-) gene corresponds to a coding strand C>T
mutation, because transcription directionality dictates that the mutated G sits on the template
strand. Splitting SNVs in this fashion requires to introduce an additional dimension of size
three (coding, template and unknown strand) to the count tensor CSNV 2 N3⇥2⇥p⇥n0 (where
p = 96 and n is the number of samples).
Replication directionality To assign single base substitutions to leading and lagging
strand, we leveraged Repli-seq data from the ENCODE consortium (Hansen et al., 2010;
Thurman et al., 2012), which map the sequences of nascent DNA replication strands through-
out the whole genome during each cell cycle phase. Repli-seq profiles relate genomic
coordinates to replication timing (early and late), where local maxima (peaks) and minima
(valleys) correspond to replication initiation and termination zones. Regions between those
peaks and valleys are characterised by steep slopes, whose algebraic sign (rep(+) or rep(-))
indicate whether the leading strand is replicated to the left or right direction (left or right
replication) when the DNA is viewed in standard orientation (Fig. 2.5).
To partition the genome into non-overlapping right and left replicating regions, we
computed the mean of slopes from Repli-seq profiles of five cell lines (GM12818, K564,
Hela, Huvec and Hepg2) using finite differences (Koren et al., 2012). We marked regions
with a plus (+) if the slope was positive (and therefore left-replicating), and with minus
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Fig. 2.5 Partitioning the genome by replication direction. The upper panel depicts a
schematic RepliSeq profile with peaks and valleys known as constant timing regions (CTRs),
which comprise predominantly early and late firing ORIs, respectively. On the other hand,
regions between peaks and valleys, transition timing regions (TTRs), are characterised by a
slope of large magnitude in which the algebraic sign (+/-) indicates whether the region is
mostly replicated to the right (+) or left direction (-) when DNA is viewed in standard orien-
tation. In genomic regions where the slope of the RepliSeq curve has a large magnitude, the
directionality of the replication bubble can be determined (green leading strand polymerase,
purple lagging strand polymerase).
(-) if the slope was negative (and hence right-replicating). To confidently assign these
states, we required that the absolute value of the mean of slopes was at least larger than two
times its standard deviations, otherwise we assigned the unknown (*) state to the respective
region. Consensus annotations enable to annotate 24.9 % of the genome (in comparison
to approximately 38% of the genome which may be achieved with tissue specific repli-
seq annotations). Using this convention, for example, a C>A variant in a rep(+) region
corresponds to a template C for leading strand DNA synthesis (and a template G for lagging
strand). Subsequent assignment of single base substitutions to leading and lagging strand is
analogous to the procedure we used for transcription strand assignment, and adds another
dimension of size of three to the count tensor ( CSNV 2 N3⇥3⇥2⇥p⇥n0 ).
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Fig. 2.6 Nucleosomal states mark minor grooves facing towards, and away from hi-
stones, and linker regions. We used the coordinates of DNA dyads from MNase cut
efficiency experiments to annotate nucleosomal DNA with annotations, marking the minor
grooves facing away and towards histone proteins, and linker DNA (purple).
Nucleosomal states Although nucleosomal DNA binding is mostly non-sequence specific,
histone bound DNA often features AT-rich followed by GC-rich minor grooves, which have
the propensity to bend the molecule favourably, thus facilitating histone interactions. For this
reason, nucleosomal DNA organisation may lead to differential susceptibility to mutational
processes (see also Sec. 1.1, Fig. 1.1). To assign single base substitutions to minor grooves
facing away from and towards histones, and linker regions in between nucleosomes, we used
nucleosome dyad (midpoint) positions of human lymphoblastoid cell lines mapped in MNase
cut efficiency experiments (Pich et al., 2018). We partitioned nucleosomal DNA by first
adding 7 bp to both sides of a dyad, and assigning to the following 50 bp alternating 5 bp
minor out and minor in DNA stretches, followed by a linker region with a maximum of 58
bp (Fig. 2.6). Subsequent assignment of SNVs to these states adds another dimension of size
four to the count tensor (CSNV 2 N3⇥3⇥4⇥2⇥p⇥n0 ).
Epigenetic states To assign single base substitutions to different epigenetic environments,
we used functional annotations from the 15-state ChromHMM model provided by the
Roadmap epigenomics consortium (Ernst and Kellis, 2012; Kundaje et al., 2015), which
integrates multiple chromatin datasets such as ChIP-seq data of various histone modifications.
To find state annotations that are robust across all cancer tissues, we defined an epigenetic
consensus state by combining state annotations from 127 different Roadmap cell lines. Here,
we required that at least 70 % of the cell lines agreed in the Chrom-HMM state to accept the
2.2 TensorSignatures 57
state for a given genomic region. Partitioning SNVs by Chrom-HMM states adds another
dimension of size 16 to the count tensor (CSNV 2 N3⇥3⇥16⇥4⇥2⇥p⇥n0 ).
Clustering states To identify clustered single base substitutions, we used inter mutation
distances (Yk in bp) between consecutive mutations on a chromosome as observations for a
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Geom(p = 1/100) if xk clustered
Geom(p = (1n Â
n
k=1 yk)
 1) if xk unclustered
(2.14)
We then computed the maximum a posteriori (MAP) state using the Viterbi algo-
rithm to assign to each mutation the state clustered or unclustered, respectively. Adding
clustered SNVs to the count tensor introduces another dimension to the count tensor
(CSNV 2 N3⇥3⇥16⇥4⇥2⇥2⇥p⇥n0 ).
Collapsing the pyrimidine/purine dimension So far, the structure of the SNV mutation
count tensor embodies redundancy with regard to the assignment of transcription and replica-
tion directionality to pyrimidine and purine mutation types. For example, the count tensor
explicitly contains the number of G>A and C>T substitutions on trx(-) genes, which corre-
spond to C>T mutations on a coding and template strand respectively if both variant types
are expressed solely in terms of pyrimidines. However, this redundancy is easily resolved by
adding the purine mutation types from corresponding trx(+)/trx(-), and rep(+)/rep(-) to their
equivalent pyrimidine mutations on template/coding and leading/lagging strand. This opera-
tion reduces the dimensionality of the final SNV count tensor CSNV 2 N3⇥3⇥16⇥4⇥2⇥p⇥n0 .
Other mutation types
The second input for TensorSignatures is a 2-dimensional matrix Cother 2 Nq⇥n0 containing
the counts of q other mutation types, i.e. multinucleotide variants, deletions and insertions,
and structural variants. While the data organisation of single base substitutions has to follow
the tensor conventions outlined in the previous section, requirements for Cother are relaxed
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and hence any mutation count matrix is accepted. The TensorSignatures’ package implements
routines to classify multinucleotide variants, deletions and insertions by type and length
(see Tab. B.2, B.3), but does not provide an automated programme to catalogue structural
variants. Representing other mutation types in a matrix (rather than a tensor) is motivated by
the fact that it is difficult to partition SVs, MNVs and larger indels (> 1bp) variants uniquely
to genomic features, as they may overlap with multiple genomic states.
2.2.2 The signature tensor
Recall that conventional mutational signature analysis uses NMF to decompose a catalogue
of cancer genomes C to a set of mutational signatures S and their constituent activities or ex-
posures E (Eq. 1.1). Similarly, TensorSignatures identifies a low dimensional representation
of a mutation count tensor, but decomposes it to mutational spectra for coding and template
strand, leading and lagging strand, and signature-specific multiplicative factors quantifying
the propensities of mutational processes within specific genomic contexts. To enable strand
specific extraction of mutational spectra requires to increase the dimensionality of the p⇥ s
sized signature matrix. To understand this, consider that two p⇥s matrices are at least needed
to represent spectra for coding (C) and template (T) strand, suggesting a three dimensional
(2⇥ p⇥ s) signature representation. Our model, however, also considers replication, which
adds another dimension of size two for leading (L) and lagging (G) strand, and thus we



















The mutation spectra T0·/· are normalised to 1 for each signature s, i.e., Âpi=1(T
·/·
0 )is =
1 8 s. However, the mutation count tensor also contains mutations from genomic regions for
which strand assignment was not applicable. To still use these data for the factorization, we
map such counts to a linear combinations of T0’s sub matrices. This is enabled by stacking
strand specific p⇥ s matrices of the core signature tensor, thereby forming linear combi-
nations. For example, coding strand mutations for which replicational strand assignment
was not applicable, are mapped to a linear combination of both coding strand specific sub
matrices TC/L0 and T
C/G





















































We use the term tensor factor for variables of the model that are factored into the signature
tensor to quantify different genomic properties of a mutational signature. The key idea
is to express a mutational process in terms of a product of strand-specific spectra and a
set of scalars, which modulate the magnitude of spectra dependent on the genomic state
combination presented in the count tensor. However, to understand how tensor factors enter
the factorisation, it is necessary to introduce the concept of broadcasting, which is the process
of making tensors with different shapes compatible for arithmetic operations.
Broadcasting It is important to realise that it is possible to increase the number of dimen-
sions of a tensor by prepending their shapes with ones. For example, a three dimensional
tensor X of shape R2⇥3⇥5+ has 2 rows, 3 columns and a depth of 5. However, we could
reshape X to R1⇥2⇥1⇥3⇥5+ , or R2⇥3⇥5⇥1+ , which would eventually change the order of values
in the array, but not its content. These extra (empty) dimensions are called singletons or
degenerates, and are required to make entities of different dimensionality compatible for






























The   operator first copies the elements along their singleton axes such that the shape of
both resulting arrays match, and then performs element-wise multiplication as indicated by
the · symbol. This concept is similar to the tensor product ⌦ for vectors, but also applies to
higher dimensional arrays, although this requires to define the shapes of all tensors carefully.
For example, if F 2 R2⇥2 and H 2 R1⇥1⇥3 then F H is an invalid operation, however,
if G 2 R2⇥2⇥1, then (G H) 2 R2⇥2⇥3 is valid. Also, note that such operations are not
necessarily commutative.
Transcriptional and replicational strand biases To quantify spectral asymmetries in
context of transcription and replication, we introduce two vectors bt,br 2 R1⇥s+ , stack and





br ·bt b 1r ·bt 1 ·bt





br ·1 b 1r ·1 1 ·1
3
75 , (2.18)
matches the shape of T1. Note that signs of bt and br are chosen such that positive values
correspond to a bias towards coding and leading strand, while negative values indicate shifts
towards template and lagging strand, respectively.
Transcriptional and replicational signature activities To assess the activity of muta-
tional processes in transcribed versus untranscribed, and early versus late replicating re-
gions, we introduce two additional scalars per signature represented in two vectors at and
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Mutational Composition Quantification of other mutation types requires another 1⇥ s
sized vector m, satisfying the constraint 0mi  1 for i = 1, . . . ,s. In order to include this
factor in the tensor factorization, we reshape the vector to M 2 R1⇥1⇥1⇥s+ , while (1 m) is
factored into the secondary signature matrix S.
The strand specific-signature tensor
We define the strand-specific signature tensor as
Tstrand := T1 B A M, where Tstrand = R3⇥3⇥p⇥s+ , (2.20)
which therefore subsumes all parameters to describe a mutational process with regard
to transcription and replication, and quantifies to what extent the signature is composed of
SNVs. To understand this, consider the entry of the signature tensor representative for coding




0 ), which explicitly states
how the low dimensional tensor factors for transcription are broadcasted into the signature
tensor.
Signature activities for nucleosomal, epigenetic and clustering states The strand-specific
signature tensor Tstrand can be considered as the basic building block of the signature tensor,
as we instantiate “copies” of Tstrand by broadcasting scalar variables for each genomic
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state and signature along their respective dimensions. For example, we split SNVs in t = 3
nucleosome states (minor in, minor out and linker regions). However, since SNVs may also
fall into regions with no nucleosomal occupancy, we distributed mutations across t +1 = 4
states in the corresponding dimension of the mutation count tensor. To fit parameters as-
sessing the activity of each signature along these states, we initialise a matrix k 2 R(t+1)⇥s,
which can be considered as a composite of a 1⇥ s constant vector (k1i = 1 for i = 1, . . . ,s),
and a t⇥ s matrix of state variables, allowing the model to adjust these parameters with
respect to the first row, which corresponds to the non-nucleosomal mutations (baseline). To
include these parameters in the factorization, we first introduce singleton dimensions into the
strand-specific signature tensor such that Tstrand 2 R3⇥3⇥1⇥p⇥s+ , and reshape k to match the
dimensionality of Tstrand,
k 2 R(t+1)⇥s+ ) K 2 R
1⇥1⇥(t+1)⇥1⇥s
+ . (2.21)
Both tensors have now the right shape to enable element wise multiplication with broad-
casting
T = Tstrand K where T 2 R3⇥3⇥(t+1)⇥p⇥s+ . (2.22)
We proceed similarly for all remaining genomic properties such as activities along
epigenetic domains, and clustering propensities. Generally, to assess l genomic properties, we
first introduce l singleton dimensions to the strand-specific signature tensor Tstrand, instantiate
l matrices kj 2 R
(t j+1)⇥s
+ for j = 1, . . . , l each with t j states, reshape them appropriately to
tensor factors Kj, and broadcast them into the strand specific signature tensor T2. Here,
we introduced new dimensions for epigenetic domains (epi), nucleosomal location (nuc)
and clustering propensities (clu), and thus we reshaped the strand specific signature tensor
to Tstrand 2 R3⇥3⇥1⇥1⇥1⇥p⇥s+ , instantiated kepi 2 R16⇥s+ , knuc 2 R4⇥s+ and kclu 2 R2⇥s+ and
computed
T = Tstrand Kepi Knuc Kclu where T 2 R3⇥3⇥16⇥4⇥2⇥p⇥s+ (2.23)
to obtain the final signature tensor T. Note that the parametrisation of nucleosomal,
epigenetic and clustering states is generalisable, i.e. it can easily be modified to accommodate




The model assumes that the expected values of CSNV and Cother are determined by the inner
product of the signature tensor (using the convention that ⇥ is taken over the last dimension
of the array on its left – denoting each different signature – and the first dimension of the
array on its right) and the exposure matrix and similarly for the non-SNV signature matrix S
and the same exposure matrix E
E[CSNV] = T⇥E and E[Cother] = (S0  (1 m))| {z }
S
⇥E. (2.24)
To prevent oversegmentation and ensure a robust fit of signatures, we assume that the
data follows a negative binomial distribution (Sec. 2.1) with mean T⇥E and S⇥E, and
dispersion t
CSNVi...n ⇠ NB((T⇥E)i...n,t) and Cothermn ⇠ NB((S⇥E)mn,t). (2.25)
We use the Tensorflow framework (Sec. 2.1.4) to find the maximum likelihood estimates
(MLE) T̂, Ŝ, Ê for T, S and E, respectively, using the parametrisation defined in the previous
section. We initialise the parameters of the model with values drawn from a truncated normal
distribution, transform them appropriately to meet the requirements of non-negativity, and
compute T̂⇥ Ê and Ŝ⇥ Ê which are fed into the negative binomial likelihood function
























The total log likelihood logL is then given by the sum of individual log-likelihoods
logL(CSNV,Cother;T,S,E,t)= logLSNV(CSNVi...n ;(T⇥E)i...n,t)+ logLother(Cothermn ;(S⇥E)mn,t)
(2.28)
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and thus the optimisation problem is equivalent to maximise the total log likelihood (or
equivalently to minimise the negative total log-likelihood)





Moreover, inferring T̂, Ŝ, and Ê enables us to calculate log-likelihood of the MLE
log L̂= logL(CSNV,Cother; T̂, Ŝ, Ê,t). (2.30)
2.2.4 Numerical optimisation
Fitting signatures, exposures and tensor factors simply requires to minimise the negative
total log-likelihood (Eq. 2.28). However, it is important to note that non-negative matrix
factorisation produces “stochastic” solutions, i.e. each decomposition represents a local
minimum of the objective function that is used to train the model, and often strongly depends
on the initialisation of the parameters. For this reason, it is worthwhile to sample the solution
space thoroughly, and to pick the solution which minimised the value of the objective function
(see also Sec. A.3.3).
We minimise the negative total log-likelihood using an ADAM Grad optimiser with an
exponentially decreasing learning rate and starting value of 0.1. The number of epochs to
train the model depends on the size of the dataset. Generally, the model should be trained
long enough to achieve convergence of the objective function, i.e. the gain of log-likelihood
between consecutive epochs should tend towards zero (see also Sec. A.3.3).
2.2.5 Model selection
Choosing an appropriate column rank prior to the decomposition is crucial to determine
mutational signatures accurately. The algorithm fails to detect mutational processes if the
chosen decomposition rank is too small, and may infer artefact signatures if it is too large.
Alexandrov et al. (2013b) determine the rank by selecting s such that the reconstruction error
of SE is low and the reproducibility of solutions is large. In our framework, this problem is
slightly more complicated, because in addition to the right column rank, we have to identify
the appropriate dispersion t for the data as well. For this reason, we decided to fix t prior
to the analysis, and only compare models of different decomposition rank across the ones
which were fitted using the same dispersion.
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Fig. 2.7 Choosing the appropriate column rank of the signature decomposition using
the BIC. In this simulation experiment, we simulated mutation counts using 10 mutational
signatures and random exposures of 100 samples, and subsequently applied TensorSignatures
decompositions with the dispersion used to simulate the data. Applying the BIC to these
extractions accurately identifies the true number of signatures as indicated by the kink of the
BIC curve.
To select the appropriate number of signatures s for a model with dispersion t , we
compute for each decomposition rank the Bayesian Information Criterion (BIC, Schwarz
(1978))
BICt(s) = log(n) · k(s) 2 · log L̂, (2.31)
where n is the number of observations (total number of counts in CSNV and Cother), k
represents number of parameters in the model (which depends on the rank s), and log L̄ is
the log-likelihood of the MLE. The BIC tries to find a trade-off between the log-likelihood
and the number of parameters in the model; chosen is the rank which minimises the BIC. In
our simulation experiments, we found that the BIC accurately determines the appropriate
column rank given the correct dispersion of the simulated data (Fig. 2.7).
2.2.6 Bootstrap Confidence Intervals
To compute bootstrap confidence intervals (CIs) for inferred parameters, we randomly select
2
3 of the samples in the dataset, initialise the model with the MLE for T̂ and Ŝ while randomly
perturbing the 10 % of their estimates, and subsequently refit T̂, Ŝ and Ê to the subset of
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samples. Initialising the parameters with the MLE results from computational constraints, as
this step needs to be repeated for 300 - 500 times to obtain a representative distributions of
the parameter space. Next, we match refitted signatures to the MLE reference by computing
pairwise cosine distances, and accept bootstrap samples if the total variation distance between
the bootstrap candidate and the reference is smaller than 0.2. Finally, we compute 5 % and
95 % percentiles on accepted bootstrap samples to indicate the CIs of our inference.
2.3 Assessment of TensorSignatures
2.3.1 Simulation Studies
To learn more about the conditions that affect the ability to extract tensor signatures, we
simulated data under different scenarios, and compared obtained solutions with the ground
truth. If not otherwise specified, we selected a pre-described number of COSMIC signatures
and multiplied them with randomly generated tensor factors (transcription biases etc.), and
exposures from 10 to 1,000 genomes. We chose the simulation parameters such that the
average number of mutations per genome ranged between 50 and 1,000, and created different
realisations of the data by perturbing the resulting counts ten times with negative binomial
noise (t = 50). We performed each tensor factorization 10 times on each of these ten
realisations and selected for each realisation the solution in which the negative log-likelihood
was minimised. All models were trained for 50,000 epochs using an ADAMgrad optimiser
and a constant learning rate of 0.1. Shown figures in this section always report means and
standard deviations.
Accuracy of signature and exposure inference
Most importantly, mutational signature analysis should accurately decipher the mutational
patterns underlying different mutational processes, and equivalently determine their muta-
tional loads in each genome of the dataset. To assess how the number of mutations per sample
(m) and the size of the dataset (n) affect the quality of signature extraction in a cancer catalog
simulated from five mutational processes, we compared extracted and true spectra by comput-
ing cosine distances (indicated as signature recognition, i.e. 1  cosinedist(true, inferred)),
and the difference between true and deciphered exposures (Fig. 2.8a and b respectively).
This analysis revealed that either 100 genomes with 100 mutations, or 10 samples with 1,000
mutations each suffice to accurately determine signature spectra with a signature recognition
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Fig. 2.8 Accuracy of tensor signature inference. a. Accuracy of signature inference with
respect to the number of samples (n) and the number of mutations per sample (m) in the
simulated dataset. Signature recognition is defined as 1 minus cosine distance of the inferred
and true signature. b. Accuracy of exposure inference with respect to the number of samples
(n) and the number of mutations per sample (m) in the simulated dataset.
responding exposures, whose relative errors decrease with increasing mutation and sample
numbers (Fig. 2.8b).
Relative errors of tensorfactors quickly decrease as the number of mutations per sam-
ple and the dataset size increases
Likewise, we tested the algorithm’s ability to infer tensor factors quantifying the genomic
properties from mutational signatures in simulated datasets with different number of mu-
tations and sample sizes (Fig. 2.9). To ensure that these tests closely resemble real-world
scenarios, we simulated the number genomic dimensions and states similarly to the analysis
presented in this work, i.e. three genomic dimensions resembling epigenetic, nucleosomal,
and clustered mutations with 16, 4 and 2 states, respectively. The results of this analysis
suggest that relative errors of all tensor factors quickly decrease as the size of the cancer
catalogue and the number mutations per sample increase (Fig. 2.9).











































m = 103 | n = 10
0.5 0.0 0.5
True parameter
m = 103 | n = 102
0.5 0.0 0.5
True parameter
m = 103 | n = 103
Accuracy of inferred transcriptional and replicational activities (a0) and
strand biases (b0), and SNV composition (m1) with respect to number











































m = 103 | n = 10
2 0 2
True parameter
m = 103 | n = 102
2 0 2
True parameter
m = 103 | n = 103
Accuracy of inferred epigenetic (k0) and nucleosomal actitivies (k1),
and clustering propensites (k2) with respect to number of samples (n)





Fig. 2.9 Relative errors of tensor factors diminish with increasing numbers of genomes
and mutation numbers. a. Accuracy of inferred transcriptional and replicational activities
(a0) and strand biases (b0), and SNV composition (m1) with respect to the number of samples
(n), and the number of mutations per sample (m) in the simulated dataset. b. Accuracy of
inferred epigenetic (k0) and nucleosomal activities (k1), and clustering propensites (k2) with
respect to the number of samples (n) and the number of mutations per sample (m) in the
simulated dataset.
The number of extractable tensor signatures depends on the size of the dataset and the
average number of mutations per sample
Next, we tested how many tensor signatures the algorithm reliably detects given a fixed
number of mutations and a varying number of samples, and conversely, given a fixed number
of genomes and a varying number of mutations per sample (Fig. 2.10). The number of
mutations per sample strongly influences the accuracy of signature detection. While it is
theoretically possible to detect 40 signatures with high accuracy using a dataset comprising
only 100 samples with 10,000 mutations, it requires at least 2,000 genomes to achieve
a similar quality of signature recognition with genomes containing 1,000 mutations (Fig.
2.10). These results are underpinned by the complementary experiment shown in Fig.
2.10. Although the signature recognition improves considerably from additional samples in
simulation experiments with 100 and 1,000 mutation per samples, respectively, the accuracy
of signature detection hardly improves from additional samples once these contain 10,000
mutations on average.
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Fig. 2.10 Signature recognition benefits from larger datasets and mutation numbers
per sample. Accuracy of signature recognition at different ranks with respect to sample size
(n) and number of mutations (m).
2.3.2 Comparison of TensorSignatures to conventional NMF methods
TensorSignatures addresses many unresolved issues in the field of mutational signature
analysis. For example, it allows to natively quantify the activity of mutational processes
in various genomic regions and links other mutation types to SNV spectra. To generate
similar results, previous approaches used to regress out the activity of mutational processes
within specific genomic domains, or made use of post-hoc “posterior” calculations. Another
common practice is to correlate the exposures of independent NMFs to associate the spectra
from other mutation types to corresponding SNV signatures. In this section, we compare the
algorithm to these aforementioned approaches.
Extracting the genomic properties of mutational signatures by regression
We tried to quantify the genomic properties of mutational signatures using a less principled
approach by simulating a mutation count tensor (CSNV 2 N3⇥3⇥16⇥4⇥2⇥p⇥n0 ). To recover
mutational signatures and corresponding sample exposures, we factorised the marginalised
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TensorSignatures vs. Post-hoc regression approach
Fig. 2.11 TensorSignatures determines the properties of mutational signatures more
accurately in comparison to post-hoc regression approaches. Upper panel: Schematic
depiction of a simulation approach which recovers signature activities similar to TensorSig-
natures by regressing their prevalence in different genomic dimensions post-hoc. Lower two
panels depict relative and absolute errors respectively.
(summed) single base substitution count tensor on the 96-trinucleotide and sample dimension
(Cmarg 2 Np⇥n0 ). To determine strand biases and signature activities across genomic states,
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TensorSignatures vs. Post-hoc posterior calculations
Fig. 2.12 TensorSignatures assigns mutations more accurately to genomic compart-
ments in comparison to post-hoc posterior calculations. Upper panel: Schematic depic-
tion of the simulation approach which uses a maximum a posteriori (MAP) estimation to
assign mutations to their respective mutational signature as described by Morganella et al.
Lower panel: Per sample absolute errors of the tensor factorisation and the aforementioned
strategy.
single base substitutions of a specific state only (e.g. template strand mutations, TssA). To
obtain a scalar parameter similar to TensorSignatures’ tensor factors, we regressed state
specific exposures to respective baseline exposures (e.g. exposures of template strand
mutations against exposures of unassigned mutations), and compared obtained regression
coefficients with the equivalent parameter of the tensor factorisation and the ground truth.
To assess the error, we computed the vector 2-norm and cosine similarity for strand biases,
genomic activities and exposures, and signature spectra, respectively. We performed this
experiment for datasets with sizes (100; 1,000; 10,000) and different numbers of mutations
per sample (100; 1,000; 10,000). Note that this approach fails to recover signature activities
in untranscribed/transcribed and early/late replicating regions (indicated as “Amplitudes” in
the following Fig. 2.11).
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Our simulations revealed increasing relative errors for all assessed parameters as sample
size and mutation loads increase (Fig. 2.11, middle panel). To understand this, consider
that only TensorSignatures may leverage the additional information encoded in the tensor
representation of larger datasets to improve the estimates of signature defining properties
such as strand biases and genomic activities. Although it is possible to find reasonable
parameter estimates by fitting signature spectra first and subsequently regressing out the
effect of genomic determinants, absolute errors are always larger at similar samples sizes and
mutation loads (Fig. 2.11, lower panel).
Assigning single base substitutions to their source signature with maximum a posteri-
ori approaches
To compare the ability to assign mutations to their respective source signature, we designed a
simulation experiment in which we used two very similar signatures (TS05 and TS06) to
simulate a mutation count tensor. We then applied conventional NMF on the marginalised
(summed) count tensor and determined the maximum a posteriori (MAP) signature for each
trinucleotide context in each simulated sample as described in (Morganella et al., 2016).
Absolute errors (vector 2-norm) of post-hoc assigned single base substitutions increase as
the number of mutations per sample get larger, while the predictions of the equivalent tensor
factorisation become more accurate. This is expected as the post-hoc signature posterior
probability is only conditioned on the mutation type and the sample exposure. Furthermore,
shown results are likely to underestimate errors as our simulations and inferences were
performed using only two signatures, and thus correct signature assignment is likely to
happen by chance (Fig. 2.12).
Stability of solutions
Another challenge in mutational signature analysis is the problem of unambiguously asso-
ciating other variant types to respective single base substitution spectra. Common practice
is to perform independent NMFs on each variant type, and to subsequently match muta-
tion subtype specific signatures to the SBS correlate by assessing exposures. In contrast,
TensorSignatures decomposes SNV and other mutation type counts simultaneously, thus
circumventing the problem of post-hoc associating different mutation types, and delivering a
more robust signature inference by pooling the evidence from the entire mutational imprint.
To illustrate this, we ran independent NMFs on SNV and other mutation count matrices
of the PCAWG dataset. To match resulting mutational spectra, we computed the correla-
tion coefficients of exposures and paired highest correlating SNV and other mutation type
72 Methods
Supplementary Figure 4























1. Extract SNV spectra
Extract other mutation type
signatures







Stability of TensorSignature solution vs. concatenated independent NMFs
Fig. 2.13 TensorSignatures assigns other mutation types more confidently to associated
SNV spectra. Left panel: Matching SNV and other mutation type spectra (from independent
NMFs) by correlating their exposures. Right panel: Signature stability across several ranks
using TensorSignatures and the signature matching approach.
signatures. We repeated these steps 50 times to obtain a set of 50 initialisations of paired
mutational signatures (SNV + other mutation types), and compared the stability of these
solutions with TensorSignature decompositions by computing the silhouette scores across
several ranks (Fig. 2.13). Our results indicate a higher stability of TensorSignatures solutions
across all tested ranks implying that the tensor framework more consistently reproduced
SNV and their accompanying other mutation type spectra.
TensorSignatures in context of other tools
There is a wide range of software packages that aim to extract mutational signatures. In this
section, I will review a selection of tools which differ in their methodology and application,
and discuss them while relating them to TensorSignatures (a brief comparison table is
provided in Tab. B.6).
SigProfiler SigProfiler is perhaps the most commonly used tool in mutational signature
analysis, and has been used in landmark studies such as PCAWG (Alexandrov et al., 2020).
The software comprises of a set of utilities including SigProfiler MatrixGenerator, SigProfiler
Extractor, SigProfiler Plotting (Bergstrom et al., 2019), and SigProfiler Simulator (Bergstrom
et al., 2020) which enable convenient data preparation, signature extraction and visualisation,
as well as the simulation of synthetic cancer genomes, respectively. In comparison to
SigProfiler, TensorSignatures allows the concurrent extraction of mutational signature across
all variant types, and accounts for a wide range of different genomic factors.
Sparse Signatures SparseSignatures puts particular emphasis on avoiding signature overfit-
ting by applying a LASSO penalty on signatures to favor the extraction of “well-differentiated”
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spectra, and by taking into account the standard replication error (Lal et al., 2020). Finally,
it implements cross-validation for model selection, which according to the authors, more
reliably detects the appropriate number of signatures. In contrast, TensorSignatures addresses
overfitting by employing a robust noise model based on an overdispersed negative binomial
distribution to model mutation count data, and uses the conservative BIC estimator to identify
the most likely number of signatures.
deconstructSigs DeconstructSigs focuses on fitting the exposures of a pre-defined set of
signatures to new datasets, which is useful when only a few samples are available, and
therefore the denovo extraction of mutational signatures is infeasible (Rosenthal et al., 2016).
The software uses a multiple linear regression model with the caveat that any coefficient
must be greater than 0, as negative contributions make no biological sense. TensorSignatures
provides a similar feature, i.e. it enables to refit a set of tensor signatures to novel samples if
the user runs the tool using the refit option (Sec. Appendix A).
EMu EMu is a conceptually interesting tool as it deciphers the activity of mutational
signatures both genome-wide and within local regions of the genome (Fischer et al., 2013).
However, in comparison to TensorSignatures, which relies on state assignments to SNVs,
EMu divides each genome into non-overlapping 1Mb regions and extracts the activity of
each signature globally as well as locally. This approach enabled the authors to associate
certain mutational processes to phenomena like kataegis and epigenetic features such as
chromatin modifications. From a methodological point of view, EMu employs an expectation-
maximization algorithm to conduct the inference and uses the Bayesian information criterion
to perform model selection.
Mutalisk Mutalisk is a web-based tool that identifies up to seven active signatures from
a set of reference signatures using linear regression, and assesses uploaded VCF files with
respect to kataegis, transcriptional strand bias, DNA replication timing, GC content and
histone modifications (Lee et al., 2018). The tool computes correlation coefficients between
aforementioned features and the provided list of somatic mutations and displays these
conveniently on the website. In contrast, TensorSignatures deconvolves mutational signatures
while accounting for such genomic factors. This enables TensorSignatures to associate
mutational processes with genomic features rather than only certain mutation types.
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2.4 TensorSignatures in the cloud
Running TensorSignatures on larger datasets requires a GPU with CUDA support to make
use of hardware accelerated tensor computations. Additionally, identifying an appropriate
solution requires the user to run the analysis for different decomposition ranks and multiple
initialisations, suggesting to run Tensorsignatures ideally in parallel with multiple GPUs.
These entry requirements may be prohibitive for some users, which is why I decided to built
a web application enabling the community to run TensorSignatures online, thus providing a
low entry barrier for new users to try out the software. In this chapter, I outline how modern
web and cloud technologies may be employed to deploy research pipelines, and demonstrate
this by explaining the TensorSingatures web application stack.
2.4.1 Deploying research pipelines using microservices
Cloud computing platforms encourage to break down larger applications to atomic, inde-
pendently running components, called microservices that interact and communicate with
each another, thus providing the accustomed experience from a single application. Each
individual service focuses on a single task, while the ensemble communicates through HTTP
calls (request/response). The big advantage of microservices are apparent: decoupled ser-
vices can be developed, deployed, and scaled on their own, allowing them to be upgraded
quickly and on demand. In larger applications, clear separation between services enables to
easily split responsibilities between many developers. For example, front-end developers can
focus on the client facing website, while treating the backend as a blackbox, because proper
communication between services is ensured via their application program interfaces (APIs).
Because each service works independent from the rest of the application, microservices tend
to have smaller code bases that are easier to test, refactor and scale. Clear separation also
ensures that errors are localised, such that breaking a single service does not automatically
affect the whole application.
However, the microservice architecture has also many drawbacks. First of all, deciding to
split an application into many pieces is difficult, as it requires to split apart whole components
into independently working units, which is in most cases much harder then to refactor parts
to separate modules. For example, it is quite difficult to isolate stateful layers like databases
or task queues which require some form of data persistence, such that their state is not
shared or duplicated. The microservice pattern also increases the network complexity of the
application, since operations that used to be handled within function calls of a single process,
now often require network calls to different services, requiring to carefully coordinate APIs
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to properly work with each other. Also, it is highly recommended to write more complex
integration tests when developing applications with the microservice architecture to ensure
that independent parts work well together. Finally, with multiple services, complexity shifts
from the codebase to the infrastructure, which might be more costly and difficult to maintain.
2.4.2 Building modern web appplications with Docker and Kubernetes
The reason why microservice patterns became recently more popular are the two core tech-
nologies Docker and Kubernetes (k8s). Docker packages applications and their dependencies
in containers that can run on any Linux server, which helps to provide portability, enabling
microservices to be run in various locations. The framework uses native resource isolation
features of linux kernels, which avoid much of the overhead that would otherwise be con-
sumed by virtual machines (VMs), making Docker containers lightweight such that a single
server can run many containers at once. On the other hand, k8s allows to automate scheduling,
configuration, supervision and failure handling of (Docker packaged) microservices. In this
way, k8s shifts the responsibility of deploying an application from the operations3 team to the
developers, enabling them to update and release their work themselves. K8s also takes care
of monitoring and rescheduling applications in case of hardware failures, allowing system
administrators to shift their focus from individual apps (often many hundreds in large data
centres) to ensure that k8s is up and running.
Docker container package microservices
The biggest problem in deploying applications with smaller components is that developers
have to deal with differences in the environments they run their microservices on. A multitude
of factors contribute to these discrepancies, ranging from different hardware setups of
development and production machines to operating systems and available libraries. One
solution to this problem are VMs and container technologies, which dedicate resources of
a host machine to provide isolated environments, thus allowing to run the same operating
system, libraries and configuration during development and production. However, since VMs
produce large overheads and require more configuration, linux container prevailed, mainly
because they only consume the resources the application requires, thus allowing to run a
larger number of microservices with the same resources.
Although container technologies existed for a long time, they only became widely adopted
with the rise of the Docker platform, which made the container system easily portable and
3Operations refers to the set of processes and services that are administered by an IT department within a
larger organisation or business.
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simplified the process of packaging up whole applications including their dependencies.
However, Docker is more than that, as it also provides a platform for packaging, distributing
and running applications, making it possible to transfer packages to a central repository,
from which it can be downloaded to any machine with Docker and subsequently be executed.
To understand this better, it is necessary to define the most important Docker concepts,
namely Images, Registries and Containers (Fig. 2.14). A Docker Image is defined by the
instructions of a Docker file that tells Docker exactly what libraries to install, and what
application files should be copied and executed when the image is run. Importantly, Images
are immutable meaning that they represent an unmodifiable snapshot of an application at
a given point in time, ensuring that the programme will work always in a predictable way.
The Docker Registry is an online repository for Docker Images facilitating the exchange of
images between different computers. Upon building a Docker Image, it can either be directly
run on the development machine, or pushed (uploaded) to a registry, from which another
machine can pull (download) the image and run it as well. A Docker Container is created
from an Image and represents the actual process that runs on the host machine. This process
is completely isolated from any other process of the host, and only has access to limited
amounts of resources.
Kubernetes orchestrates Docker containers
K8s was developed at Google and released as an open-source project in summer 2014. The
software is a successor of Google’s proprietary systems Borg and Omega, that were used to
ship many of their containerised apps such as Gmail. In essence, k8s abstracts the hardware
infra structure of large data centres and exposes it as single computational resource, allowing
to develop applications with many components without having to understand the server
architecture under the hood. Upon deploying an multi-component application, k8s selects a
server for each microservice, and sets up the infrastructure to enable communication between
each part of the app. This makes k8s especially valuable to cloud providers, because it allows
them to provide a simple interface to their customers, while their system administrators do
not have to worry about the manifold of applications that runs on their hardware. One such
provider is the EMBL-EBI embassy4, which provides the k8s infrastructure to deploy the
TensorSignatureOnline application.
K8s can be understood as an orchestrator for microservices that make up the building
blocks of larger applications. To illustrate this, consider a simple application with two
components: a database which stores and retrieves data, and a front-end interface, allowing
users to interact with the former. In this example, the database and the front-end represent
4https://www.embassycloud.org
































Fig. 2.14 Docker and Kubernetes. a. Docker enables to run linux based microservices
within containers, and provides a distribution platform such that images can be downloaded
on any machine running Docker. b. A k8s master node accepts declarative instruction via a
REST API, saves these and in an internal cluster store and contains a scheduler and controller
unit. c. A k8s node communicates with the master via its kubelet, pulls and starts Docker
images and containers respectively using its container engine, and enables communication
between pods through a network proxy. d. A pod encapsulates a running Docker container.
e. Pods are deployed as a part of a ReplicaSet or Deployment, which not only specify which
Docker image to run, but also how many copies of such pods should be initiated, as well as
update instructions etc. f. To reliably connect different Pods, services are interposed ensuring
that requests to appropriately transmitted to respective pods.
microservices, which each run in dedicated containers, while k8s orchestrates both services
to ensure that both interact properly with each other to provide a useful application.
Kubernetes master and nodes A k8s cluster consists of one or more masters and several
nodes. The masters assign microservices to the nodes, monitor them and implement changes
upon events. In order to achieve this, masters contain four major components: an API
server, the cluster store, the controller manager and the scheduler (Fig. 2.14b). The API
server simply represents a RESTful API, that accepts YAML or JSON manifests specifying
instructions for microservices. If these pass the validation step of the API server, they get
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passed to the cluster store which can be considered as the memory of an k8s cluster, as it
stores the clusters’ configuration. While the controller manager implements a few functions,
the scheduler performs resource management and assigns workloads to nodes. In summary,
masters run all processes necessary to control and schedule workloads, and enable users to
interact with the k8s cluster.
In contrast, nodes run microservices, report back to the masters, and watch out for work
assignments. They comprise three units: the kubelet, the container runtime, and the kube-
proxy (Fig. 2.14c). The kubelet is probably the most important piece, as it registers the
host to the k8s cluster and surveils the API server for new work assignments upon which
it triggers requested steps and reports back to the master about the outcome. If the kubelet,
for example, fails to run a particular task, it reports back the failure and the master decides
about subsequent actions. The container runtime receives instruction from the kubelet and
executes all tasks necessary to manage containers, i.e. pulling images, or starting and stopping
containers. By default the container runtime uses Docker to perform all container related
tasks, although it is possible to run other container runtime software as long as these satisfy
the the k8s container runtime interface. The last important part is the kube-proxy, which
handles all network related tasks such as assigning unique internet protocol (IP) addresses to
each container of the node, and enables load-balancing.
Declarative object management and desired state principle Central to k8s are the con-
cepts of declarative object management and desired state principle. To appreciate them,
consider the deployment of k8s applications: The manifest file defines the desired state of the
application by declaring parameters such as the specific Docker image, number of replicas,
and update rules. After posting the file to the API server, k8s inspects and records the
manifest in the cluster store as part of the cluster’s overall desired state. Then, the nodes of
the cluster take over, which pull respective images and build the desired network. To ensure
that the cluster does not deviate from its desired state, k8s sets up watch loops that constantly
surveil the current state of the cluster, and trigger appropriate actions if the cluster varies from
it. Importantly, this process is handled in a declarative manner, i.e. rather than specifying a
long list of instructions leading to desired outcome, we simply declare the desired state, and
k8s takes care of the implementation. This paradigm has various advantages, for example, it
enables self-healing, automated scaling, version control and self-documentation.
Kubernetes Pods represent the atomic unit of deployment Rather than directly running
docker container on k8s nodes, Kubernetes packages containerised apps into so-called pods
which represent the atomic unit of deployment (Fig. 2.14d). A pod can be conceptualised
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as a protected environment or sandbox to run one or multiple containers. It establishes
a ring-fenced area of the host operating system to build a network stack, creates kernel
namespaces and exposes them to the inside container. For example, if multiple container
run within a single pod, they all share the same environment, including memory, volumes,
network stack and IP. Since pods are the smallest unit of deployment, they allow scaling
simply by creating several replicas of them (this is known as “horizontal scaling”). Also, they
only have two states, they are either up and running, or they fail, in which case k8s discards
them and spins up a novel pod to replace the broken instance.
Pods are deployed as a part of ReplicaSets or Deployments Pods are normally deployed
as a part of ReplicaSets or Deployments. The former simply takes the template of a pod and
deploys it for the desired number of replicas, while also instantiating background watch loops
to ensure that the number of active pods on the cluster does not deviate from the desired state.
The latter represents an higher level abstraction that encapsulate ReplicaSets, thus not only
providing their features, but also enable to define update and rollback models. ReplicaSets
and Deployments, like any other resources in k8s, are instantiated by defining a declarative































Fig. 2.15 Deploying applications with Docker and Kubernetes. To deploy an application
with Docker and Kubernetes, microservices need to be developed and packaged locally.
These are then pushed to the Docker registry, while at the same time, declarative instructions
are posted to the Kubernetes cluster. The Kubernetes cluster then takes over and instructs its
nodes to implement the application by pulling and installing respective microservices.
Services enable communication between different pods The ephemeral nature of pods
makes it difficult to reach them through the cluster internal network, e.g. upon failure, scaling
80 Methods
or updating the application, k8s instantiates new pods, each with a novel and unique IP
address. Since the microservice architecture heavily relies on the communication between
different pods, k8s provides so-called Services to ensure reliable networking endpoints for
a logical set of pods that perform a similar function (Fig. 2.14f). In this way, services
represent a persistent abstraction layer over pod(s), while enabling service discovery and
load balancing.
Persistent Volumes and Claims Although pods share resources such as CPU and RAM
with other pods running on the same host, they do not share disk storage, as each individual
container within a pod has its own isolated filesystem. As a result, pods only have access
to the files that were added to the image at build time, as well as to the files written by the
image to the pod internal disk at runtime, but not to any other external file. However, in
many scenarios it is desired to preserve data, for example to ensure that a pod starts again
at the exact same state after its life-cycle came to an end, or in data processing pipelines
when different pods need access to a particular file. K8s enables this by providing persistent
volumes which define a storage volume that is independent of the normal pod-lifecycle. Pods
need to be issued with a persistent volume claim (PVC) to access and write a persistent
volume.
Putting it all together Deploying an application using the microservice pattern with
Docker and Kubernetes involves in principle two steps (Fig. 2.15). First, developing and
packaging all required microservices with Docker locally, and specifying corresponding
Deployment files in form of YAML manifests, which tell the cluster how each service should
look like (what image to use, which ports to expose etc.), and how many replicas to create
of each component. Second, building the images, pushing them to the Docker registry, and
posting the Deployment files to the cluster. From here Kubernetes takes over, and takes
care of implementing the application by pulling all required microservices and setting up an
appropriate network.
To accomplish this, the master node validates incoming deployments and stores the
desired state of the application within its cluster store, whereupon the scheduler assigns the
workload to one of the listening nodes. A node receives the instructions from the master
via its kubelet, which subsequently instructs its container engine to pull requested images
from the Docker registry. Then the container engine launches respective containers within
dedicated pods, while the node’s network proxy puts in place the required network between
microservices. Finally, the kubelet monitors the deployment and reports back failures to the
master (Fig. 2.15).
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2.4.3 The TensorSignaturesOnline web application
With TensorSignaturesOnline I set out to create a web application that enables users to
1. inspect the results from our mutational signature analysis on the PCAWG dataset,
2. and allowing them to create user accounts that gives them access to a protected area at
which they can upload their own VCF data, and fit the exposures to the set of PCAWG
tensor signatures to their samples.
To achieve these goals, I built a web application based on the Python web server frame-
work Flask, a PostgreSQL database, and a Redis task queue. In the following, I describe the
structure and features of the application, and explain the thoughts that went into designing
the stack.
A Flask framework serves the back- and frontend of TensorSignaturesOnline
Flask is an extensible python web framework which serves in TensorSignaturesOnline both
as back- and frontend. The backend implements all routes (views) of the website, handles
user authorisation, and dispatches jobs to a Redis task queue. To enable this, the backend
tracks users, tasks and datasets within a PostgreSQL database, whose structure I describe
in the following section. Note, that the Flask pod has access to a persistent volume which
allows the app to receive and store user uploaded VCF data (Fig. 2.16).
Views of TensorSignaturesOnline In order to render the client viewing webpage, we
used Flasks template engine, which contains static HTML markup as well as placeholders
for dynamic data. To enable proper display of the website across different devices, we
employed the Bootstrap CSS framework to make the sites responsive. The pages available
in the application can be divided into those which are available to everyone, and some
which can only be accessed after a registration to the service. Among the routes which
are available to unregistered users is the welcome page (route: /, Fig: 2.17a); a overview
page of all tensor signatures (route: /signatures, Fig. 2.17b); a detailed page for each
tensor signature, including their spectra, genomic properties and a list of samples with
largest exposures (route: /signature/<signature_id>, Fig. 2.17c); an overview page
for each cancer type (route: /cancer/<cancer-type>, Fig. 2.17d); and a view for each
sample encompassing the spectra and a detailed breakdown of each active signature (route:
sample/<dataset_id>/<sample_id>, Fig. 2.17e). After logging into the application,





































World wide webLoad balancer
Fig. 2.16 The TensorSignaturesOnline stack. This schema represents the stack of the
TensorSignatureOnline web app. Users accessing the application via the world wide web hit
the NGINX load balancer which routes the user to one of the flask pods serving the front
and backend of the website. To enable processing of many user requests at the same time,
Flask pods are scaled horizontally with 16 replicas. Flask pods may access a PostgreSQL
database and a Redis task queue via indicated services (SVC), as well as a persistent volume
(PV) via the indicated persistent volume claim (PVC), which allows the Flask backend to
store user uploaded VCF data. The PostgreSQL abstracts all data required to render the web
site and stores these on a separate persistent volume. The Redis task queue coordinates the
data processing pipeline which involves three different types of worker pods, each required
to perform specific sub steps, i.e. the R Pod converts user uploaded VCF data to a data
tensor, the TS Pod runs the tensor signature inference, and python pods plot the results of the
analysis. Each of these “worker” pods are scaled horizontally to enable parallel processing
of several user requests at a time and report back to the SQL database about the success or
failure of a particular job.
collection of samples (route: /create_dataset); upload samples in VCF format to a
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dataset (route: /upload_sample/<dataset_id>); or delete a dataset from the service
(route: /delete/<dataset_id>). After creating and uploading samples to a dataset, users
may start the analysis by submitting it to the data processing and analysis pipeline (route:
/analysis/<dataset_id>) which triggers the submission of multiple jobs to a Redis task
queue that ensures that the pipeline is executed step by step (Sec. 2.4.3). Moreover, I
implemented a notification site which lists a detailed description of all submitted jobs,
enabling users to report failures in case of their occurrence.
a b c
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Fig. 2.17 Views of the TensorSignatures web application. a. The welcome page of
TensorSignaturesOnline. b. The overview page with all extracted tensor signatures and a
short description. c. Detailed signature page with SNV and other mutation type spectra
as well as genomic properties. d. Cancer overview page with links to each sample of the
respective cancer. d. Detailed sample page with true and predicted mutation type spectra, and
corresponding exposures. e. Dashboard page which allows users to create datasets, upload
samples in VCF format, and perform a TensorSignature analysis. This site becomes available
after registering to the service.
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A PostgreSQL database keeps track of users, datasets and samples
The SQL database can be considered as the heart of the application, as it represents the
abstraction for users, datasets and samples, and tracks the progress of the data processing
pipeline in respective tables. After registering to the application, a new user entry is created
in the users table. This entry contains user specific information such as its username and
email etc., and provides foreign keys to the tables tasks, notifications and datasets,
which keep track of the user’s uploaded data and submitted jobs (Fig. 2.18).
Upon login to the web application, the flask backend grants access to the dashboard route,
which enables users to view their uploaded data and to create new datasets. The latter creates
a new entry with the fields name, path, processed and analysed in the datasets table.
The name field is a user specified name for the dataset, path stores path on the persistent
volume to which all uploaded samples (VCFs) are saved to, and processed and analysed
represent boolean variables that are set to true by the Redis task queue after the completion
of certain steps in the data processing pipeline (Fig. 2.18). The dashboard displays datasets
and gives access to an upload form which allows users to add samples in VCF format to an
user owned dataset. The relationship between a dataset and a sample is represented via
the dataset foreign key which is associated with each sample entry. After uploading one
or many samples, a dataset may be subjected to the data processing pipeline, which converts
the data to a count tensor and subsequently triggers the analysis with TensorSignatures.
A Redis task queue ensures proper processing of user data
The Redis pod coordinates the data processing pipeline which comprises three major steps:
data preparation, inference and visualisation (Fig. 2.16). Each step of the pipeline runs within
a dedicated microservice, because each subtask relies on a different set of dependencies and
libraries. For example, the data preparation step is conducted within a pod that is running
R, as it requires Bioconductor packages to convert the user uploaded VCFs into a mutation
count tensor (2 GB); the inference is running in a Python container with Tensorflow (2 GB);
while the data visualisation step is performed within a microservice equipped with plotting
libraries (300-400 MB). Dedicating a single pod for each subtask enables to keep the size
of each pod small, allowing for resource-saving horizontal scaling and efficient parallel
processing of several jobs at a time.
Upon user submission of a dataset to the analysis pipeline, the Flask backend creates a
series of task entries in the tasks table, often many for each subtask of the pipeline. For
example, processing uploaded VCFs to a count tensor involves creating a variant tensor and
computing trinucleotide frequencies; running TensorSignatures requires to run the inference
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Fig. 2.18 Database structure of the TensorSignaturesOnline web application. The web
application manages users and their data in four tables. The user table contains mainly user
information and provides foreign keys to the the messages, tasks, datasets and notifications
tables, thus linking each entry in the respective table uniquely to a user. The datasets table
itself provides its id to each uploaded VCF file, thereby linking each sample each to a dataset.
and to normalise computed exposures; and finally plots need to be generated for each
individual sample of the dataset. Like each entry of the datasets table, a task entry is
uniquely associated to the user who submitted the request, and contains additional fields that
specify the type of job, the queue on which the task should run, and a status and completion
field. At the same time, each of these tasks are placed on the Redis task queuing system. As
soon as an appropriate worker pod has freed up resources, it gets assigned with one of the
outstanding tasks on the queue. Each of the worker pods run independently from the rest of
the application, and report back to the queue about the completion or failure of the task. At
this point the complete field of the respective task entry is set to true, and the status to
”success” or “failure”. Additionally, the status of each task is displayed in the notifications
page of the dashboard, allowing users to keep track of the outstanding processes that have to
be completed.
Also, to keep users informed about the progress of the analysis, a job notification is sent
to their dashboard after the completion of each major step. These notifications are highlighted
in the notification panel to enhance the user experience and provide a link to contact the
Administrator in case of unexpected failures in the pipeline. This functionality is enabled by
the notification and message tables of the database.
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To ensure that each step runs in the right order, e.g. it does not make sense to run the
inference without having the data tensor yet, jobs are scheduled with dependencies. As soon
as a subprocess finishes, and the worker pod reports “success” or “failure” to the queue, the
next job is started or all dependent jobs are cancelled, respectively. When all jobs associated
with the submission of one dataset finish successfully, the frontend displays the results of the
analysis for each sample, and allows the user to download the created data tensor in HDF5
format and the results from the TensorSignatures analysis.
Chapter 3
Results
While previous chapters mainly focused on methodological considerations and explained
theoretical approaches to characterise mutational signatures beyond their 96 single base
substitution spectra, the following focuses on applying the presented methodology to cancer
genomes to learn the genomic properties of various mutational processes. To this end, I
will present the analysis of 2,778 cancer genomes from the Pan-Cancer Analysis of Whole
Genomes (PCAWG) consortium (Sec. 3.1), as well as a validation analysis conducted on the
Hartwig Medical Foundation (HMF) dataset (Sec. 3.2).
Contributions
This chapter is mainly based on the bioarxiv manuscript “Learning Mutational Signatures
and their Genomic Properties with TensorSignatures” by Harald Vöhringer, Arne van Hoeck,
Edwin Cuppen and Moritz Gerstung. H.V. conducted all bioinformatic analyses and produced
the figures. A.v.H. and E.C. curated HMF data and provided computing resources for HMF
data analysis by H.V.. M.G. conceived and supervised the analysis and developed code for
categorising mutations. H.V. and M.G. wrote the manuscript with input from A.v.H. and E.C.
3.1 Discovering tensor signatures in the PCAWG dataset
We performed our discovery analysis on the PCAWG dataset, which is a international
collaboration with the goal to identify common patterns of mutations in more than 2,600
cancer whole genomes from the International Cancer Genome Consortium. Section 3.1.1
briefly recapitulates the most important key points of the approach, followed by an overview
of discovered tensor signatures in Sec. 3.1.2. In section 3.1.3, I will address two distinct
mutational signatures of UV-light exposure found in active and quiescent chromatin, which
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may be attributed to differential activity of nucleotide excision repair, and discuss in Sec. 3.1.4
transcription-associated mutagenesis manifesting as A[T>C] mutations. Sec. 3.1.5 discusses
APOBEC mutagenesis, which manifests in two signatures reflecting highly clustered, double
strand break repair initiated and lowly clustered replication-driven mutagenesis. The final
section 3.1.6 of this chapter dives into somatic hypermutation, which produces a strongly
clustered, TSS-associated signature in lymphoid cancers, and is distinct from a weakly
clustered TLS signature found in multiple tumour types.
3.1.1 TensorSignatures jointly decomposes mutation spectra and ge-
nomic localisation
Here we analysed the somatic mutational catalogue of the PCAWG cohort comprising 2,778
curated whole-genomes from 37 different cancer types containing a total of 48,329,388
SNVs, 384,892 MNVs, 2,813,127 deletions, 1,157,263 insertions and 157,371 SVs.
Multiple mutation types contribute to mutagenesis
Data driven discovery of mutational signatures requires a meaningful classification of muta-
tion types. We adopted the convention of classifying single base substitutions by expressing
the mutated base pair in terms of its pyrimidine equivalent (C>A, C>G, C>T, T>A, T>C and
T>G) plus the flanking 5’ and 3’ bases (Tab. B.1). We categorised other mutation types into
91 MNV classes (Tab. B.2), 62 insertion and deletion (indel) classes (Tab. B.3), and used the
classification of SVs provided by the PCAWG Structural Variants Working Group (Tab. B.4,
Li et al. (2020)).
Multidimensional genomic features produce a data tensor
Matrix-based mutational signature analysis proved to be powerful in deconvolving mutational
spectra into mutational signatures, yet it is limited in characterising them with regard to their
genomic properties. This is because individual mutations cannot always be unambiguously
assigned post hoc to a given mutational process, which reduces the accuracy of measuring the
genomic variation of closely related mutational processes. To overcome this limitation, we
use 5 different genomic annotations – transcription and replication strand orientation, nucleo-
somal occupancy, consensus epigenetic state as well as local hypermutation – and generate
96-dimensional base substitution spectra for each possible combination of these genomic
states separately and for each sample. Partitioning variants creates a seven-dimensional
count tensor (a multidimensional array), owing to the multitude of possible combinations of
different genomic features (Fig. 3.1).
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Fig. 3.1 Splitting variants by transcriptional and replicational strand, and genomic
states creates a multidimensional tensor. Splitting variants by transcriptional and repli-
cational strand, and genomic states creates an array of count matrices, a multidimensional
tensor, in which each matrix harbours the mutation counts for each possible combination of
genomic states.
Directional effects Mutation rates may differ between template and coding strand, because
RNA polymerase II recruits transcription coupled nucleotide excision repair (TC-NER) upon
lesion recognition on transcribed DNA only. Thus, TC-NER leads to lower mutation rates on
the template strand, which is best illustrated by UV-induced mutations found in skin cancers
(Pleasance et al., 2010a). TC-NER usually decreases the number of mutations in highly
transcribed genes, but also the opposite effect – transcription coupled mutagenesis (TAM) –
occurs (Haradhvala et al., 2016; Letouzé et al., 2017).
Similar to transcriptional strand asymmetries, mutation rates and spectra may differ
between leading and lagging strand in replication (Haradhvala et al., 2016; Tomkova et al.,
2018). This may be related to the fact that the leading strand is continuously synthesised by
Pol ", while lagging strand DNA synthesis is conducted by Pol  , and is discontinuous due
to formation of Okazaki fragments. Therefore, deficiencies in components involved in, or
mutational processes interfering with DNA replication may lead to differential mutagenesis
on leading or lagging strand.
Since not all mutations can be oriented either due to absent or bidirectional transcription,
or because of unknown preferred replication direction far from a replication origin, this creates
a total of 3⇥3 = (template, coding, unknown) ⇥ (leading, lagging, unknown) combinations
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Fig. 3.2 TensorSignatures factorises a mutation count tensor (SNVs) into an exposure
matrix and signature tensor. TensorSignatures factorises a mutation count tensor (SNVs)
into an exposure matrix and signature tensor. Simultaneously, other mutation types (MNVs,
indels, SVs), represented as a conventional count matrix are factorised using the same
exposure matrix
(Epi-)genomic localisation factors Numerous studies found a strong influence of chro-
matin features on regional mutation rates. Strikingly, these effects range from the 10 bp
periodicity on nucleosomes to the scale of kilo to mega bases caused by the epigenetic state
of the genome (Pich et al., 2018; Schuster-Böckler and Lehner, 2012). To understand how
mutational processes manifest on histone-bound DNA, we computed the number of variants
on minor groove DNA facing away from and towards histone proteins, and linker DNA
between two consecutive nucleosomes (Sec. 2.2.1). Additionally, we utilised ChromHMM
annotations from 127 cell-lines to define epigenetic consensus regions (Sec. 2.2.1), which
we used to assign SNVs to epigenetic contexts (Ernst and Kellis, 2012; Kundaje et al., 2015).
Together this adds two dimensions of size 4 and 16 to the count tensor (Fig. 3.1).
Currently available data does not allow to obtain a comprehensive set of epigenetic
annotations matched to the cell of origin for every cancer type. Using a consensus annotation
assigns many regions to a variable (NA) state. While it is currently possible to match 31/37
PCAWG cancer types to cell lines closely corresponding to the presumed cell of origin,
we note that 9,870,018 / 48,329,388 mutations change state using this partially matched
annotation (Fig. B.2). We tested whether this has a major impact on the inference of
epigenetic signature activities, which revealed that partially matched annotated epigenetic
states do have good concordance with the all tissue consensus (Fig. B.3).




































































Fig. 3.3 The lower dimensional structure of the signature tensor. The signature tensor
has itself a lower dimensional structure, defined by the product of strand-specific signatures,
and coefficients reflecting the activity of the mutational process in a given genomic state
combination.
Clustered mutations Finally, there are mutational processes capable of introducing large
numbers of clustered mutations within confined genomic regions. This phenomenon is
termed kataegis and is thought to be caused by multiple mutational processes (Nik-Zainal
et al., 2012; Supek and Lehner, 2017). To detect such mutations, we developed a hidden
markov model (HMM, Sec. 2.2.1) to assign the states clustered and unclustered to each
mutation based on the inter-mutation distance between consecutive mutations. Separating
clustered from unclustered mutations adds the final dimension in the mutation count tensor,
which has a total of 6 dimensions with 2 ⇥ 576 = 1,152 combinations of states (Fig. 3.1).
TensorSignatures learns signatures based on mutation spectra and genomic properties
At its core, mutational signature analysis amounts to finding a finite set of prototypical
mutation patterns and expressing each sample as a sum of these signatures with different
weights reflecting the variable exposures in each sample. Mathematically, this process can be
modelled by non-negative matrix factorisation into lower dimensional exposure and signature
matrices. TensorSignatures generalises this framework by expressing the (expected value
of the) count tensor as a product of an exposure matrix and a signature tensor (Fig. 3.2;
Methods). The key innovation is that the signature tensor itself has a lower dimensional
structure, reflecting the effects of different genomic features (Fig. 3.3). This enables the
model to simultaneously learn mutational patterns and their genomic context – by drawing
information from the whole dataset even when the number of combinations of genomic
states becomes high (1,152), thus yielding a more accurate inference to conventional NMF
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relying on a 96-trinucleotide channel decomposition only and subsequent assessment of
signature properties (Sec. 2.3.2, Fig. 2.11). In this parametrisation each signature is
represented as a set of 2 ⇥ 2 strand-specific mutation spectra and a set of defined coefficients,
measuring its activity in a given genomic state of a given dimension. TensorSignatures
incorporates the effect of other variants (MNVs, indels, SVs), which remain unoriented and
are expressed as a conventional count matrix, by sharing the same exposure matrix as SNVs,
thus enabling to jointly learn mutational processes across different variant classes more
robustly in comparison to approaches which rely on (post-hoc) matching mutational spectra
(Sec. 2.3, Fig. 2.12). TensorSignatures models mutation counts with an over-dispersed
negative binomial distribution, which we tested extensively on simulated data sets (Sec. 2.3.1,
Fig. 2.8-2.10), and enables to choose the number of signatures with established statistical
model selection criteria, such as the Bayesian Information Criterion (BIC, Sec. 2.2.5, Fig.
2.7, B.1).















































































































































































































































































































































































































































































3.1.2 Mutational Signatures are composed of a multitude of mutation
types and vary across the genome
Analysis of 2778 genomes produces 20 TensorSignatures
Applying TensorSignatures to the PCAWG dataset and using the conservative BIC (Fig.
S2) produced 20 tensor signatures (TS) encompassing mutational spectra for SNVs and
other mutation types (Fig. 3.4), and associated genomic properties (Fig. 3.5). Reassuringly,
we extracted a number of signatures with SNV spectra highly similar to the well curated
catalogue of COSMIC signatures (Tab. B.5, Alexandrov et al. (2018); Forbes et al. (2015)).
Interestingly, our analysis revealed a series of signatures that have similar SNV spectra
in common, but differ with regard to their genomic properties or mutational composition.
These signature splits indicate how mutational processes change across the genome and
will be discussed in further detail below. In the following, we refer to signatures via their
predominant mutation pattern and associated genomic properties. Of the 20 signatures, 4
were observed in nearly every cancer type: TS01-N[C>T]G, characterised by C>T mutations
in a CpG context, most likely due to spontaneous deamination of 5-meC, similar to COSMIC
SBS1, TS02-N[C>T]N of unknown aetiology, and two signatures with relatively uniform
base substitution spectra, TS03-N[N>N]N (unknown/quiet chromatin), and TS04-N[N>N]N
(unknown/active chromatin), which loosely correspond to SBS40 and SBS5 (Fig. 3.6).
Signatures are defined by diverse mutation types and genomic properties
While the most prevalent mutations are single base substitutions, there are 16/20 signa-
tures with measurable contributions from other mutation types (>1 %; Fig. 3.5). The most
notable cases are TS15-G[C>T]N;ID, which is similar to a compound of COSMIC signa-
tures SBS6/15/26 + ID1/2 and characterised by C>T transversions in a GCN context and
frequent mono-nucleotide repeat indels (Fig. C.73) indicative of MMRD. Similarly, TS16-
N[C>A]T;ID, likely to reflect concurrent MMRD and POLE exonuclease deficiency, exhibits
large probabilities for deletions (Fig. C.78) and a base substitution pattern similar to SBS14.
Large proportions of SVs (⇠25 %) were found in TS11-T[C>D]W;SV (D = A, G, or T; W =
A or T), which reflects SV-associated APOBEC mutagenesis caused by double strand break
repair with a base substitution spectrum similar to SBS2/13. Furthermore, TS19-N[N>N];SV
apparently reflects a pattern of homologous recombination deficiency (HRD), characterised
by a relatively uniform base substitution pattern similar to SBS3, but a high frequency of
SVs, in particular tandem duplications (Fig. C.93).
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Fig. 3.5 Tensor factors describe a multitude of genomic properties of each tensor signa-
ture. Heatmap visualisation of extracted tensor factors describing the genomic properties
of each tensor signature. Proportions of other mutation types and clustered SNVs are indi-
cated in percentages. Transcriptional and replicational strand biases indicate shifts in the
distribution of pyrimidine mutations on coding/template and leading/lagging strand. Coef-
ficients < 1 (pink) indicate signature enrichment on template or lagging strand DNA, and
conversely values > 1 (green), a larger mutational burden on coding or leading strand (a
value of 1 indicates no transcriptional or replicational bias). Relative signature activities
in transcribed/untranscribed and early/late replicating regions. Coefficients > 1 (turquoise)
indicate enrichment in transcribed and early replicating regions, while values < 1 (brown)
indicate a stronger activity of the mutational process in untranscribed or late replicating re-
gions. Relative signature activities on nucleosomes and linker regions, and across epigenetic
states as defined by consensus ChromHMM states. Scores indicate relative signature activity
in comparison to genomic baseline activity. A value of 1 means no increase or decrease of a
signature’s activity in the particular genomic state, while values > 1 indicate a higher, and
values < 1 imply a decreased activity.
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APOBEC associated signatures TS11 and TS12 as well as mutational processes TS13
and TS14 due to AID activity induce clustered mutations
9/20 signatures displayed a measurable propensity to generate clustered mutations (>0.1
%; Fig. 3.5). The proportions of clustered mutations produced by each mutational process
were highest in signatures associated with APOBEC and activation-induced deaminase
(AID) activity: Up to 79 % and 0.6 % of SNVs attributed to TS11-T[C>D]W;SV and TS12-
T[C>D]W, respectively, were clustered, with otherwise indistinguishable base substitution
spectra. A similar phenomenon was observed in two signatures reflecting Pol ⌘ driven SHM.
While both TS13-N[C>K]H (K = G or T; H = A, C, or T) and TS14-W[T>V]W (V = A, C,
or G) have only mildly diverging base substitution spectra, with TS14 being similar to SBS9,
they dramatically differ in the rates at which they generate clustered mutations, which are 59
% and 1 %, respectively (Fig. 3.5).
UV-light associated TS06 and an unknown mutational process TS08 linked to A[T>C]W
mutagenesis predominantly affect coding and template strand DNA
5/20 signatures exhibit substantial transcriptional strand bias (TSB  10 %; Fig. 3.5). This is
strongest in the UV-light associated signature TS06-Y[C>T]N (Y = C or T), similar to SBS7b,
where the rate of C>T substitutions on the template strand was half of the corresponding value
on the coding strand, highly indicative for active TC-NER. In contrast, TS08-A[T>C]W,
similar to SBS16, shows largest activities in liver cancers and preferably produces T>C
transitions on template strand DNA. In line with a transcription-coupled role, the activity of
TS08 shows a noteworthy elevation in transcribed regions. Both signatures will be discussed
in more detail later on (Sec. 3.1.3 and 3.1.4).
Mutational processes TS12 and TS17 linked to APOBEC and POLE activity introduce
single base substitution with strong replicational strand biases
Analysis of pyrimidine/purine shifts in relation to the direction of replication indicated 9/20
signatures with replication strand biases (RSB  10%). In accordance with previous studies,
TS12-T[C>D]W asserts a higher prevalence of APOBEC-associated C>D mutations, con-
sistent with cytosine deamination, on lagging strand DNA which is thought to be exposed
for longer periods as opposed to more processively synthesised leading strand DNA. Con-
versely, TS17-T[C>A]T, associated with POLE exonuclease variants (SBS10a/b), displays a
pyrimidine bias towards the leading strand (Fig. 3.5, Haradhvala et al. (2018)). Since Pol "
performs leading strand synthesis, the strand bias indicates that C>A (G>T) mutations arise
on a template C, presumably through C·dT misincorporation (Shinbrot et al., 2014). Further
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Mean number of mutations
Fig. 3.6 Signature activity in different cancer types (Exposures). Signature activity in
different cancer types (Exposures). Upper triangles (green) indicate the mean number of
mutations contributed by each signature, lower triangles show the percentage of samples
with a detectable signal of signature defined as the number of mutations attributed to the
signature falling into a signature-specific typical range (Methods). Greyed boxes indicate
cancer types for which a signature was not found to contribute meaningfully.
examples with replication strand biases include the MMRD-associated signatures TS15
and TS16 discussed above. Of note, the two SHM-associated signatures TS13 and TS14
displayed opposing patterns with respect to their activity in oriented (early) and unoriented
(late) replicating regions (Fig. 3.5).
Genomic localisation factors modulate signatures activities, with epigenetic states hav-
ing the greatest influence
To understand how mutational processes manifest on nucleosomal DNA, we estimated
signature activities on minor groove DNA facing away from and towards histone proteins,
and linker DNA between two consecutive nucleosomes (Fig. 3.5). Almost all signatures
showed either an increase or a decrease of mutational rates across all nucleosomal states. The
only exception to this rule is TS20-N[T>G]T (SBS17a/b), which showed a slight decrease in
the outward facing minor groove, while the inwards facing showed elevated mutation rates
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(Pich et al., 2018). TS20 is likely caused by incorporation of dUTP or oxo-dTTP (Tomkova
et al., 2018), possibly, but not necessarily, due to 5-FU treatment (Christensen et al., 2019).
Considering the activities of mutational processes across epigenetic domains, our analysis
indicates that there is not a single mutational process which is acting uniformly on the genome
(Fig. 3.5). However, our results suggest that mutational processes may be categorised into
two broad groups: Those that are elevated in active (TssA, TssAFlnk, TxFlnk, Tx and
TxWk) and depleted in quiescent regions (Het, Quies), and vice versa. This phenomenon
includes the two omnipresent signatures with relatively uniform spectra TS03-N[N>N]N
and TS04-N[N>N]N, suggesting a mechanism associated with the chromatin state behind
their differential manifestation (Fig. 3.4). This also applies to two signatures associated with
UV exposure, TS05-T[C>T]N and TS06-Y[C>T]N, and also two signatures of unknown
aetiology, most prominently found in liver cancers, TS07-N[T>C]N, similar to SBS12, and
TS08-A[T>C]W, which we will discuss in detail in the following section.
3.1.3 The spectrum of UV mutagenesis changes from closed to open
chromatin
Two signatures, TS05-T[C>T]N and TS06-Y[C>T]N, were exclusively occurring in Skin-
Melanoma and displayed almost perfect correlation (Spearman R2 =0.98, Fig. B.4) of
attributed mutations, strongly suggesting UV mutagenesis as their common cause. Both
signatures share a very similar SNV spectrum, only differing in the relative extent of C[C>T]N
and T[C>T]N mutations, which is more balanced in TS06 (Fig. 3.7). However, they strongly
diverge in their activities for epigenetic contexts and transcriptional strand biases: TS05 is
enriched in quiescent regions, and shows no transcriptional strand bias, while the opposite is
true for TS06, which is mostly operating in active chromatin (Fig. 3.5). Of note, the spectra
of these signatures closely resemble that of COSMIC SBS7a and SBS7b, which have been
suggested to be linked to different classes of UV damage (Hayward et al., 2017). However,
as our genomically informed TensorSignature inference and further analysis show, the cause
for the signature divergence may be found in the epigenetic context, which seemingly not
only determines mutation rates, but also the resulting mutational spectra.
Diverging transcriptional strand biases and base substitution spectra differentiate TS05
and TS06
A characteristic difference between the two signatures is the presence of a strong transcrip-
tional strand bias in signature TS06, which is almost entirely absent in signature TS05 (Fig.
3.7). To verify that this signature inference is correct, and the observed bias and spectra
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Fig. 3.7 TS05 and TS06 spectra for coding and template strand DNA, and pooled
PCAWG Skin-Melanoma C>T variant counts. C>T mutation probabilities of TensorSig-
natures TS05 and TS06 for coding and template strand DNA (upper panel), and pooled
PCAWG Skin-Melanoma C>T variant counts (lower panel) from coding and template strand
DNA in epigenetically active (TssA, TssAFlnk, TxFlnk, Tx and TxWk, right) and quiescent
regions (Het and Quies, left).
are genuinely reflecting the differences between active and quiescent chromatin, we pooled
C>T variants from Skin-Melanoma samples which revealed that the data closely resembled
predicted spectra (Fig. 3.7). In addition, quiescent chromatin also displays a predominant
T[C>T]N substitution spectrum (5’C/5’T = 0.3), while the spectrum in active chromatin is
closer to Y[C>T]N (5’C/5’T = 0.58), as predicted by the signature inference (Fig. 3.7). This
difference does not appear to be related to the genomic composition, and holds true even
when adjusting for the heptanucleotide context (Fig. B.5).
The spatial distribution of SNVs in Skin-Melanoma corroborate properties of TS05
and TS06
To verify this, we sought to understand the spatial distribution of mutations in Skin-Melanoma
across the genome. Concretely, if properties of TS05 and TS06 prove well-founded, we
would expect changes in the number of C>T mutations on coding and template strand DNA,
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Fig. 3.8 A spatial analysis of UV-mutagenesis in Skin Melanoma (n=107). Upper panel:
Consensus ChromHMM states from a representative 10 Mbp region on chromosome 1, and
the corresponding mutational density of pooled Skin-Melanoma samples. Middle panel:
N[C>T]N and N[G>A]N counts in 50kbp bins, and their respective ratios (thin blue line:
ratio; thick blue line: rolling average over 5 consecutive bins) illustrate the transcriptional
strand bias of C>T mutations in quiescent and active regions of the genome. Lower panel:
Relationship between expression strength and the spectral shift of C>T mutations in terms
of binned C>T variant counts in TpC and CpC context and their respective ratios (thin blue
line) as well as a rolling average (thick blue line).
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active genomic regions. To demonstrate this, we selected a representative 10 Mb region from
chromosome 1 comprising a quiescent and active genomic region as judged by consensus
ChromHMM states, and the varying mutational density from pooled Skin-Melanoma samples
(Fig. 3.8, upper panel).
To visualise the transcriptional strand bias of UV mutagenesis, we counted the number
of N[C>T]N and its purine equivalent N[G>A]N in 50 kb bins, because dependent on
transcription directionality, these mutations reflect C>T substitutions on template or coding
strand. Strikingly, our analysis revealed that numbers of N[C>T]N and N[G>A]N counts
are roughly equal in quiescent regions, but start to fluctuate in active genomic compartments
which is best visualised by their ratios (Fig. 3.8, middle panel).
Next, to test whether the distribution of C>T mutations changes from quiescent to active
genomic regions, we counted pooled C[C>T]N and T[C>T]N variants in 50 kb bins (Fig. 3.8).
While the difference of T[C>T]N and C[C>T]N mutations is largest in quiescent regions, it
almost diminishes in transcribed genomic regions. We then hypothesised that the degree of
expression may modulate the spectrum of C>T mutations, and computed therefore median
gene expression quartiles from Skin-Melanoma samples (n = 11), which we show together
with the ratio of C[C>T]N and T[C>T]N variants. Strikingly, this analysis showed that
the ratio equals roughly 0.2 in quiescent regions but rises to approximately 0.7 in highly
transcribed regions which closely resembles the prediction of TS05 and TS06 respectively
(Fig. 3.8, lower panel).
































































Fig. 3.9 The effects of gene expression on the transcriptional strand bias and the mu-
tational spectrum of C>T mutations in Skin-Melanoma (PCAWG, n=107). Gene ex-
pression strength vs. transcriptional strand bias (measured by the ratio normalised C>T
variants in Skin-Melanoma on coding and template strand), and gene expression strength vs.
C[C>T]/T[C>T] spectral shift (indicated as the ratio of normalize C>T mutations in 5’C and
5’T context).
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RNA-seq expression data substantiate the evidence for epigenetic modulation of UV-
mutagenesis
These observations are further corroborated by RNA-seq data available for a subset of samples
(n = 11): The transcriptional strand bias is most pronounced in expression percentiles greater
than 50 leading to an increased ratio of coding to template strand mutations (Fig. 3.9).
Again, the decline is accompanied by a shift in the mutation spectrum: While both C[C>T]N
and T[C>T]N variant counts decline steadily as gene expression increases, the reduction of
C[C>T]N mutations is larger in comparison to T[C>T]N mutations, which manifests as an
increasing C[C>T]N and T[C>T]N ratio, reaching a ratio of approximately 0.5 in the highest
expression quantiles (Fig. 3.9).
TS05 and TS06 may represent the interplay of UV-mutagenesis and different modes of
nucelotide excision repair
The diverging activity in relation to the chromatin state suggests an underlying differential
repair activity. Global genome nucleotide excision repair (GG-NER) clears the vast majority
of UV-lesions in quiescent and active regions of the genome and is triggered by different
damage-sensing proteins. Conversely, TC-NER is activated by template strand DNA lesions
of actively transcribed genes. As TS05 is found in quiescent parts of the genome, it appears
likely that it reflects the mutation spectrum of UV damage as repaired by GG-NER (Sec.
1.4.2). Based on the activity of TS06 in actively transcribed regions and its transcriptional
strand bias, it seemingly reflects the effects of a combination of GG- and TC-NER, which are
both operating in active chromatin. This joint activity also explains the fact that the spectrum
of TS06 is found on both template and coding strands.
GG-NER deficient XPC /  cutaneous squamous cell carcinomas genomes lack TS05
This attribution is further supported by data from n = 13 cutaneous squamous cell carcinomas
(cSCCs) of n = 5 patients with Xeroderma Pigmentosum, group C, who are deficient of
GG-NER and n = 8 sporadic cases which are GG-NER proficient (Zheng et al., 2014).
XPC/GG-NER deficiency leads to an absence of TS05 in quiescent chromatin and to a
mutation spectrum that is nearly identical in active and quiescent regions of the genome
(Fig. 3.10). Furthermore, the UV mutation spectrum of XPC/GG-NER deficiency, which is
thought to be compensated by TC-NER, differs from that of TS06, reinforcing the notion that
TS06 is a joint product of GG- and TC-NER. This is further supported by the observation that
XPC/GG-NER deficiency leads to a near constant coding strand mutation rate, independent
of transcription strength (Fig. 3.10, Zheng et al. (2014)), indicating that the transcriptional
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Fig. 3.10 The spectrum C>T mutations of pooled XPCwt and XPC /  cSCC genomes.
Pooled cSCC C>T variant counts from coding and template strand DNA in epigenetically
active (TssA, TssAFlnk, TxFlnk, Tx and TxWk, right) and quiescent regions (Het and Quies,
left), as well as the relationship between gene expression and transcriptional strand bias
(measured by the ratio normalised C>T variants), and the relation between gene expression
and the C[C>T]/T[C>T] spectral shift (indicated as the ratio of normalised C>T mutations in
5’C and 5’T context) in GG-NER wildtype (XPCwt , upper panel) and deficient (XPC / ,
lower panel) cSCC genomes. Blue curves: quadratic fit.
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dependence of coding strand mutations in GG-NER proficient melanomas and cSCCs is due
to transcriptionally facilitated GG-NER.
While the activity patterns of TS05/06 and appear to be well aligned with GG-NER
and GG/TC-NER, these observations, however, do not explain the observed differences
in mutation spectra. The fact that the rates of C[C>T]N and T[C>T]N mutations change
between active and quiescent chromatin – and the fact the these differences vanish under
XPC/GG-NER deficiency – suggests that DNA damage recognition of CC and TC cyclobu-
tane pyrimidine dimers by GG-NER differs between active and quiescent chromatin, with
relatively lower efficiency of TC repair in quiescent genomic regions, as evidenced by TS05.
3.1.4 Transcription-associated mutagenesis manifests in an ApT con-
text in highly transcribed genes
Diverging mutational spectra between active and quiescent chromatin were also observed
in liver cancers (Fig. 3.5, 3.6), driven by differential activity of TS07-N[T>C]N and TS08-
A[T>C]W, which closely resemble COSMIC signatures SBS12 and SBS16, respectively.
In line with previous findings, there was a strong transcriptional bias of TS08, introducing
1.6⇥ more T>C variants on the template strand (Fig. 3.5). While both signatures are
most frequently found in liver cancers, where they are strongly correlated (R2 = 0.68, Fig.
B.6), they are also observed in a range of other cancers, indicating that they are reflecting
endogenous mutagenic processes.
TS08 is characterised by a depletion of single base substitutions in 5’-B context and a
strong transcriptional strand bias towards template strand DNA
The most prominent difference between these signatures is the depletion of mutation types
in 5’-B context on coding strand DNA in TS08 (Fig. 3.11; B = C, G, or T). This attribution
into signatures is confirmed when directly assessing mutation spectra in active and quiescent
regions of Liver-HCC (Fig. 3.11). TS08 displays a strong transcriptional strand bias,
as previously noted for SBS16 (Letouzé et al., 2017), and is confirmed here by a direct
investigation of variant counts. A further defining feature of TS08 are indels  2 bp (Fig. 3.4,
C.38), which were reported to frequently occur in highly expressed lineage-specific genes in
cancer (Imielinski et al., 2017), consistent with experimental data of transcription-replication
collisions (Sankar et al., 2016).
3.1 Discovering tensor signatures 105
AA AC AG A
T





























AA AC AG A
T
















AA AC AG A
T








T TA TC TG T
T










AA AC AG A
T








T TA TC TG T
T






Fig. 3.11 Spectral differences of T>C mutagenesis in liver cancers. Upper panel: T>C
mutation type probabilities of TensorSignatures TS07 and TS08 for coding and template
strand DNA. Lower panel: Pooled PCAWG Liver-HCC T>C variant counts for coding and
template strand DNA in epigenetically active and quiescent regions.
Active and quiescent genomic regions determine the interplay of the mutational pro-
cesses TS07 and TS08 in Liver-HCC
In Liver-HCC, these two processes produce a regionally changing mutation spectrum between
active and quiescent genomic environments (Fig. 3.12). Indeed, the ratio of T>C and
complementary A>G mutations confirmed that the transcriptional strand bias of TS08 arises
exclusively in active genomic regions (Fig. 3.12). These are accompanied by a change from
a N[T>C]N and to an A[T>C]W spectrum, changing from a 5’A/5’B ratio of approximately
0.4 in quiescent regions to a value of up to 1 in active regions (Fig. 3.12, B.7).
Transcription-associated mutagenesis manifesting as A[T>C] mutations is found in a
range of cancer types
We then systematically analysed the effect of transcription strength on T>C mutagenesis
in samples with detectable TS07 and TS08 exposures in Liver-HCC and different cancer
types. Mutation rates showed a dynamic relation to transcriptional strength (Fig. 3.13).
Initially, normalised counts of T>C mutations on coding and template strand initially decline
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Fig. 3.12 Spatial analysis of T>C mutagenesis in liver cancers. Upper panel: Consensus
ChromHMM states from a representative 10Mbp region on chromosome 2 depicting an active
and quiescent genomic region, and the corresponding mutational density from pooled Liver-
HCC samples. Middle panel: Illustration of the transcriptional strand bias in terms of 100kbp
binned N[T>C]N and N[A>G]N counts, and respective ratio (thin blue line). The thick blue
line depicts the corresponding rolling average over 5 consecutive bins. Lower panel: Changes
in the distribution of T>C mutations in an active and quiescent genomic regions in terms of
100kpb binned A[T>C]N and B[T>C]N counts. Thin orange line: A[T>C]/B[T>C] ratio,
thick orange line: rolling average over 5 consecutive bins.
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Expression strength vs. strand bias and spectralshift
Fig. 3.13 Transcription strand bias and spectral shift in samples from different cancers
with TS07 and TS08 contributions. Blue and orange lines correspond to quadratic fits of
respective ratios.
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quantiles (>50), but reverses on the template strand, producing more N[T>C]N mutations
the higher the transcription, in line with previous reports of TAM (Haradhvala et al., 2016).
Of note, this process mostly generated A[T>C]N mutations, in line with our signature
inference. This effect is commonest in Liver-HCC samples, but is also found in Head-SCC,
Stomach-AdenoCa and Biliary-AdenoCa (Fig. 3.13), showing that A[T>C]W TAM and
N[T>C]N mutagenesis in quiet regions occur in a range of cancers and also normal Esophagus
(Martincorena et al., 2018). In fact, it has been observed that SBS5, one of three widely
active signatures, displays signs of potential contamination by SBS16/TS08, which may be
more precisely resolved by the genomically informed TensorSignature analysis.
3.1.5 Replication- and DSBR-driven mutagenesis by APOBEC3A and
APOBEC3B
In the following, we turn our focus to TS11-T[C>D]W;SV and TS12-T[C>D]W, which both
share a base substitution spectrum attributed to APOBEC mutagenesis, but differ greatly
with regard to their replicational strand bias, broader mutational composition, and clustering
properties. While TS12 is dominated by SNVs (99 %) with strong replicational strand bias,
SNVs in TS11 make up only 64 % of the overall spectrum and are highly clustered. The
rest of the spectrum is mostly dominated by structural variants (Fig. 3.14, upper panel; Fig.
C.53). This signature split reveals two independent triggers of APOBEC mutagenesis, which
is thought to require single stranded DNA as a substrate, present either during lagging strand
replication, or double strand break repair (DSBR). In the following, we will further assess
the genomic properties of these two different modes of action.
Pooled base subtitution spectra spectra verify the genomic properties of TS11 and
TS12
To verify the split, we pooled C>G and C>T variants from 30 and 15 samples with high
TS11 and TS12 exposures, respectively (TS11 and TS12 contributions >10 % and 70 %
respectively, Fig. 3.14, lower panel). We noticed that the spectrum in TS12-high samples was
clearly dominated by T[C>D]N mutations, whereas the distribution in TS11-high samples
was cross-contaminated by other mutational processes. However, assessment of replicational
strand biases revealed that lagging strand mutations were twice as large as leading strand
mutations in TS12-high samples, but not in TS11-high samples. Moreover, the proportion of
clustered variants in TS12-high samples was much lower than in TS12-high in line with the
signature inference (Fig. 3.14, lower panel).
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Fig. 3.14 Diverging properties of TS11 and TS12. Upper panel: C>G and C>T spectra
of TS11 and TS12 for leading and lagging strand DNA. Pie charts underneath indicate
percentages of clustered mutations and the contribution of other mutation types in TS11 and
TS12. Lower panel: Observed unclustered (top) and clustered variants (bottom) in TS11 and
TS12 high samples.
The association of SVs as well as genomic properties of TS11 indicate colocalisation of
clustered mutations at sites of structural variation
The association of TS11 with structural variants suggests clustered APOBEC mutagenesis
at sites of DNA double strand break events. This is confirmed by the spatial co-occurrence
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Fig. 3.15 TS11 mutation cluster coincide with sites of structural variation. Rainfall plots
with SV annotations from a typical sample with high TS11 (top) and TS12 contributions
(bottom).
of SVs and clustered mutations (a feature not directly measured by TensorSignatures; Fig.
3.15). Furthermore, SV-proximal clustered variants do not display a replicational strand
bias, adding further weight to the notion that these arise in a DSBR-driven, replication-
independent manner (Fig. B.8). Interestingly, SV-distal clusters displayed, on average, only
a very weak replicational strand bias, indicating that the majority of these foci arose in a
replication-independent fashion, presumably during successful DSBR, which did not create
SVs.
TensorSignatures helps to tell apart differences in the distribution of clustered variants
due to replication- and DSBR driven APOBEC mutagenesis
Next, we assessed whether differences exist in the characteristics of clustered variants, beyond
the fact that these are much more frequent in DSBR driven mutagenesis. To this end, we
pooled clustered variants from TS11/12-high samples and computed their size distribution,
which revealed that the length of mutation clusters tend to be larger at SVs (Median 717 vs.
490bp, Fig. 3.16). This goes in line with the observation that clustered mutations at DSBRs
tend to have more mutations per cluster (Median 5 vs. 4 variants; Fig. 3.16).
Differential size distributions of clustered variants suggest APOBEC isoform-specific
activities
Differential size distributions of TS11/12 mutation clusters raise the question if an APOBEC
subtype-specific activity is underlying their distinct genomic manifestation. Previous studies
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Fig. 3.16 Size distribution of TS11 and TS12 mutation clusters. Size distribution of muta-
tion clusters (consecutive clustered mutations), and the distribution of number of variants per
mutation cluster in TS11 and TS12 high samples respectively. Curves depict corresponding
kernel density estimates.
linked the motifs YT[C>T]A and RT[C>T]A to APOBEC3A and APOBEC3B mutagenesis,
respectively (Roberts et al., 2013). To test whether TS11 or TS12 clusters may be linked one
or the other isoform, we extracted the pentanucleotide context at clustered T[C>T]A sites
from samples with high TS11 or TS12 contributions. Clustered TS12 mutations comprise
only a small fraction of purines, while this proportion increases to approximately 50 % in
TS11 samples. These findings may indicate larger contributions of APOBEC3A and 3B in
TS12 and TS11 samples, respectively (Fig. 3.17, B.9). To confirm this, we assessed samples
that harboured a germline copy number polymorphism that effectively deletes APOBEC3B
(Nik-Zainal et al., 2014). This analysis was unfortunately inconclusive, as the subset of
PCAWG samples for which this annotation was available, did not show any activity for TS11.
Taken together, these results indicate that there are two distinct triggers of APOBEC
mutagenesis, induced by DSBR or replication. Higher rates, longer stretches and larger
proportions of RT[C>T]A APOBEC mutation clusters in the vicinity of SVs, as evidenced
by TS11, suggests that DSBR leads to larger and possibly longer exposed stretches of
single-stranded DNA, possibly due to APOBEC3B. Conversely, lower rates, shorter stretches
and a high fraction of YT[C>T]A mutation clusters of TS12 in conjunction with a strong
replicational strand bias indicate APOBEC3A mutagenesis during lagging strand synthesis,
which is more processive than DSBR, allowing for fewer and shorter mutation clusters only.
3.1.6 Clustered somatic hypermutation at TSS and dispersed SHM
Two other TensorSignatures produced substantial amounts of clustered variants with, but
different epigenomic localisation. TS13-N[C>K]H showed largest activities in lymphoid
cancers and produced 60 % clustered variants (Fig. 3.5). The SNV spectrum resembles
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Fig. 3.17 Higher order tetranucleotide motif logo plots at clustered TS11 and TS12
mutations indicate prevalent APOBEC3A and 3B mutagenesis. Motif logo plots of the
tetranucleotide context at mutated TCA sites in yeast cells exposed to APOBEC3A and 3B
mutagenesis respectively (Chan et. al.), and similar motif logo plots extracted at clustered
mutations from samples with high TS11 or TS12 exposures.
the c-AID signature reported previously (Kasar et al., 2015), suggesting an association
with activation-induced cytidine deaminases (AID), which initiates somatic hypermutation
in immunoglobulin genes of germinal centre B cells. Like its homolog APOBEC, AID
deaminates cytosines within single stranded DNA, although it targets temporarily unwound
DNA in actively transcribed genes, rather than lagging strand DNA or DSBRs (Muramatsu
et al., 2000; Pham et al., 2003).
TS13 activity is strongly associated with transcription start sites, while mutations of
TS14 disperse genome wide
TensorSignatures analysis reveals that TS13 activity is 9⇥ and 8⇥ enriched at active tran-
scription start sites (TssA) and flanking transcription sites (TxFlnk, Fig. 3.5), respectively. To
illustrate this, we pooled single base substitutions from Lymph-BHNL samples and identified
mutational hotspots by counting mutations in 10 kb bins (Fig. 3.18). Inspection of hotspots
confirmed that clustered mutations often fell accurately into genomic regions assigned as
TssA (Fig. 3.18). The aggregated clustered mutation spectrum in TssA/TxFlnk regions across
lymphoid neoplasms (Lymph-BNHL/CLL/NOS, n = 202) indeed showed high similarity to
TS13, possibly with an even more pronounced rate of C>K (K=G or T) variants similar to
SBS84 (Fig. 3.18, Alexandrov et al. (2019)). Conversely, the clustered mutational spectrum
from all other epigenetic regions was characterised by a larger proportion of T>C and T>G
mutations, similar to TS14-W[T>V]W, which only produces about 1 % clustered mutations
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Fig. 3.18 TS13 and TS14 mutation clusters occur at genomically distinct regions. Upper
panel: Rainfall plot of pooled variants from Lymph-BHNL samples on chromosome 1
(highlighted dots indicate clustered mutations). Binned (10 kb) SNV counts of chromosome
1. Numbers 1-4 indicate mutation hotspots. Middle panel: Consensus ChromHMM states
and rainfall plots of mutation hotspots. Lower panel: Pooled clustered variants from PCAWG
Lymph-BHNL/CLL/NOS samples from TssA or TxFlnk (TS13-like), and all other epigenetic
states (TS14-like).
and closely resembles SBS9, attributed to Pol ⌘-driven translesion synthesis (TLS) during
somatic hypermutation.
TS13 mutation cluster are longer and contain more variants per cluster in comparison
to TS14 mutation cluster
While TS13 and TS14 are strongly correlated (R2 = 0.88, Fig. B.10), the diverging lo-
calisation pattern and SNV spectrum, characterised by higher rates of C>K mutations in
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Fig. 3.19 Size distribution and number of mutations in TS13 and TS14 mutation clus-
ters. Size distribution of mutation clusters (consecutive clustered mutations), and the distribu-
tion of number of variants per mutation cluster in TS13 and TS14 high samples respectively.
TS13, indicates that a related, but different mutational process drives TSS hypermutation,
seemingly linked to AID. The differential mechanism behind TS13 also manifests as longer
clusters (Median: 1,068 vs. 183bp), which contain more variants per cluster (Median: 8 vs.
3 mutations) in comparison to TS14 (Fig. 3.18).
TS14 is found in a broad range of cancers and is predominantly active in late replicat-
ing region; TS13, on the other hand, in early replicating regions
As a further distinction, the weakly clustered TLS signature TS14 can be found in more
than 15 cancer types, suggesting a broad involvement of this mutagenic process in resolving
endogenous and exogenous DNA alterations (Supek and Lehner, 2017). Pol ⌘ has also been
described to compete with lagging strand DNA synthesis (Kreisel et al., 2019), which is
further corroborated by the fact that TS14 displays a mild replicational strand bias (RSB =
0.9; Fig. 3.5). Interestingly, TS14 is found to be predominantly active in regions without
replication orientation (aRS = 0.7), which are usually far from the origin of replication (Fig.
3.5). Conversely, TS13 is mostly found in oriented, early replicating regions, but does
not display a measurable replicational strand bias (Fig. 3.5), indicating different modes of
activation.
The HMF cohort contains a third mutational signature of somatic hypermutation
Finally, a third mutational signature of somatic hypermutation, TS30 (see next section Fig.
3.22), was found in lymphoid and other cancers of the HMF cohort. This signature displayed
a large proportion of clustered mutations and an enrichment in early replicating regions
similar to TS13, combined with an SNV spectrum that was closer to TS14 (Cosine distance
0.13 vs. 0.25), suggesting that TS30 may represent a combination of TS13 and TS14.
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3.2 Validating tensor signatures in the HMF cohort
The aforementioned observations were replicated in a fully independent second cohort of
whole genomes from the Hartwig Medical Foundation with 3,824 samples from 31 cancers
encompassing 95,531,862 SNVs, 1,628,116 MNVs, 9,228,261 deletions, 5,408,915 insertions
and 1,001,433 structural variants (Priestley et al., 2018).
3.2.1 Applying TensorSignatures to the genomes of the HMF cohort
produced 27 tensor signatures
Applying TensorSignatures to this data set produced 27 tensor signatures (Fig. 3.20, 3.22,
3.23, and B.11). Of these 10 closely resembled (cosine distance < 0.2) signatures of the
discovery analysis with closely matching genomic activity coefficients (Fig. 3.21, B.12).
These include the signatures of spontaneous deamination TS01, the two signatures of UV
mutagenesis TS05/06, SV-associated APOBEC mutagenesis TS11, as well as signatures of











































































































































Fig. 3.20 Validated HMF signatures. Validated tensor signatures with high similarity
(indicated as cosine distance) to the mutational processes extracted in our discovery analysis
























































































3.2 Validating tensor signatures in the HMF cohort 117
A further 7 signatures seemingly constitute splits of tensor signatures from the PCAWG
cohort (Fig. 3.22). A complex three-way split appeared to occur for TS03 and TS04, which
were found in a broad range of cancer types. One of the derivative signatures resembles
the mutation spectrum of SBS8 from the COSMIC catalogue, however without measurable
transcriptional strand bias. A second derived signature is similar to SBS39; our analysis
reveals replication strand bias for C>G variants and a potentially wider range of cancer types
for both signatures. Further, signature TS12, resembling replication associated APOBEC
mutagenesis, split into two signatures with base substitution spectra similar to SBS2 (C>T)
and SBS13 (C>G), but preserving the strong replication strand bias. Lastly, a split of TS10,




























































































Fig. 3.22 Split HMF signatures. TensorSignature splits that seemingly represent derivatives
of tensor signature TS03, TS04, TS10 and TS12. Single base substitution spectra and a
summarised representation of other mutation types, as well as replication and transcription
biases (representation analogous to Fig. 3.4).
Finally a set of 10 novel signatures without close match to those in the PCAWG cohort
was found (Fig. 3.23). This includes five spectra linked to cancer therapies, illustrating the
additional insights on preceding therapies provided by the HMF metastatic cancer cohort.
TS21 is characteristic of treatment with the methylating agent temozolomide (SBS11);
the observed transcriptional strand bias reflects a higher rate of G>A mutations on the
coding strand (equivalent to higher rates of C>T on the template strand), consistent with
methyl guanine being removed by TC-NER in the absence of MGMT. TS22 and TS23
have been previously associated with cisplatin (termed E-SBS21 and E-SBS14, Christensen
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et al. (2019); Pich et al. (2019)). While both signatures exhibit mild transcriptional strand
biases, only TS23 shows a strong association with MNVs going in line with the propensity
of cisplatin/oxaliplatin to form intrastrand DNA adducts (Fig. 3.23). TS24 displays the
characteristics of treatment with 5-FU, which inhibits thymine synthesis and has been
proposed to be mutagenic via genomic fluorouracil incorporation (Christensen et al., 2019).
TS28, with similarity to SBS41, was only found in two samples, possibly due to treatment
with the experimental drug SYD985, which consists of a duocarmycin-based HER2-targeting









































































































































Fig. 3.23 New HMF signatures. Novel tensor signatures of the HMF cohort. Single base
substitution spectra and a summarised representation of other mutation types, as well as
replication and transcription biases (representation analogous to Fig. 3.4).
Further, TensorSignatures detected a signature of colibactin, TS25, which has been
previously characterised (Pich et al., 2019; Pleguezuelos-Manzano et al., 2020). TS25
displays contributions of MNVs and short indels, activity in active genomic regions and
concomitant transcriptional strand bias of T>C mutations (Fig. 3.23, 3.21). TS26’s indels and
similarity to SBS15 suggests an association with MMRD; TS27 has an unknown aetiology
and displays strong replicational strand bias. The large proportion of structural variants
and the flat SNV spectrum of TS29 may represent non-specific mutagenesis at SVs. TS30
was found in lymphoid and other cancers and had a high proportion of clustered mutations,
similar, but not identical to TS14 (Fig. 3.21).
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3.2.2 TC-NER changes the mutation spectrum of tobacco-assocatiated
mutations
A similar split of an exogenous mutational signature into quiet and active chromatin was
observed in lung cancers (pooled squamous cell and adeno-carcinoma) of the HMF cohort
where TS10 splits into two signatures, HMF TS10-q, which shows largest activity in hete-
rochromatin, while HMF TS10-a is enriched in actively transcribed regions, and exhibits
a strong transcriptional strand bias with lower rates of C>A changes on the coding strand,
equivalent to G>T transversions on the template strand (Fig. 3.22, 3.21, 3.24). This strand
bias has been attributed to TC-NER removing benzo[a]pyrene derived adducts on guanines
from the template strand (Pleasance et al., 2010b).
The emergence of two mutational signatures indicates that this repair process also changes
the mutation spectrum. The suggested split is also evident in pooled mutations from HMF
lung cancers in quiescent and active genomic regions, respectively, revealing that predicted
spectra coincide with corresponding tensor signatures HMF TS 10-q and TS10-a (Fig. 3.24).
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Fig. 3.24 TC-NER changes the mutation spectrum of tobacco-assocatiated mutations.
C>A mutation type probabilities of HMF TS10-q and TS10-a for coding and template strand
DNA.
The C>A (G>T) mutation spectrum observed in quiescent regions, extracted by HMF
TS10-q, displays highest rates of mutations in a CCN (NGG) context (Fig. 5a). Interestingly,
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the same pattern is also observed in actively transcribed regions for C>A on the template
strand, equivalent to G>T mutations on the coding strand. This is in contrast to the C>A
coding strand pattern, and HMF TS10-a, for which this difference is largely eroded. These
observations reflect how TC-NER removes genotoxic guanine adducts from the template
strand, which leads to lower mutation rates and also a more homogeneous base context of
G>T mutations. The differentential mutation spectrum indicates that either the efficiency of
TC-NER – or the mutagenicity of residual genomic alterations – differs depending on the
base context, analogous to observations in UV-induced mutagenesis. The result being that
the mutation types and rates caused by tobacco-associated carcinogens differ between coding
and template strand in transcribed regions and also to different mutation spectra in quiescent
and active genomic regions.
3.3 Further tensor signatures in cancer and normal tissues
During my PhD, I applied TensorSignatures to a variety of datasets. These included studies
with the aim to delineate the genomic effects of proofreading deficiencies in replicative
DNA polymerases (Sec. 3.3.1) and mismatch repair deficiency (Sec. 3.3.2), an analysis of
the mutational landscape in oesophageal adenocarcinoma (Sec. 3.3.3) and human bladder
urothelium (Sec. 3.3.4), as well as a comparative study with the goal to understand the
mutational processes in normal and tumorous samples from various tissues (Sec. 3.3.5).
Following sections briefly describe my contributions to these analyses.
3.3.1 Elevated somatic mutation burdens in normal human cells due
to defective DNA polymerases
Replicative DNA polymerases Pol " and Pol   are characterised by remarkably low base
substitution error rates, which are partly due to their intrinsic proofreading activities, en-
abling them to detect and remove wrongly incorporated bases during DNA replication (Sec.
1.2.3). However, germline mutations in the POLE and POLD1 exonuclease domain may
cause polymerase proofreading associated polyposis, which manifests as early-onset cancer,
especially in fast dividing epithelia from tissues such as the colon, rectum and endometrium.
An appealing hypothesis for the aetiology of this syndrome are elevated mutation rates due
to the defects in the aforementioned enzymes. To understand the consequences of proofread-
ing deficiencies in Pol " and Pol  , this study sequenced normal tissues from individuals
with germline exonuclease mutations in POLE (L424V, n = 8) and POLD1 (S478N, n = 4;
L474P, n = 1; D316N, n = 1). Here, I analysed the somatic mutational catalogue of 211
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samples, which represent branches in reconstructed phylogenetic trees of fourteen individ-
uals, comprising a total of 1,971,246 SNVs, 2,594 MNVs, 26,869 deletions and 135,452
insertions.
Contributions
This chapter is based on data from the bioarxiv manuscript “Elevated somatic mutation
burdens in normal human cells due to defective DNA polymerases” by Philip S. Robinson,
Tim H.H. Coorens, Claire Palles, Emily Mitchell, Federico Abascal, Sigurgeir Olafsson,
Bernard Lee, Andrew R.J. Lawson, Henry Lee-Six, Luiza Moore, Mathijs A. Sanders,
James Hewinson, Lynn Martin, Claudia M.A. Pinna, Sara Galvotti, Peter J. Campbell, Inigo
Martincorena, Ian Tomlinson, Michael R. Stratton. H.V. conducted the mutational signature
analysis and produced the figures presented in this section. The authors acknowledged my
efforts.
The mutational signatures of proofreading deficient replicative DNA polymerases
The TensorSignatures analysis revealed eight mutational processes (Fig. D.1), four of which
closely resemble previously presented tensor signatures, as well as additional four mutational
processes that seemingly represent the consequences of proofreading deficiencies. Former
include TS01, indicative for spontaneous deamination of 5-meC, two cancer treatment
associated signatures TS23 and TS24 (Pich et al., 2019), as well as a TS25-like signature,
likely due to colibactin exposure (Pleguezuelos-Manzano et al., 2020). The remaining
four mutational processes are characterised by sharp C>A peaks at TT contexts and strong
replicational strand biases towards leading (TS17 and TS17-a) and lagging strand DNA
(TS-POLD1 (Ins) and TS-POLD1), consistent with defects in the exonuclease domain of Pol
" and Pol  , respectively (Fig. 3.25, D.2, D.3, D.4, and D.5).
Closer inspection of TS17 reveals low contributions of insertions and a decreased signa-
ture activity in transcribed epigenetic states (Tx, TxWk), while TS17-a exhibits a characteris-
tic C>T pattern, closely resembling COSMIC SBS10b, and a slight enrichment in transcribed
regions (Fig. 3.25). To verify the epigenetic activation pattern of both signatures, I pooled
mutations from POLE L475V samples in transcribed and heterochromatic regions, revealing
that the C>A/C>T ratio decreases from 1.2 in heterochromatic to 0.6 in transcribed regions,
going in line with a higher activity of TS17-a in transcribed regions (Fig. D.6). A similar
pattern was observed for both POLD1 tensor signatures, albeit the contribution of insertions
in TS-POLD1 (Ins) makes up a substantially larger fraction of 31 %. Inspection of pooled





































































































Fig. 3.25 Tensor signatures and accompanying tensor factors of proofreading deficient
DNA polymerases (Robinson et al., 2020). Upper panel: single base substitution spectra
and a summarised representation of other mutation types, as well as replication and transcrip-
tion biases (representation analogous to Fig. 3.4). Lower panel: accompanying tensor factors
(representation analogous to Fig. 3.5).
C>A mutations in TT and TA context in transcribed regions, consistent with higher activity
of TS-POLD1, as predicted by the inference (Fig. D.6).













































































Fig. 3.26 The signature composition of samples with defects in the proofreading domain
of replicative DNA polymerases (Robinson et al., 2020). Absolute and relative signature
contributions, each bar represents a sample.
POLD1 L478P and D316N samples exhibit TS-POLD1 (Ins) mutations but lack TS-
POLD1 activity
The attribution of TS17 and TS17-a to POLE defects, as well as TS-POLD1 (Ins) and
TS-POLD1 to POLD1 deficiencies is corroborated by analysing the signature composition of
respective samples (Fig. 3.26). Samples harbouring the L472V mutation in the exonuclease
domain of Pol " are largely composed of TS17-a and TS17 mutations, while most POLD1
S478N samples are dominated by TS-POLD1 (Ins) mutations, and a few samples with
substantial contributions of TS-POLD1. On the other hand, POLD1 L478P and D316N
exhibit milder contributions of TS-POLD1 (Ins), and almost no TS-POLD1 contributions,
indicating that these mutations cause a less severe phenotype in comparison to the S478N
mutation.
3.3.2 The mutational signatures of DNA mismatch repair deficiencies
The DNA mismatch repair pathway is crucial to ensure high fidelity DNA replication, and is
mediated in humans by the orchestration of the proteins Msh2, Msh6, Mlh1 and Pms2. DNA
mismatches occur when DNA polymerases insert wrong bases opposite to template DNA
and fail to excise them via their proofreading activities, or at sites of small insertions and
deletions. Shortly after DNA replication, the Msh2:Msh6 heterodimer MutS scans newly
synthesised DNA for mismatches, and recruits upon lesion detection a second heterodimer
MutL composed of Mlh1 and Pms2, that nicks the DNA segment containing the mismatch,
thus preparing it for excision and subsequent repair (Sec. 1.4.2). This study aimed to
characterise the genomic effects of germline mutations in MSH6, PMS2 and MLH1 in a
cohort of 215 samples, which represent branches in reconstructed phylogenetic trees of 15
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individuals. The dataset comprised 1,253,549 SNVs, 4,200 MNVs, 359,471 deletions and
252,982 insertions.
Contributions
This sections contains preliminary results obtained in collaboration with Mathijs A. Sanders
and contains the results of a manuscript in preparation. H.V. conducted the mutational


















































































































































10 2 0.3 0.1 1.2 1.4 NA 0.8 1.3 1.5 NA NA NA 0.6 1.4 1.4
1.2 0.5 0.7 0.6 0.8 NA 0.2 1.1 1.2 NA NA NA 1.5
2.7 2.1 0.7 0.8 NA 0.5 0.8 0.8 NA NA NA 0.9 0.7
1.8 1.2 0.6 0.7 0.8 NA 1.2 0.7 1.5 NA NA NA 1.7 1.6
10 2 0.4 NA 1.2 1.5 NA 1.2 0.8 1.6 NA NA NA 0.6 1.2 2.1
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Fig. 3.27 Tensor signatures and accompanying tensor factors of mismatch repair defi-
ciencies. Upper panel: single base substitution spectra and a summarised representation of
other mutation types, as well as replication and transcription biases (representation analogous
to Fig. 3.4). Lower panel: accompanying tensor factors (representation analogous to Fig.
3.5).





























































Fig. 3.28 The mutational composition of samples with defects in the mismatch repair
pathway. Absolute and relative signature contributions, each bar represents a sample.
The analysis of 215 MMRD deficient samples revealed six tensor signatures
The analysis revealed six mutational processes (Fig. D.7), comprising TS01 and TS20,
representative for spontaneous deamination of 5-meC and an unknown mutational process
(possibly 5-FU treatment), respectively, as well as four additional signatures, which are likely
to depict the mutational imprints of mismatch repair deficiencies (Fig. 3.27). TS-MMRD
(T>C) base substitution spectrum is characterised by T>C mutations, smaller contributions
of insertions, and a slight replicational strand bias towards lagging strand DNA (Fig. D.8).
TS-MMRD (C>A) exhibits a sharp C>A peak at a CT context, and comprises roughly 20 %
of other mutation types (Fig. D.9). Finally, there are two mutational processes, TS-MMRD
(Ins) and TS-MMRD (Del), which are mainly consist of insertions and deletions, respectively,
although the former signature also features a distinct C>T pattern with a peak at GG contexts
(Fig. D.10, D.11).
MSH6 deficient samples fail to repair demethylated 5me-C, while defects in the MMR
endonuclease lead to the accumulation of insertions
The decomposition of active mutational processes in MSH6 deficient samples revealed TS01
as a major contributor to the mutational landscape, suggesting that the MutS protein complex
fails to detect T:G mispairs, which result from spontaneous demethylation of 5-meC (Sec.
1.3.1). Moreover, MSH6 deficient samples showed elevated activities of TS-MMRD (T>C)
and TS-MMRD (C>A), but harboured only smaller contributions of TS-MMRD (Ins) and
TS-MMRD (Del), indicating that the recognition of indels is less impaired. In contrast,
MLH1 and PMS2 deficient samples showed strong contributions of the insertion signature
TS-MMRD (Ins), suggesting that the endonuclease activity of MutL is crucial to deplete this
mutation type from the genome (Fig. 3.28).
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3.3.3 The mutational landscape of oesophageal adenomacarcinoma
Oesophageal cancer is one of the most prevalent form of malignant tumours in western
countries, and ranks as the sixth most common cause of cancer-related death worldwide
(Frankell et al., 2019). Particularly, oesophageal adenoma carcinomas (OACs) are highly
aggressive, clinically late diagnosed and often highly resistant to chemo therapy. Also, OACs
exhibit very high mutation rates, as well as marked chromosomal instability, and are thus
classified as C-type neoplasm, which are predominantly caused by SVs rather than mutations
(Frankell et al., 2019). The OCCAMS study aimed to characterise genomic biomarkers
in OAC by analysing the genomes from patients recruited across the UK. Here, I applied
TensorSignatures to a dataset of 383 OAC samples with variable chemo therapy status,
comprising 12,877,577 SNVs, 77,034 MNVs, 623,030 deletions, 327,308 insertions and
106,599 SVs.
The analysis of the OCCAMS dataset revealed 15 tensor signatures
The analysis of the OCCAMS dataset revealed 15 mutational processes, indicative for the
highly heterogenous mutational landscape of OACs. Ten of these mutational processes closely
resemble previously described signatures: TS01, descriptive for spontaneous demethyla-
tion of 5-meC; an TS08-like signature, possibly due to transcription coupled mutagenesis;
TS12, indicative of APOBEC mutagenesis on lagging strand DNA; TS15, most likely due
to MMRD; TS18, indicative of defects in the BER pathway; TS11, implying failure of
homologous recombination; two signatures TS20-early and TS20-late, possibly associated
with 5-FU treatment, and whose split shall be discussed later on; TS23, indicative of cancer
treatment with cisplatin; and a TS25-like signature, which is associated with the exposure to
colibactin. In addition, the tensor decomposition gave rise to five novel signatures. These
include TS-OAC (flat), which is slightly clustered and exhibits a relatively flat spectrum,
as well as TS-OAC (C>T), whose single base substitutions remind of COSMIC SBS30, a
signature that has been associated with defects in the NHTL1 gene of the BER pathway (Sec.
1.6). The remaining three signatures TS-OAC (Indel), TS-OAC (Del) and TS-OAC (SV)
were associated with other mutation types and displayed rather cryptic SBS spectra.
The tensor factorisation revealed a split of TS20, which is likely to be driven by dif-
ferential activity in early and late replicating regions (Fig. D.13). In agreement with this
hypothesis, TS20-early exhibits a slightly stronger replicational strand bias in comparison to
TS20-late, and is detectable in epigenetically active genomic regions (Fig. D.13), which tend
to colocalise at early firing ORIs.
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Fig. 3.29 The tensor signatures of oesophageal adenomacarcinomas. The representation
of tensor signatures analogous to Fig. 3.4.
The mutational composition of chemotherapy naive and treated OACs
Next, I analysed the mutational composition of chemotherapy naive and treated OACs (Fig.
3.30), which both exhibit a very heterogenous mutational composition, often indicating
substantial contributions from four or more mutational processes. The great majority of
samples show high activity of TS18, TS20-early and TS20-late, as well as to lower extend
contributions from TS25 and TS-OAC (C>T). Samples with high mutational burden show
strong activities of TS08, TS15 and TS-OAC (Del). The co-occurrence of TS-OAC (Del)

































































































Fig. 3.30 The signature composition of chemo therapy naive and treated oesophageal
adenocarcinoma. Absolute and relative signature contributions, each bar represents a
sample.
3.3.4 Extensive heterogeneity in somatic mutation and selection in the
human bladder
Bladder urothelium is constantly exposed to urine, which may contain mutagenic molecules
such as aromatic amines from tobacco smoke or aristocholic acid from herbal remedies.
Although the tissue is known to quickly regenerate upon injuries, bladder urothelium is
generally considered as a slowly dividing epithelium. This circumstance makes it surprising
that cancers arising from urothelium represent one of the neoplasms with highest mutation
rates of all major cancer types. To better understand the extent of mutagenesis in human
bladder, the present study sequenced samples from normal urothelium.
Contributions
This chapter is based on the manuscript “Extensive heterogeneity in somatic mutation and
selection in the human bladder” by Andrew R. J. Lawson, Federico Abascal, Tim H. H.
Coorens, Yvette Hooks, Laura O’Neill, Calli Latimer, Keiran Raine, Mathijs A. Sanders,




























































































Fig. 3.31 The tensor signatures and exposures of bladder normal urothelia. Upper panel:
The representation of tensor signatures analogous to Fig. 3.4. Lower panel: Absolute and
relative signature contributions, each bar represents a sample.
Anne Y. Warren, Krishnaa T. A. Mahbubani, Bethany Bareham, Timothy M. Butler, Luke M.
R. Harvey, Alex Cagan, Andrew Menzies, Luiza Moore, Alexandra J. Colquhoun, William
Turner, Benjamin Thomas, Vincent Gnanapragasam, Nicholas Williams, Doris M. Rassl,
Harald Vöhringer, Sonia Zumalave, Jyoti Nangalia, Jose M. C. Tubio, Moritz Gerstung,
Kourosh Saeb-Parsy, Michael R. Stratton, Peter J. Campbell, Thomas J. Mitchell, Inigo
Martincorena. H.V. validated the mutational signature analysis and produced the figures
presented in this section.
The mutational signature analysis of normal urothelial revealed four tensor signatures
The tensor decomposition of normal bladder urothelia revealed four mutational processes (Fig.
D.14). These comprise replication-driven APOBEC mutagenesis (TS12), as well as three
novel tensor signatures TS-BLADDER (T>N), TS-BLADDER (C>T) and TS-BLADDER
(T>C), whose spectra are characterised by T>N mutations, C>T mutations and indels, and
T>C mutations with a transcriptional strand bias, respectively (Fig. 3.31, D.15). The great
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majority of samples is characterised by high activities of TS-BLADDER (T>C), although
the samples with highest mutation burden show substantial contributions from TS12.
3.3.5 The mutational processes of normal and tumorous cells
Cancer arises through the accumulation of somatic mutations throughout an individual’s
lifetime. For this reason, cells may acquire substantial amounts of mutations, often long
before they become cancerous. Since the characterisation of mutational processes in normal
tissues is likely to be important to better understand the development of cancer, the present
study collected 1,511 normal and 664 tumorous samples from 981 individuals, comprising
11,226,385 SNVs and 18,895 MNVs.
Fig. 3.32 The tensor signatures of normal cells. The representation of tensor signatures
analogous to Fig. 3.4.
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Contributions
This section contains preliminary results of an collaboration with Hyunchul Jung and contains
the results of a manuscript in preparation. H.V. conducted all bioinformatic analyses and
produced the figures presented in this section.
The TensorSignatures analysis of normal and tumorous cells revealed 12 tensor signa-
tures
Applying TensorSignatures to the dataset of normal and tumorous cells uncovered twelve
tensor signatures (Fig. D.16), ten of which closely resemble previously described tensor
signatures. These mutational processes include 5-meC deamination (TS01), transcription-
coupled damage (TS08), signatures indicative of exposure to aflatoxin and tobacco smoke
(TS09 and TS10), mutagenesis due to SV and replication driven APOBEC mutagenesis
(TS11 and TS12), signatures due to defects in BER and homologous recombination repair
(TS18 and TS19), a cancer treatment associated signature (TS20), as well as a mutational
pattern that strongly resembles the spectrum of the colibactin signature (TS25, Fig. 3.32). In
addition, the analysis revealed two novel signatures TS03-like and TS04-like, whose base
substitution spectra and epigenetic activation patterns remind of TS03 and TS04 (Fig. 3.32,
D.17).
Distinct mutational signatures in cancer samples
The analysis of mutation counts revealed that tumours harbour 5 ⇥ greater mutational loads
in comparison to normals (Median 1,029 vs. 5,789). However, although most normal tissue
types exhibit mild mutational loads (median ranges from 574 in breast to 2,415 in colon),
lung normal samples showed surprisingly high mutational burdens with a median of 102,306.
In comparison, median mutation counts in tumours ranged from 3,035 in prostate to 40,844
in squamous lung cancers (Fig. D.18).
Next, I aggregated the exposures of identified tensor signatures to understand the contribu-
tion of different mutational processes across tissues (Fig. 3.33). The mutational spectrum of
normal breast cells is characterised by spontaneous demethylation of 5-meC (25 %, Median:
129), as well as TS03 and TS04, which contribute 25 % (Median: 107) and 21 % (112) of
mutations, respectively. Breast tumours, on the other hand, are dominated by mutagenesis
due to APOBEC and failure of homologous recombination, contributing 29 % (293) and 22
% (641), respectively (Fig. 3.33, first row). Normal colon samples were dominated by TS01
contributing 48 % (Median: 1,118) of mutations, while the tumorous counterpart (colorectal
adeno-carcinoma) was seemingly affected by defects in the BER pathway, as indicated by
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Fig. 3.33 Aggregated exposures of normal and tumour samples. Left column: The dis-
tribution of mutation counts of each mutational process in normals and tumours (breast
carcinoma, colorectal adenocarcinoma, endometrial adenocarcinoma, oesophageal adenocar-
cinoma, hepatocellular carcinoma, squamous cell carcinoma and prostate adenocarcinoma)
of each tissue. Right column: Overall contribution of each mutational process in normals
and tumours of each tissue.
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the large fraction of TS18 mutations (2,975, Fig. 3.33, second row). The composition of the
mutational spectrum in endometrial samples is similar to breast, with TS01, TS03 and TS04
making up the majority of mutations in normals, and TS12 and TS19 in tumours, respec-
tively (Fig. 3.33, third row). Oesophageal normals display the activity of many mutational
processes, with TS04 being the most prominent, making up to 29 % (481) of mutations. In
contrast, the mutational landscape in oesophageal adenocarcinoma is clearly dominated by
TS20, which is responsible for more than half of the mutations (7,126), even though TS20
was hardly detectable in corresponding normals (Median: 5, Fig. 3.33, fourth row). Liver
samples depicted a heterogenous mutational landscape, with substantial contributions of at
least six mutational processes, and TS03 being the main contributor in normals and tumours
(Median: 219 vs. 2,334, Fig. 3.33, fifth row). Normal lung samples showed high activity
of the transcription coupled DNA damage associated process TS08, which dominated the
mutational spectrum by contributing 33 % of mutations (Median: 22,860). Corresponding
squamous lung cancers, however, predominantly exhibit TS10 mutations (47 %, Median:
18,555, Fig. 3.33, sixth row). Prostate normals and tumours were characterised by TS01 and
TS03 activity, each contributing 21 % (Median: 105 and 522), respectively.
3.4 Summary
I presented TensorSignatures, a novel framework for learning mutational signatures jointly
from their mutation spectra and genomic properties to better understand the underlying
mutational processes. I illustrated the capabilities of this algorithm by presenting a set of
20 mutational signatures extracted from 2,778 cancer genomes of the PCAWG consortium,
and validated my analysis on additional 3,824 metastatic samples from the HMF cohort.
The number of signatures was deliberately kept low for the signatures to be interpretable.
The analysis demonstrated that the majority of mutational signatures comprised different
variant types, and that no single mutational signature acted uniformly along the genome.
Measuring how mutational spectra are influenced by their associated genomic features sheds
light on the mechanisms underlying mutagenesis. A joint inference also helps to dissect
mutational processes in situations where mutation spectra are very similar, such that genomic
associations cannot be unambiguously attributed based on the mutation spectrum alone.
1. Studying the resulting signatures revealed that the SNV spectra of TS05 and TS06
show high similarity to signatures SBS7a and SBS7b of the COSMIC catalogue of
mutational signatures. Due to the high similarity of the mutational spectra, it is difficult
to unambiguously attribute individual mutations to these signatures and measure their
genomic activity and transcriptional strand biases based on the mutation spectra alone.
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TensorSignature analysis reveals that the two processes are strongly differing with
respect to their epigenetic context and transcriptional strand bias pointing towards
differentially active GG-NER to be the underlying cause of the regional signature,
which is confirmed by analysing cSCCs from GG-NER deficient XPC patients.
2. A similar change of the mutation spectrum was observed in Liver-HCC and other cancer
types, reflected by the diverging activity of TS07 and TS08. The activity of TS08
is most prominent in highly transcribed genes, indicative of transcription-associated
mutagenesis (Haradhvala et al., 2016; Imielinski et al., 2017). TensorSignatures unifies
the overarching mutational spectrum of this process and sheds light on its genomic
determinants. Furthermore, its ability to detect mutational signatures in specific
genomic regions also increases the sensitivity to detect signature activity, which may
only contribute low levels of mutation at a genome wide scale. Here, we find TS08
also in Bladder-TCC, ColoRectal-AdenoCa, Lung-AdenoCa, Prostate-AdenoCa and
Stomach-AdenoCa in addition to Billiary-AdenoCa, Head-SCC, and Liver-HCC, where
it has been previously found (Alexandrov et al., 2020).
3. TensorSignatures’ capability to detect signatures with a confined regional context
was also highlighted by detecting a highly localised signature associated with AID,
TS13, which specifically manifests in and around transcription start sites in lymphoid
neoplasms (Kasar et al., 2015). This signature has a base substitution spectrum similar
to TS14 (SBS9), which does not display the tight localisation to TSS and is found in a
range of cancer types, likely reflecting Pol⌘-driven TLS during replication.
4. Inclusion of other mutation types led to the discovery of two APOBEC-associated
signatures representative for mutagenesis during replication and at DSBRs, which differ
with regard to their replicational strand bias and clustering propensity. Specifically,
APOBEC-mediated mutagenesis at SVs lacks any preference for leading or lagging
strand and is up to 80% clustered, suggesting that the formation of single stranded DNA
during DSBR may trigger APOBEC activity. While an association of rearrangement
events was reported earlier (Nik-Zainal et al., 2012), our study adds that DSBR- and
replication-driven APOBEC mutations can be discerned by replication strand bias,
clustering rate and size of clusters, indicating differential processivity of these two
processes enabling different rates of mutation.
Validation of TensorSignature’s predictions was achieved by applying the algorithm to
a second cohort of whole genomes from the HMF. Reassuringly, the algorithm confirmed
spectra and genomic properties from our primary analysis, thereby demonstrating the ro-
bustness of this approach, and the value of assessing additional genomic dimensions and
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other mutation types to gain more in depth insights to mutagenesis. Moreover, I applied the
software in various collaboration projects to smaller datasets, thus demonstrating the value




The accumulation of genomic mutations eventually leads to the formation of cancer, a
disease which is often associated with terminal outcomes for affected individuals. For this
reason, many efforts have been undertaken to characterise mutational processes in terms
of their genomic imprints. A particularly successful approach is matrix-based mutational
signature analysis, which identifies prototypical mutation patterns by applying non-negative
matrix factorisation to catalogues of single nucleotide variants and other mutation types. So
far, the methodology has provided more than 50 different single base substitution patterns,
indicative of a range of endogenous mutational processes, as well as genetically acquired
hypermutation and exogenous mutagen exposures. However, mutagenesis is a multifaceted
event that is affected by the genomic organisation of DNA and cellular processes such as
transcription, replication, and DNA repair processes. Moreover, since many mutational
processes also generate characteristic multi nucleotide variants, insertion and deletions, and
structural variants, it appears valuable to jointly deconvolve broader mutational catalogues to
better understand the complex nature of mutagenesis.
4.1 Summary of the main findings
In this thesis, I presented TensorSignatures, an algorithm to learn mutational signatures jointly
across all variant categories and genomic context. I described how this method incorporates
various mutation types and employs five different genomic annotations – transcription and
replication strand orientation, nucleosomal occupancy, epigenetic states as well as local
hypermutation – to create a seven-dimensional count tensor, enabling the algorithm to charac-
terise mutational signatures with respect to the aforementioned phenomena. TensorSignatures
is implemented using the powerful TensorFlow backend, benefits from GPU acceleration,
and is available as Python package as well as a web application.
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By applying TensorSignatures to 2,778 primary and 3,824 metastatic cancer genomes of
the Pan Cancer Analysis of Whole Genomes consortium and the Hartwig Medical Foundation
cohort, I found that practically all signatures operate dynamically in response to various
genomic and epigenomic states. My analysis pinned differential spectra of UV mutagenesis
found in active and inactive chromatin to global genome nucleotide excision repair. TensorSig-
natures accurately characterised transcription-associated mutagenesis, which is detected in
7 different cancer types. My analysis also unmasked replication- and double strand break
repair-driven APOBEC mutagenesis, which manifests with differential numbers and length
of mutation clusters indicating a differential processivity of the two triggers. As a fourth
example, TensorSignatures detected a signature of somatic hypermutation generating highly
clustered variants around the transcription start sites of active genes in lymphoid leukaemia,
distinct from a more general and less clustered signature of Pol⌘-driven translesion synthesis
found in a broad range of cancer types. Finally, I demonstrate TensorSignatures’ utility by
applying it to multiple datasets in various collaboration projects.
Taken together, TensorSignatures adds great detail and refines mutational signature
analysis by jointly learning mutation patterns and their genomic determinants. This sheds
light on the manifold influences that underlie mutagenesis and helps to pinpoint mutagenic
influences which cannot easily be distinguished based on the mutation spectra alone. As
mutational signature analysis is an essential element of the cancer genome analysis toolkit,
TensorSignatures may help make the growing catalogues of mutational signatures more
insightful by highlighting mutagenic mechanisms, or hypotheses thereof, to be investigated
in greater depth.
4.2 Conclusions
This analysis maps out the regional activity of mutational processes across the genome
and pinpoints their various genomic determinants, thereby enabling to discover mutational
processes not only in terms of their single base substitution spectra, but also with respect to
their multi-facetted properties. This revealed that the appearance of a mutational signature is
often driven by a combination of genomic determinants, other mutation types and intrinsic
properties of the mutational process, e.g.
• epigenetic activity and transcriptional strand bias (TS05/TS06 and TS07/TS08),
• epigenetic activity and propensity to cluster (TS13/TS14),
• association with other mutation types, propensity to cluster and replicational strand
bias (TS11/TS12).
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Thus, providing a method with the capability to factor in all of these variables adds
tremendous value to the field of mutational signature analysis. Particularly, it enables to
• generate a more informed hypothesis about the attribution of a mutational signature to
its underlying origin.
• unravel interesting phenomena associated with certain mutational processes, helping
to guide further downstream analysis.
• simplify the analysis by providing a general framework for the methodology, which in
addition is easily extensible to account for different questions.
4.3 Limitations of the analysis and potential improvements
TensorSignatures promises to provide a robust framework for mutational signature analysis
that enables to characterise mutational processes with respect to different genomic factors
and the full mutational imprint. Despite the tool being fully tested and usable, there are
several issues which I could not, or only partially address during the time of my PhD.
Algorithmic improvements
One drawback of the tensor representation is the memory footprint which scales multiplica-
tively with each genomic dimension. To illustrate this, consider the mutation count tensor
presented in this thesis, which features 3 transcriptional, 3 replicational, 16 epigenetic, 4
nucleosomal, and 2 clustering states, as well as 96 mutation types and n samples, giving rise
to a multidimensional array with 3⇥3⇥16⇥4⇥2⇥96⇥n entries. This results in a ⇠2.6
GB large mutation count tensor for the PCAWG dataset (n = 2778), and raises the question
whether the algorithm is capable to handle substantially more samples and/or additional
genomic covariates. Possible solutions to this problem include distributing the workload to
multiple devices, training the model in batches, or marginalising the mutation count tensor
iteratively.
The first option implies to distribute parts of the data to distinct GPUs, which then
independently compute a single epoch including a forward and backward pass, after which
gradients are collected and applied to the parameters of the model. In this way, the memory
load is decreased on individual devices, thus enabling to train the model, even when the
number genomes is large. However, this solution does not really solve the problem, because
at some stage there will be surely enough data to overwhelm even the most sophisticated
hardware setup. Moreover, this setup has other drawbacks, for example, collecting gradients
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after each epoch requires to synchronise devices, which often results in poorer performance,
especially when workloads are distributed unequally across GPUs.
The second approach may be implemented with batch- or mini-batch gradient descent.
The former loads smaller batches of data to memory, calculates their log-likelihood and
accumulates gradients, and updates the model after all training examples have been evaluated.
While this is indeed a feasible solution, it makes the inference significantly slower, because
loading batches into (GPU-) memory involves slow I/O-operations. Similarly, mini-batch
gradient descent splits the dataset into small batches that are used to calculate the model
log-likelihood and gradients, but directly updates model coefficients. In theory, the gradients
computed from the batch represent noisy estimates of the true gradient, which should enable
the algorithm to converge as if the gradient was computed on the complete dataset, thus
allowing the model to converge faster.
The final proposal makes use of TensorSignatures’ parametrisation, which models the
effect of each genomic factor independently. This should allow to marginalise each genomic
factor of the count tensor at a time, such that in addition to transcriptional and replicational
states, as well as the dimensions for mutation types and samples, only one additional genomic
dimension remains (e.g. Ânuc, clu CSNV = CSNVepi 2 N
3⇥3⇥16⇥p⇥n
0 , Âepi, clu CSNV = CSNVnuc 2
N3⇥3⇥4⇥p⇥n0 , and Âepi, nuc CSNV = CSNVclu 2 N
3⇥3⇥2⇥p⇥n
0 ). Each marginalised count tensor
has a significantly smaller memory footprint in comparison to the full tensor, enabling to
store them all in memory, and train the model by iterating over each marginalised count
tensor while accumulating gradients, and applying them after each such iteration.
Due to decreasing cost of sequencing and the thrive of personalised medicine, it is not
too unlikely that whole genome sequencing becomes part of the standard clinical routine.
While these developments bring the great opportunity to learn novel mutational processes
from vast amounts of data, they will also represent a computational challenge to current
NMF algorithms. Particularly, TensorSignatures tensor representation of mutation count data
may soon exceed the memory boundaries of currently available hardware. To avoid these
limitations, it is necessary to develop novel optimisation techniques for NMF, eventually
based on batch gradient descent, or in the case of TensorSignatures, by marginalising the
count tensor.
The TensorSignatures API
Regarding the current implementation of the TensorSignature software, I find two issues
worth following up. First, the TensorSignature software requires to run a R pipeline to
compute the SNV count tensor and the other mutation type matrix prior to the actual analysis,
thus making the usage of the software difficult, as the installation of R and Bioconductor
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packages depends on a plethora of dependencies. This could be resolved by performing
these steps in Python, or providing a Docker image dedicated to this task (which is the
current solution). Second, TensorSignatures was written using Tensorflow 1.x, which has
received a major update in the meantime, suggesting to rewrite the software to make use of
the Tensorflow 2.0 API. Also, I optimised the command line interface, as well as the API of
the tensorsignatures Python package for the usage on high performance computing clusters,
which question many of the design choices of the API when the software is run in different
environments. With regards to theses issues, more development of the software needs to be
done.
TensorSignatures Online
Cloud computing technologies offer interesting possibilities regarding the deployment of
research pipelines, and thus many ideas come to mind to further improve the features of
TensorSignatures’ web application. At the time of writing, TensorSignaturesOnline allows to
fit the exposures of a set of reference signatures to user samples. An evident extension is to
provide the functionality to perform denovo signature fits, thus allowing users to extract the
mutational processes present in their datasets.
Other ways to improve the web application involve its implementation and user experi-
ence. While the current version of TensorSignaturesOnline uses the Python web framework
Flask to render the views of the page, it may be beneficial to provide a decoupled REST-API
service, that is accessible without having to navigate to the webpage. This would enable to
implement a Python independent front-end, for example, on basis of the Javascript framework
React, which allows to build more elaborate user interfaces, thus making the usage of the
application more convenient and intuitive.
Cancer specific annotations
Currently, TensorSignatures uses consensus annotations to classify single base substitutions
with respect to replicational orientation, epigenetic and nucleosomal states. This simplifies
data preprocessing steps, i.e. a single normalisation constant may be employed to account for
different nucleotide compositions across genomic states, and provides conservative estimates
for inferred tensor factors, because assignment of single base substitutions is based on
conserved genomic regions. However, the usage of consensus states may also preclude signal
due to the assignment of mutations to the NA state when cell-type specific genomic states
fail to reach the threshold for the consensus.
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While currently available data does not allow to obtain a comprehensive set aforemen-
tioned annotations matched to the cell of origin for every PCAWG cancer type, it is possible
to partially match epigenetic ChromHMM annotations, which is the genomic variable having
arguably the greatest impact on mutagenesis. Although I found that the analysis on partially
matched annotations yields concordant results (Fig. B.3), it may be desirable to use fully
matched annotations in future.
Additional genomic states
TensorSignatures’ extensibility enables to assess mutational processes with respect to any
genomic annotation. Some interesting factors could be easily gathered from standard genomic
data such as chromosomes, introns, or exons; but certainly from more specific annotations
as well, for example, chromosomal contact sites captured by Hi-C data. To illustrate this,
consider the following two examples.
The genome consists of several higher order DNA domains, occupying different territories
within the nucleus, either in the periphery close to the nuclear envelope, or central at its core.
It has been reported that the availability of DNA repair mechanisms differ between these
higher order domains. Particularly, nuclear-lamina-associated regions are more likely to use
error prone alternative non-homologous end joining, and are less efficient in recruiting the
proteins of the NER-pathway to lesions, as only XPC allocates to the nuclear periphery but
not XPA (Sec. 1.4.2). For this reason, different mutational signatures were observed across
high order DNA domains (Smith et al., 2017). However, a more thorough analysis might be
easy to achieve using TensorSignatures, for example, by utilising genomic annotations for
Chip-Seq data gathered from lamin proteins to partition single base substitutions by nuclear
localisation.
While TensorSignatures may resolve mutagenesis in large genomic regions, it may also
be used to detect mutational processes at smaller scales. Another interesting property of
DNA is its propensity to form secondary structures at certain motifs. In particular, guanine
rich sequences have the propensity to form so-called G-quadruplexs (G4s), which are often
found in telomeric regions but also at gene regulatory loci. G4 may obstruct the movement
of DNA polymerases, thus increasing the risk of DNA breakage, and have been shown to
associate with copy number alterations. Regions with the propensity to generate G4s could
be introduced as an additional genomic dimension to the mutation count tensor, enabling to
assess the mutational processes acting at these genomic regions. However, the incorporation
of additional genomic states should be accompanied by larger catalogues of cancer genomes
to preserve the statistical power of the analysis.
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Tensor for other mutation types
Another possibility to further improve the tensor factorisation approach is to partition other
mutation types with respect to various genomic annotations. The difficulty herein is that
annotating a subset of mutation types such as structural variants, larger MNVs and indels
with respect to various genomic states is not straightforward. To understand this, consider
that sites of structural variation usually affect both DNA strands, thus making it impossible
to assign them with regards to transcription or replicational directionality. On the other hand,
larger MNVs and indels may overlap with two adjacent genomic states, thereby making
unambiguous state assignments difficult. These issues may be partly resolved by finding
more elaborate mutation type classifications.
Partitioning other mutation types by genomic factors, especially indels, could greatly
help to make sense out of the large number of mutational signatures that have been attributed
to mismatch repair deficiency (MMRD, Sec. 1.6.2). Cancers harbouring defects in this DNA
repair pathway are associated with the formation of indels, especially at sites of repetitive
DNA sequences, and are therefore called microsatellite instable. Moreover, it has been
reported that MMR is underlying differential mutation rates across early and late replicating
regions. Stratifying indels by epigenetic factors could therefore help to disentangle the
association of certain MMRD signatures and link them to genomic factors.
Metadata
Another exciting avenue to drive forward the field of mutational signature analysis is to
extend the method to incorporate patient meta data such as age, treatment history, smoking
status etc. Such data could be incorporated in secondary matrices, much like the incorporation
of other mutation types in TensorSignatures, thus helping to guide signature inference at the
stage of training. Concrete parameterisations of such models need yet to be developed, and
are likely to depend on the data type added, but could help to link the origin of unknown or
novel signatures to their respective origin.
4.4 Outlook and future research
Although the origins of mutational signature analysis lie in the decomposition of (primary)
cancer genomes, it is evident that cancer development is a continuous process that eventually
starts in a normal cell. An interesting avenue of research is therefore to assess the mutational
composition of normal cells at consecutive stages during cancer development to learn more
about the different phases of carcinogenesis. Indeed, various recent studies started to delineate
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the mutational composition of normal cells in different tissues including liver, colorectal,
bronchial, bladder and endometrial epithelia (Brunner et al., 2019; Lee-Six et al., 2019;
Moore et al., 2020; Yoshida et al., 2020), but further research is required to obtain a more
comprehensive view on the activity of mutational processes in normals, and at certain stages
of tumor development. Likewise, it may be beneficial to sequence more metastatic tumours,
albeit the HMF study provided a quite comprehensive catalogue of approximately 4,000
samples (Priestley et al., 2018).
The human body consists of approximately 40 trillion cells and more than 100 different
cell types. Given this large diversity, it is not surprising that most tissues as well as malignant
tumours contain a plethora of different cell types. Nonetheless, conventional sequencing
experiments typically explore cells in bulk, for which reason the results of such experiments
reflect entire cell populations rather than a single cell. The reason for the lack of resolution
is that the amount of DNA that can be extracted from a single cell is often not sufficient to
enable genome-scale analysis, even though such information could help delineate the clonal
aetiology of cell sub populations in cancers. Recent advances in single cell genomics could
help to unravel the signals of such samples, thereby delivering cleaner signals that may help,
for example, to associate certain mutational signatures with distinct cell types.
Despite the temporal and spatial characterisation of mutational processes in tumours, inte-
gration of other ”omics” data from the epigenome, transcriptome, proteome, metabolome and
microbiome may further help to make mutational signature analysis more powerful. While
TensorSignatures took first steps to integrate data from the epigenome and transcriptome, my
consensus approach is likely to be overwhelmingly crude in comparison to the resolution
that may be gathered from profiling tumours with respect to these modalities. In addition,
proteomics data, which is used to quantify peptide abundance, interaction and modification,
may help to uncover mechanistic details of the action of tumour surpressors and oncogenes
by unravelling their abundance and state as protein. Metabolomics quantifies multiple small
molecules, such as amino acids, fatty acids and other products of the cellular metabolism, and
may therefore help to elucidate the genomic consequences of exogenous mutagens, as well
as the effects of an altered metabolism in deregulated cancerous cells. Finally, integration of
the microbiome may help to unravel the interactions between (epithelial) cancers and the
surrounding microenvironment.
Many of the mutational signatures present in the COSMIC catalogue lack an attribution
to a concrete mutational process. To learn more about the aetiology of unknown spectra,
multiple studies simulated carcinogenesis in various model organisms on the bench, including
genetically modified C. elegans (Meier et al., 2018; Volkova et al., 2019), CRISPR-Cas9
modified iPSC and cancer cell lines (Petljak et al., 2019; Zou et al., 2018), as well as human
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organoids (Drost et al., 2017). Each of these approaches have their pros and cons: studies
conducted in C. elegans, for example, enable to perform large scale screens, i.e. it is possible
to expose genetically modified C. elegans with defects in tumour suppressive or oncogenic
genes to a wide range of mutagenic substances, which helps to identify the mutational spectra
of interactions, but obviously the model system is evolutionary distant from humans. In
contrast, CRISPR-Cas9 modified cell lines as well as organoids are more likely to reflect
mutagenesis in human cells, but require very laborious and expensive experiments. Moving
forward, further experimental work is required to complement and validate the advances and
findings in the field of mutational signature analysis, ideally in experimental setups that are




TensorSignatures is a tensor factorisation framework for mutational signature analysis, which
in contrast to other methods, deciphers mutational processes not only in terms of mutational
spectra, but also assess their properties with respect to various genomic variables, allows
the inclusion of different mutation types and integrates a robust noise model to perform the
inference.
TensorSignatures is a young project and breaking changes are to be expected. We keep a
changelog and it will have possible breakage clearly documented.
A.1 Installing TensorSignatures
TensorSignatures makes use of the TensorFlow 1.5.x framework requiring the user to install a
separate package to enable GPU support, i.e. tensorflow-gpu instead of tensorflow. We
highly recommend to install TensorSignatures into an environment with tensorflow-gpu,
as the tensor computations greatly benefit from GPU-acceleration.
A.1.1 Installation via GitHub
To obtain the most recent version of TensorSignatures, we recommend to download the
repository directly from GitHub and to install the package into a virtual environment. To get
started, clone the repository by executing the following commands in your terminal
$ git clone https://github.com/gerstung-lab/tensorsignatures.git && \
cd tensorsignatures
Then, create a new virtual environment and install all dependencies. If you have access
to a GPU with cuda support use requirements-gpu.txt instead of requirements.txt
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$ python -m venv env
$ source env/bin/activate
$ pip install --upgrade pip setuptools wheel && \
pip install -r requirements.txt
Finally, install TensorSignatures.
$ python setup.py install
A.1.2 Installation via Pypi
To install tensorsignatures via Pypi simply type
$ pip install tensorsignatures
into your shell.
A.1.3 Installation via Docker
To run TensorSignatures within a docker environment clone the the repository
$ git clone https://github.com/gerstung-lab/tensorsignatures.git
$ cd tensorsignatures
and then start the image using docker-compose.
$ docker-compose up --build
This spins up a jupyter server including notebooks with tutorials on http://localhost:8889.
A.2 Quick Start
Running TensorSignatures involves three steps: preparing the input data, i.e. creating the
mutation count tensor as well as the mutation count matrix, computing a trinucleotide
normalisation to account for differences in the nucleotide composition of different genomic
regions, and running TensorSignatures.
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A.2.1 Step 1: Data preparation
Preparing the input data for TensorSignatures involves creating the single base substitution
count tensor and the other mutation type count matrix with multinucleotide variants, deletions
and insertions (currently we do not provide a automated way of generating a structural variant
table yet). Despite the fact that TensorSignatures is written in Python, this part of the pipeline
runs in R and depends on the Bioconductor packages VariantAnnotation and rhdf5.
Preparing input data using docker
We provide a docker image that contains all R and bioconductor dependencies to create
the variant tensor and the other mutation type matrix. To use it, pull the image from docker.
Note that the image is approximately 5 GB large.
$ docker pull sagar87/tensorsignatures-data:latest
To use the image switch into the folder containing your VCF data. Then run image using
the following command and supply the VCF files as well as the name of the hdf5 output file
(must be the last argument) as arguments.
$ docker run -v $PWD:/usr/src/app/mount sagar87/tensorsignatures-data \
<vcf1.vcf> <vcf2.vcf> ... <vcfn.vcf> <output.h5>
Then continue with Step 2 (Sec. A.2.2).
Preparing the input data using a custom installation
Make sure you have R3.4.x (!) and the packages VariantAnnotation and rhdf5 installed.
You can install them, if necessary, by executing
$ Rscript -e "source(’https://bioconductor.org/biocLite.R’); \
biocLite(’VariantAnnotation’)"
and
$ Rscript -e "source(’https://bioconductor.org/biocLite.R’); \
biocLite(’rhdf5’)"
from your command line. Then, download the following files and place them in the same
directory:
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• Constants.RData (contains GRanges objects that annotate transcription/replication
orientation, nucleosomal and epigenetic states)
• mutations.R (all required functions to partiton SNVs, MNVs and Indels)
• processVcf.R (loads vcf files and creates the SNV count tensor, MNV and indel
count matrix; eventually needs custom modification to make the script run on your
vcfs.)
• genome.zip.
To obtain the SNV count tensor and the matrices containing other mutation types, execute
processVcf.R and pass the VCF files you want to convert, as well as a name for an output
hdf5 file as command line arguments, e.g.
$ Rscript processVcf.R <vcf1.vcf> <vcf2.vcf> ... <vcfn.vcf>\
<output.h5>
In case of errors please check wether you have correctly specified paths in line 6-8. Also,
take a look at the readVcfSave function and adjust it when it fails.
A.2.2 Step 2: Computing trinucleotide normalisation
TensorSignatures requires a trinucleotide normalisation constant to account for differences in
the nucleotide composition of genomic states. To compute it, invoke the prep sub routine of
TensorSignatures and pass the hd5 file from Step 1 (Sec. A.2.1) as well as the path for the
output file as positional arguments to the programme.
$ tensorsignatures prep <output.h5> <tsdata.h5>
A.2.3 Step 3: Run TensorSignatures
There are two ways to run TensorSignatures using either the refit option, which fits the
exposures of a set of pre-defined signatures extracted from the PCAWG cohort to your dataset,
or via the train subroutine, that performs a denovo extraction of tensor signatures. Refitting
tensor signatures is computationally fast but does not allow to discover new signatures, while
extracting new signatures from scratch is computationally intensive (GPU required) and
requires ideally larger numbers of samples. For most use cases, with a small number of
samples, we advice to use the refit option:
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$ tensorsignatures --verbose refit tsData.h5 refit.pkl -n
To run a denovo extraction use
$ tensorsignatures --verbose train tsData.h5 denovo.pkl <rank> \
-k <size> -n -ep <epochs>
where rank specifies the decomposition rank, size controls the dispersion of the model,
and epochs the number of desired epochs to fit the model. TensorSignatures outputs value of
the objective function (log likelihood) that is minimised during training as well as the change
of the objective during an epoch interval (delta). When deciding on the number of epochs
to train the model ensure that it is sufficiently large such that the objective function converges,
i.e. the delta value is close to, or fluctuates around zero. For more information on how
to run TensorSignatures in a practical setting see Sec. (A.3.3). Running TensorSignatures
will yield a pickle dump which can subsequently inspected using the tensorsignatures
package (A.3.4).
A.3 Tutorials
TensorSignatures extracts mutational signatures and their genomic properties from a mutation
count tensor that partitions single base substitutions with respect to a multitude of genomic
states. Moreover, the algorithm links other variant types to these signatures by taking into ac-
count a secondary mutation matrix. In following tutorials, we want to convey an intuition for
working with such highdimensional data, and explain the usage of the tensorsignatures
API and command line interface (CLI).
A.3.1 Understanding the mutation count tensor
Let us start by creating a simulated mutation count tensor to better understand the structure of
this data type. The data module of tensorsignatures provides a TensorSignatureData
class which allows us to simulate such data. To do so, we import the package and create a
TensorSignatureData instance.
> import tensorsignatures as ts
> data = ts.TensorSignatureData(
seed=573, # set a seed for reproducibility
rank=5, # number of signatures
samples=100, # number of samples
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dimensions=[3, 5], # number of arbitrary genomic dimensions
mutations=1000)
This command generates data from five signatures (rank) to simulate 100 genomes
(samples) each with 1000 mutations (mutations). By passing the list [3, 5] to the
dimensions argument, we create two additional genomic dimensions1 with 3 and 5 states
respectively. To obtain the SNV count tensor, we invoke the snv method of data, which
returns the single base substitution count tensor.
> snv = data.snv()
Similarly, we can extract a simulated matrix of other mutation counts by invoking the
other() method.
> other = data.other()
The mutation count tensor is a multidimensional array with a specific structure
The snv object is simply a 6-dimensional numpy array,
> snv.ndim
6
whose shape attribute is a tuple of integers indicating the size, i.e. the number of states,
of the array in each dimension.
> snv.shape
(3, 3, 3, 5, 96, 100)
TensorSignatures expects the structure of the count tensor to follow a specific convention:
the first and second dimension (snv.shape[0] and snv.shape[1]) split counts by tran-
scription and replication strand, following dimensions partition single base substitution by ge-
nomic factors, and the penultimate (snv.shape[-2]) and last dimension (snv.shape[-1])
represent substitution types and samples respectively. Table A.1 summarises the structure of
the count tensor.
1in addition to the dimensions specifying transcription and replication
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Table A.1 The structure of the SNV count tensor.
Dimension Size Index State / Variants
0 Coding strand
Transcription 3 1 Template strand
2 Unassigned
0 Leading strand
Replication 3 1 Lagging strand
2 Unassigned
0 Unassigned
First genomic dimension t+1 1 State 1
(eg. epigenetic states) ... ...
t State t
0 Unassigned
Last genomic dimension r+1 1 State 1
(eg. nucleosomal states) ...
r+1 State r
0 A[C>A]A






Extracting the single base substutions from specific genomic states
We index the SNV tensor like any other numpy array. For example, to obtain variants
from template and leading strands, and from the “unassigned” state of additional genomic
dimensions, we simply index the tensor with snv[0, 1, 0, 0, :, :] which returns a two
dimensional array with mutation types along the first axis and samples along the other.
> slice = snv[0, 1, 0, 0, :, :]
> slice.shape
(96, 100)
Note, that we can reconstruct the p⇥n mutation count matrix, which usually serves as
an input for conventional mutational signature analysis, by summing over all dimensions
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except the last two (representing single base substitution types and samples respectively).
The following code illustrates this operation.
> collapsed = snv.sum(axis=(0, 1, 2, 3))
> collapsed.shape
(96, 100)
Another useful technique is to first index a specific state, and then to sum over all other
dimensions to exclude. This allows us to extract the spectra from specific genomic states,
for example, to extract all coding and template strand mutations from the tensor we would
simply run
> coding = snv[0].sum(axis=(0, 1, 2, 4))
> template = snv[1].sum(axis=(0, 1, 2, 4))
of course this also works for any other dimension, for example, leading and lagging
strand mutations maybe extracted as follows.
> leading = snv[:, 0].sum(axis=(0, 1, 2, 4))
> lagging = snv[:, 1].sum(axis=(0, 1, 2, 4))
To understand how they differ we may plot them,
> fig, axes = plt.subplots(2, 2, sharey=True)
> axes[0, 0].bar(np.arange(96), coding, color=ts.DARK_PALETTE)
> axes[0, 0].set_title(’Pooled coding strand mutations’)
> axes[0, 1].bar(np.arange(96), template, color=ts.DARK_PALETTE)
> axes[0, 1].set_title(’Pooled template strand mutations’)
> axes[1, 0].bar(np.arange(96), leading, color=ts.DARK_PALETTE)
> axes[1, 0].set_title(’Pooled leading strand mutations’)
> axes[1, 1].bar(np.arange(96), lagging, color=ts.DARK_PALETTE)
> axes[1, 1].set_title(’Pooled lagging strand mutations’)
> plt.tight_layout()
which reveals that some variant types, e.g. C>A (blue), C>T (red) and T>A (grey), seem
to occur with different frequencies across transcription and replication states.
By indexing the SNV tensor appropriately, we can also recover mutational spectra from
different state combinations, eg. snv[0,:,2].sum(axis=(0,1)) would return a p⇥ n
matrix representing the coding strand mutations in state 2 of the first additional genomic
dimension.
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A.3.2 Understanding tensor factors
In the previous section, we created a simulated dataset using the TensorSignaturesData
class, and investigated the data by plotting mutational spectra in various genomic contexts.
While doing so, we discovered that some variant types occur with different frequencies in
different genomic states, for example, frequencies of coding strand C>A, C>T and T>A
variants seemed to be twice as large in comparison to corresponding numbers on template
strand DNA. Strand asymmetries have been observed for several mutational processes and
are often attributed to DNA repair mechanisms. Transcription coupled repair (TCR), for
example, actively depletes mutations on template strand DNA in gene encoding regions.
Transcriptional and replicational biases
TensorSignatures models variability in mutagenesis due to transcription and replication by
1. extracting separate single base substitution spectra for coding and template strand, and
leading and lagging strand DNA
2. fitting a scalar for each signature in context of transcription and replication that
quantifies the overall strand asymmetry of single base substitutions (bias matrix b)
3. fitting a scalar for each signature that is interpreted as the relative signature activity of
signature in transcribed vs untranscribed regions, and early and late replicating regions
(activity matrix a).




> ts.plot_signatures(data.S.reshape(3, 3, -1, 96, data.rank))
This reveals the SNV spectra (rows) in context of transcription and replication in the
left and right column. Colors indicate the mutation type (blue C>A, black C>G, red C>T,
grey T>A, green T>C and salmon T>G), while the shading indicates the mutation type
probabilities for coding strand and leading strand DNA (dark), and for template and lagging
strand DNA (light), respectively. Notice, for example, how in the fourth signature (last row),
the amplitude of dark and light grey bars differ, indicating that this mutational process is
more likely to produce T>A mutations on coding and leading strand DNA respectively.
TensorSignatures models the propensity of a mutational process to generate strand specific
mutations by scaling the SNV spectra for coding and template, and leading and lagging
strand with a multiplicative scalar variable. To visualise the strand biases for our simulated




vmin=.5, vmax=2, # allows to specify the limits of the colorbar
row_labels=[’transcription’, ’replication’],
cbarlabel=’Strand bias (No bias = 1)’ # color bar label
)
Rows of the heat map depict the context and columns signatures. Note the logarithmic
scaling of the color bar, which indicates that a baseline value of 1 resembles a mutational
process with no strand preference. Coefficients < 1 (red) indicate signature enrichment on
template or lagging strand DNA, and conversely, values > 1 (blue), an asymmetry towards
the on coding or leading strand.
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Signature activities in specific genomic regions
The multidimensional representation of SNV count data allows TensorSignatures to quantify
the propensity of mutational processes within confined genomic regions. These genomic
contexts, thereafter also genomic states, may represent genomic features such as specific
chromatin marks or nucleosome occupancy. To illustrate this, we depicted a genomic region
in the Fig. A.1 together with arbitrary genomic states and respective mutations.
Fig. A.1 The distribution of single base substitutions may vary due to differences in
genome organisation and other factors. The horizontal bar plot in the upper panel depicts
genomic states, which represent confined genomic regions with certain features. The rainfall
plot underneath shows the variant types at these genomic loci.
The rainfall plot representation may not always reveal changes in the mutational spectrum
on first sight. However, the SNV count tensor contains the mutational spectra of each
state combination. We can inspect them by indexing the respective state and summing
over all remaining dimensions except the one for trinucleotides (Sec. A.3.1). To visualize,
for example, pooled mutation spectra along the five states of the fourth dimension in our
simulated dataset we would execute the following code.
> fig, ax = plt.subplots(1, 5, figsize=(16, 2.5), sharey=True)




> ax[1].bar(np.arange(96), snv[:, :, :, 1].sum(axis=(0, 1, 2, 4)), \
color=ts.DARK_PALETTE)
> ax[1].set_title(’Genomic state 1’)
> ax[2].bar(np.arange(96), snv[:, :, :, 2].sum(axis=(0, 1, 2, 4)), \
color=ts.DARK_PALETTE)
> ax[2].set_title(’Genomic state 2’)
> ax[3].bar(np.arange(96), snv[:, :, :, 3].sum(axis=(0, 1, 2, 4)), \
color=ts.DARK_PALETTE)
> ax[3].set_title(’Genomic state 3’)
> ax[4].bar(np.arange(96), snv[:, :, :, 4].sum(axis=(0, 1, 2, 4)), \
color=ts.DARK_PALETTE)
> ax[4].set_title(’Genomic state 4’)
This plot nicely illustrates that different genomic states may have a variable exposure
to different mutational signatures. For example, judging from the prevalence of C>A and
T>A variants in genomic state 2 and 4, it appears likely that these states are dominated by
signature 3 and 4 respectively. TensorSignatures models the activity of each signature by
fitting a single coefficient for each signature and genomic state. To visualize the coefficients
used to generate our simulated dataset we execute
> plt.figure(figsize=(6,2))
> ts.heatmap(data.k1,
row_labels=[’Genomic state 1’, ..., ’Genomic state 4’, ],
col_labels=[’{}’.format(i) for i in range(5)],
cbarlabel=’Relative Signature\nactivity (Baseline = 1)’)
which confirms our suspicion about the elevated activities of signature 3 and 4 in genomic
state 3 and 4 respectively. To interprete this correctly, keep in mind that usually majority
of SNVs do not fall into specific genomic states and therefore end up in the baseline or
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“unassigned” state (Tab. A.1), which is in TensorSignatures always 1, and to which all other
coefficients are inferred relatively to. In other words, signature 3, for example, shows 5.77
times higher activities in genomic state 3 in comparison to the genomic baseline.
A.3.3 The TensorSignatures CLI
The TensorSignatures CLI comes with six subroutines,
• boot: computes bootstrap intervals for a TensorSignature initialisation,
• data: simulates mutation count data for a TensorSignature inference,
• prep: computes a normalisation constant and formats a count tensor (Sec. A.2.2),
• refit: refits the exposures to set of fixed tensor signatures (Sec. A.2.3),
• train: runs a denovo extraction of tensor signatures (Sec. A.2.3),
• write: creates a hdf5 file out of dumped tensor signatures pkls.
The goal of this tutorial is to illustrate how to run TensorSignatures in a practical setting.
For this reason we will first simulate mutation count data using tensorsignatures data,
and subsequently run tensorsignatures train to extract constituent signatures. In the
next section we will then analyse the results of this experiment in jupyter with help of the
tensorsignatures API (Sec. A.3.4).
Simulate data via the CLI
To create a reproducible (the first positional argument sets a seed: 573) synthetic dataset
from 5 mutational signatures (second positional argument) with the CLI, we invoke the data
subprogram
$ tensorsignatures data 573 5 data.h5 -s 100 -m 10000 -d 3 -d 5
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which will simulate 100 samples (-s 100) each with 10,000 mutations (-m 10000),
and two additional genomic dimensions with 3 and 5 states (-d 3 -d 5) respectively. The
program writes a hdf5 file data.h5 to the current folder containing the datasets SNV and
OTHER representing the SNV count tensor and all other variants respectively.
Running TensorSignatures using the command line interface
Since we know the number of signatures that made up the dataset we can run a TensorSigna-
tures decomposition simply by executing
$ tensorsignatures --verbose train data.h5 my_first_run.pkl 5
which saves a pickle able binary file to the disk, which we can load into a interactive
python session (eg. a Jupyter notebook) for further investigation (see Sec. A.3.4)
> init = ts.load_dump(’my_first_run.pkl’)
> init.S.shape
(3, 3, 3, 5, 96, 5, 1)
However, usually we do not know the number of active mutational processes a priori. For
this reason, it is necessary to run the algorithm using different decomposition ranks, and to
subsequently select the most appropriate model for the data. Moreover, we recommend to run
several initialisations of the algorithm at each decomposition rank. This is necessary, because
non-negative matrix factorisation produces stochastic solutions, i.e. each decomposition
represents a local minimum of the objective function that is used to train the model. As a
result, it is worthwhile to sample the solution space thoroughly, and to pick the solution
which maximised the log-likelihood. Running TensorSignatures at different decomposition
ranks while computing several initialisations is easy using the CLI. For example, to compute
decompositions from rank 2 to 10 with 10 initialisation each, we would simply write a nested
bash loop.
$ for rank in {2..10}; do
$ for init in {0..9}; do
$ tensorsignatures train data.h5 sol_${rank}_${init}.pkl ${rank} \




Also note the additional arguments we pass here to the programme; the -i argument
identifies each initialisation uniquely (mandatory), and the -j parameter allows us to name
the experiment, which in this context denotes multiple TensorSignature decompositions
across a range of ranks extracted using the same hyper parameters (number of epochs,
dispersion, etc).
Summarising the result from many initialisations with tensorsignatures write
This command produces for each rank (2-10) ten initialisation and saves the results as
pickleable binary files to the hard disk. Loading the 9 x 10 initialisations manually using
ts.load_dump would be quite tedious and even impracticable in larger experiments. For
this reason, we included the subprogram tensorsignatures write, which takes a glob
filename pattern and an output filename as arguments to generate a hdf5 file containing all
initialisations.
$ tensorsignatures write "sol_*.pkl" results.h5
Processing 90 files.
A.3.4 The TensorSignatures API
The TensorSignatures API provides useful functions to analyse results from TensorSignature
decompositions. Since running the tool usually involves creating several initialisations at
different decomposition ranks (Sec. A.3.3), we provide three classes that abstract
• Experiments (Experiment), i.e. multiple initialisation at different decomposition
ranks extracted using the same hyper parameters,
• Cluster (Cluster), i.e. multiple initialisations at a specific decomposition rank,
• Initialisations (Initialization): a single decomposition.
Importing data and performing model selection using the Experiment class
The Experiment class loads and clusters initialisations of each decomposition rank of a
hdf5 file written by tensorsignatures write (Sec. A.3.3)
> experiment = ts.Experiment("results.h5")
The data field of an Experiment instance returns a set of keys, which allow us to
access the Cluster of the experiment (Sec. A.3.4). Keys follow the format to prefix the
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decomposition rank with the name of the experiment, which we set earlier using the -j flag
when we ran tensorsignatures train (Sec. A.3.3).
> experiment.data
{’/MyFirstExperiment/10’, ’/MyFirstExperiment/2’, ..., \
’/MyFirstExperiment/9’}
The Experiment class computes a table of useful statistics,
> experiment.summary_table.head()
which, for example, enable us to inspect log likelihood of each initialisation2,
> sns.swarmplot(x=’rank’, y=’log_L’, hue=’init’, \
data=experiment.summary_table, color=’C0’, palette=’deep’)
The summary_table also allows us to perform model selection using the Bayesian
Information Criterion (BIC). This estimator tries to find a trade-off between the log-likelihood
and the number of parameters in the model; chosen is the rank which minimises the BIC. To
understand which model to choose in our experiment, we will quickly plot the rank against
BIC,
> import seaborn as sns
> sns.boxplot(x=’rank’, y=’BIC’, data=experiment.summary_table, color=’C0’)
indicating that rank 5 is most appropriate for our dataset.
2Here we use the the seaborn library to create the plot. You can install the package, if necessary, by
executing pip install seaborn in your terminal.
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The Cluster class wraps multiple TensorSignature initialisations
We can extract the cluster of a specific decomposition rank by passing these keys to the getter
function of an Experiment object. For example, to extract the rank 5 solution, we execute
> cluster = experiment[‘/MyFirstExperiment/5’]
A Cluster instance is essentially a wrapper for multiple Initializations (Sec. A.3.4).
It embodies attributes to access the parameters of a tensor signature inference, for example,
we may access the extracted signature tensor(s) through the S field of Cluster.
> cluster.S.shape
(3, 3, 3, 5, 96, 5, 10)
Note the similarity between the shape of the extracted signature tensor and the shape of
the input snv count tensor ((3, 3, 3, 5, 96, 100)). First few indices match the size of
corresponding genomic dimensions, i.e. transcription and replication directionality (each 3),
genomic dimension 1 and 2 (3 and 5) and single base substitution types (96). The following
two indices, however, indicate the decomposition rank (5) rather than the number of samples,
and the number initialisations in the cluster.
Other model parameters may be accessed through the following fields:
• Other mutation type signatures: result.T
• Exposures: result.E
• Transcription and replicational strand biases: result.b
• Signature activities in transcribed/untranscribed regions and early/late replicating
regions: result.a
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• Arbitrary genomic property (like epigenetic signature activities): result.k0, result.k1,
..., result.kx
• Mixing proportions: result.m
The last dimension of an extracted Cluster parameter always indicates the number of
available initialisations. To extract the solution of a particular initialisation, we can can
simply index it using standard numpy indexing. Here we make use of the so called ellipsis
operator (...) which enables to index the last dimension of an multidimensional array
> solution = cluster.b[..., 3]
> solution.shape
(2, 7)
Cluster objects provide an init field containing the index of the initialisation with the
highest log-likelihood. To extract this particular Initialization from a cluster, we simply
pass it to the Cluster getter function.
> init = cluster[cluster.init]
A Initialization object stores tensor signatures, factors and exposures
Similar to TensorSignature Cluster objects, Initializations contain the fitted model
including all parameters. For example, we can access the extracted signature tensor by
accessing the S field from init.
> init.S.shape
(3, 3, 3, 5, 96, 5, 1)
Note that the last dimension of S has a size of one, indicating an initialisation rather
than a clustered signature tensor. Two other useful methods of Initialization objects are
to_dic and dump, which let us serialise and save the result of a TensorSignature initialisation
to the hard disk.
> # returns a dictionary with all parameters
> init.to_dic()




The TensorSignatures API features some basic plotting function which allow us to
visualise the extracted parameters of an Initialisation.
• plot_signatures: plots single base substitution spectra in context of transcription
and replication
• heatmap: plots tensor factors (transcription and replication biases (b), signature activi-
ties (a), and genomic activities (k0, k1, . . . , kx))
The ts.plot_signatures function expects an 5 dimensional array (3, 3, -1, 96,
rank). Due to the fact that we can have an arbitrary number of genomic states, we first have
to reshape the signature tensor before we can pass it to the plotting function.
> plt.figure(figsize=(16, 5))
> ts.plot_signatures(init.S.reshape(3, 3, -1, 96, init.rank))
We can plot extracted tensor factors result.b, result.a, result.k0 and result.k1
using the ts.heatmap function. Note, that similarly to the the signature tensor, the Initialization
object appends an additional dimension to indicate its index. For this reason, we need to
reshape the arrays containing tensor factors or index them appropriately.
> result.b.shape # transcription and replication strand biases
(2, 5, 1)





col_labels=[’{}’.format(i) for i in range(5)],
cbarlabel=’Strand bias (No bias = 1)’ # color bar label
)
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Exercise: Compare how extracted parameters differ from the ground truth (Sec.
A.3.2).
Running TensorSignatures through the API
In some scenarios it might be desirable to run TensorSignatures via the API rather than the
CLI (for example when integrating TensorSignatures into custom pipelines). To illustrate
this, we first simulate data and extract the SNV count tensor and the matrix containing other
mutation types. Here it is important to notice that the sample dimensions have to match, e.g.
snv[..., 4] has to match other[..., 4].
> data = ts.TensorSignatureData(
seed=573, # set a seed for reproducibility
rank=5, # number of signatures
samples=100, # number of samples
dimensions=[3, 5], # number of arbitrary genomic dimensions
mutations=1000)
> snv = data_set.snv() # the SNV count tensor (3, 3, 3, 5, 96, 100)
> other = data_set.other() # other mutation type matrix (234, 100)
The next step is to pass the desired decomposition rank, as well as the input data, i.e.
the snv count tensor and the other mutation matrix, to the TensorSignature class3. The
TensorSignature constructor also receives other model hyperparameters such as learning
rate of the model or the number of epochs to train the model. By default, TensorSignatures
uses the outlier robust negative binomial distribution with a dispersion t = 50 to model the
mutation count, and trains the model for 10,000 epochs.
# perform a rank 5 decomposition
model = ts.TensorSignature(snv, other, rank=5, verbose=True, epochs=20000)
3When working with real genomic data it is also necessary to pass a normalisation tensor (via the argu-
ment N) which accounts for differences in the nucleotide composition of different genomic regions to the
TensorSignature constructor.
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To fit the signatures to our data, we simply invoke the fit method of the model instance,
which will return a Initialization object after finishing to train the model.
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Model selection via BIC for the PCAWG dataset
Fig. B.1 Model selection in the PCAWG dataset. Chosen number of signatures 20 with a
size t of 50.
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Fig. B.2 Distribution of PCAWG SNV count data across Chrom-HMM states using an
all tissue and tissue specific consensus.
Fig. B.3 Annotating SNVs with consensus and partially matched ChromHMM states.
Comparison of inferred epigenetic signature activities using an all tissue (upper triangle) and
tissue specific (lower triangle) consensus (grey triangles indicate NA values).
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Fig. B.4 Correlation of TS05 and TS06 exposures in Skin-Melanoma samples. Blue line
indicates the identity line (y = x).
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1e3 Pooled Skin-Melanoma (active)
AA AC AG A
T






























1e4 Pooled Skin-Melanoma (quies.)
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1e 1 Heptanucleotide normalization (active)
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1e 1 Heptanucleotide normalization (quies.)
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Hepta-nucleotide normalised mutational spectra of Skin-Melanoma
Fig. B.5 Heptanucleotide context normalised C>T mutation counts in active and quies-
cent genomic regions.
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Fig. B.6 Correlation of predicted TS07 and TS08 mutation counts in Liver-HCC sam-


























































































































































































































































































































































































































































































Fig. B.8 Pancancer-wide pooled C>G and C>T clustered variants proximal and distal
to SVs.
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Fig. B.9 Tetranucleotide motifs at sites of APOBEC mutations.
Fig. B.10 Correlation of TS13 and TS14 exposures in lymphoid cancers (Lymph-
BNHL/CLL/NOS).
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Fig. B.13 C>T mutation type probabilities of TS22 for coding and template strand
DNA, and the MNV spectrum of TS23.
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Table B.5 TensorSignatures and equivalent SigProfiler (SBS) signatures.
type feature
TS1 SBS1












































































































































































































































































































































































































































































































































































































































































































































































































































Fig. C.1 TS01: Single base substitution spectrum.
Fig. C.2 TS01: Single base substitution spectra for template/coding and leading/lagging
strand DNA.
184 Vignettes
Fig. C.3 TS01: Spectrum other mutation types.
Fig. C.4 TS01: Signature activity in different cancer types.
Fig. C.5 TS01: Signature specific tensor coefficients.
C.2 TS02-N[C>T]N (unknown) 185
C.2 TS02-N[C>T]N (unknown)
Fig. C.6 TS02: Single base substitution spectrum.
Fig. C.7 TS02: Single base substitution spectra for template/coding and leading/lagging
strand DNA.
Fig. C.8 TS02: Spectrum other mutation types.
186 Vignettes
Fig. C.9 TS02: Signature activity in different cancer types.
Fig. C.10 TS02: Signature specific tensor coefficients.
C.3 TS03-N[N>N]N-q (unknown/quiet) 187
C.3 TS03-N[N>N]N-q (unknown/quiet)
Fig. C.11 TS03: Single base substitution spectrum.
Fig. C.12 TS03: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.13 TS03: Spectrum other mutation types.
188 Vignettes
Fig. C.14 TS03: Signature activity in different cancer types.
Fig. C.15 TS03: Signature specific tensor coefficients.
C.4 TS04-N[N>N]N (unknown/active) 189
C.4 TS04-N[N>N]N (unknown/active)
Fig. C.16 TS04: Single base substitution spectrum.
Fig. C.17 TS04: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.18 TS04: Spectrum other mutation types.
190 Vignettes
Fig. C.19 TS04: Signature activity in different cancer types.
Fig. C.20 TS04: Signature specific tensor coefficients.
C.5 TS05-T[C>T]N (UV/GG-NER) 191
C.5 TS05-T[C>T]N (UV/GG-NER)
Fig. C.21 TS05: Single base substitution spectrum.
Fig. C.22 TS05: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.23 TS05: Spectrum other mutation types.
192 Vignettes
Fig. C.24 TS05: Signature activity in different cancer types.
Fig. C.25 TS05: Signature specific tensor coefficients.
C.6 TS06-Y[C>T]N (UV/GG+TC-NER) 193
C.6 TS06-Y[C>T]N (UV/GG+TC-NER)
Fig. C.26 TS06: Single base substitution spectrum.
Fig. C.27 TS06: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.28 TS06: Spectrum other mutation types.
194 Vignettes
Fig. C.29 TS06: Signature activity in different cancer types.
Fig. C.30 TS06: Signature specific tensor coefficients.
C.7 TS07-N[T>C]N (unknown) 195
C.7 TS07-N[T>C]N (unknown)
Fig. C.31 TS07: Single base substitution spectrum.
Fig. C.32 TS07: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.33 TS07: Spectrum other mutation types.
196 Vignettes
Fig. C.34 TS07: Signature activity in different cancer types.
Fig. C.35 TS07: Signature specific tensor coefficients.
C.8 TS08-A[T>C]W (unknown/TAM) 197
C.8 TS08-A[T>C]W (unknown/TAM)
Fig. C.36 TS08: Single base substitution spectrum.
Fig. C.37 TS08: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.38 TS08: Spectrum other mutation types.
198 Vignettes
Fig. C.39 TS08: Signature activity in different cancer types.
Fig. C.40 TS08: Signature specific tensor coefficients.
C.9 TS09-N[T>A]N (PAH/AA) 199
C.9 TS09-N[T>A]N (PAH/AA)
Fig. C.41 TS09: Single base substitution spectrum.
Fig. C.42 TS09: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.43 TS09: Spectrum other mutation types.
200 Vignettes
Fig. C.44 TS09: Signature activity in different cancer types.
Fig. C.45 TS09: Signature specific tensor coefficients.
C.10 TS10-N[C>A]N (PAH/B[a]P) 201
C.10 TS10-N[C>A]N (PAH/B[a]P)
Fig. C.46 TS10: Single base substitution spectrum.
Fig. C.47 TS10: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.48 TS10: Spectrum other mutation types.
202 Vignettes
Fig. C.49 TS10: Signature activity in different cancer types.
Fig. C.50 TS10: Signature specific tensor coefficients.
C.11 TS11-T[C>D]W;SV (APOBEC) 203
C.11 TS11-T[C>D]W;SV (APOBEC)
Fig. C.51 TS11: Single base substitution spectrum.
Fig. C.52 TS11: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.53 TS11: Spectrum other mutation types.
204 Vignettes
Fig. C.54 TS11: Signature activity in different cancer types.
Fig. C.55 TS11: Signature specific tensor coefficients.
C.12 TS12-T[C>D]W (APOBEC) 205
C.12 TS12-T[C>D]W (APOBEC)
Fig. C.56 TS12: Single base substitution spectrum.
Fig. C.57 TS12: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.58 TS12: Spectrum other mutation types.
206 Vignettes
Fig. C.59 TS12: Signature activity in different cancer types.
Fig. C.60 TS12: Signature specific tensor coefficients.
C.13 TS13-N[C>K]H (AID/SHM) 207
C.13 TS13-N[C>K]H (AID/SHM)
Fig. C.61 TS13: Single base substitution spectrum.
Fig. C.62 TS13: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.63 TS13: Spectrum other mutation types.
208 Vignettes
Fig. C.64 TS13: Signature activity in different cancer types.
Fig. C.65 TS13: Signature specific tensor coefficients.
C.14 TS14-W[T>V]W (POLH) 209
C.14 TS14-W[T>V]W (POLH)
Fig. C.66 TS14: Single base substitution spectrum.
Fig. C.67 TS14: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.68 TS14: Spectrum other mutation types.
210 Vignettes
Fig. C.69 TS14: Signature activity in different cancer types.
Fig. C.70 TS14: Signature specific tensor coefficients.
C.15 TS15-G[C>T]N;ID (MMRD) 211
C.15 TS15-G[C>T]N;ID (MMRD)
Fig. C.71 TS15: Single base substitution spectrum.
Fig. C.72 TS15: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.73 TS15: Spectrum other mutation types.
212 Vignettes
Fig. C.74 TS15: Signature activity in different cancer types.
Fig. C.75 TS15: Signature specific tensor coefficients.
C.16 TS16-N[C>A]T;ID (MMRD:POLE-exo) 213
C.16 TS16-N[C>A]T;ID (MMRD:POLE-exo)
Fig. C.76 TS16: Single base substitution spectrum.
Fig. C.77 TS16: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.78 TS16: Spectrum other mutation types.
214 Vignettes
Fig. C.79 TS16: Signature activity in different cancer types.
Fig. C.80 TS16: Signature specific tensor coefficients.
C.17 TS17-T[C>A]T (POLE-exo) 215
C.17 TS17-T[C>A]T (POLE-exo)
Fig. C.81 TS17: Single base substitution spectrum.
Fig. C.82 TS17: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.83 TS17: Spectrum other mutation types.
216 Vignettes
Fig. C.84 TS17: Signature activity in different cancer types.
Fig. C.85 TS17: Signature specific tensor coefficients.
C.18 TS18-N[C>A]W (BERD/MUTYH) 217
C.18 TS18-N[C>A]W (BERD/MUTYH)
Fig. C.86 TS18: Single base substitution spectrum.
Fig. C.87 TS18: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.88 TS18: Spectrum other mutation types.
218 Vignettes
Fig. C.89 TS18: Signature activity in different cancer types.
Fig. C.90 TS18: Signature specific tensor coefficients.
C.19 TS19-N[N>N]N;SV (HRD/BRCA) 219
C.19 TS19-N[N>N]N;SV (HRD/BRCA)
Fig. C.91 TS19: Single base substitution spectrum.
Fig. C.92 TS19: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.93 TS19: Spectrum other mutation types.
220 Vignettes
Fig. C.94 TS19: Signature activity in different cancer types.
Fig. C.95 TS19: Signature specific tensor coefficients.
C.20 TS20-N[T>G]T (unknown/5FU) 221
C.20 TS20-N[T>G]T (unknown/5FU)
Fig. C.96 TS20: Single base substitution spectrum.
Fig. C.97 TS20: Single base substitution spectra for template/coding and lead-
ing/lagging strand DNA.
Fig. C.98 TS20: Spectrum other mutation types.
222 Vignettes
Fig. C.99 TS20: Signature activity in different cancer types.
Fig. C.100 TS20: Signature specific tensor coefficients.
Appendix D
Additional Analysis
D.1 Elevated somatic mutation burdens in normal human



































Fig. D.1 Model selection in the dataset from Robinson et al. (2020). Chosen number of
signatures 8 with a size t of 10,000.
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Fig. D.2 TS17: Single base substitution spectra for template/coding and leading/lagging
























































































































































































































































































































































































































































































































































AA AC AG A
T

























AA AC AG A
T








T TA TC TG T
T
C>G
AA AC AG A
T








T TA TC TG T
T
Flanking 5' and 3' base (Leading strand dark, lagging strand light)
C>T
AA AC AG A
T








T TA TC TG T
T
T>A
AA AC AG A
T








T TA TC TG T
T
T>C
AA AC AG A
T








T TA TC TG T
T
T>G
AA AC AG A
T


























AA AC AG A
T








T TA TC TG T
T
C>G
AA AC AG A
T








T TA TC TG T
T
Flanking 5' and 3' base (Coding strand dark, template strand light)
C>T
AA AC AG A
T








T TA TC TG T
T
T>A
AA AC AG A
T








T TA TC TG T
T
T>C
AA AC AG A
T








T TA TC TG T
T
T>G
Fig. D.3 TS17-a: Single base substitution spectra for template/coding and lead-
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Fig. D.4 TS-POLD1 (Ins): Single base substitution spectra for template/coding and
leading/lagging strand DNA, as well as the the spectrum for other mutation types.
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Fig. D.5 TS-POLD1: Single base substitution spectra for template/coding and lead-










































Pooled SBS POLD1 S478N
(Het & Quies)
C>A/C>T ratio = 0.6 C>A/C>T ratio = 1.2
Fig. D.6 Pooled POLE L424V and POLD1 S478N single base substitutions from active
and heterochromatic regions.
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Fig. D.7 Model selection in the dataset from Mathijs A. Sanders. Chosen number of
signatures 6 with a size t of 100.
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Fig. D.8 TS-MMRD (T>C): Single base substitution spectra for template/coding and
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Fig. D.9 TS-MMRD (C>A): Single base substitution spectra for template/coding and
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Fig. D.10 TS-MMRD (Ins): Single base substitution spectra for template/coding and
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Fig. D.11 TS-MMRD (Del): Single base substitution spectra for template/coding and
leading/lagging strand DNA, as well as the the spectrum for other mutation types.
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Fig. D.12 Model selection in the OCCAMS dataset. Chosen number of signatures 15
with a size t of 50.
230 Additional Analysis
Fig. D.13 Tensor factors extracted from the OCCAMS dataset (Frankell et al., 2019).
Accompanying tensor factors to the signatures depicted in Fig. 3.29.
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D.4 Extensive heterogeneity in somatic mutation and selec-


































Fig. D.14 Model selection in the normal bladder urothelium dataset. Chosen number
of signatures 4 with a size t of 50.
D.5 The mutational processes in normal and tumorous cells
232 Additional Analysis
Fig. D.15 Tensor factors extracted from the normal bladder urothelium dataset. Ac-
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Fig. D.16 Model selection in the normal and tumour dataset. Chosen number of signa-
tures 12 with a size t of 1000.
D.5 The mutational processes in normal and tumorous cells 233
Fig. D.17 The tensor signatures of normal cells. The representation of tensor factors
analogous to Fig. 3.5.
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